

Supplement to

Volume 5 • Number 3S • June 2011

# Journal of Clinical Lipidology

Official Journal of the National Lipid Association


## **Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients**

Clinical Guidance from the National Lipid Association Expert Panel  
on Familial Hypercholesterolemia

ELSEVIER

[www.LipidJournal.com](http://www.LipidJournal.com)

Submit Manuscript: <http://ees.elsevier.com/jclinlipid/>



ISSN 1933-2874



# Journal of Clinical Lipidology

Official Journal of the National Lipid Association

## EDITOR-IN-CHIEF

**W. Virgil Brown**  
Charles Howard Candler  
Professor Emeritus  
Emory University School of Medicine  
Atlanta, GA 30305

## MANAGING EDITOR

**Angelica Kerr**  
Elsevier, New York  
360 Park Avenue South  
New York, NY 10010

## ASSOCIATE EDITORS

Section Specialty: Cardiovascular Disease  
Prevention, Vascular Medicine

**Christie M. Ballantyne, MD**  
Methodist DeBakey Heart and  
Vascular Center and Baylor College  
of Medicine Houston, TX

Section Specialty: Lipidology,  
Arteriosclerosis,  
Thrombosis, and Vascular Biology

**Thomas P. Bersot, MD**  
University of California, San Francisco  
San Francisco, CA

Section Specialty: Cardiovascular Disease,  
Preventive Cardiology, Lipidology

**Vera A. Bittner, MD, MSPH**  
University of Alabama  
Birmingham, AL

Section Specialty: Endocrinology,  
Nutrition and Metabolism

**Alan Chait, MD**  
University of Washington  
Seattle, WA

Section Specialty: Preventive Cardiology,  
Atherosclerosis

**Jerome D. Cohen, MD**  
St. Louis University School of Medicine  
St. Louis, MO

Section Specialty: Preventive  
Cardiology and Atherosclerosis, Pharmacology

**Michael H. Davidson, MD**  
Radiant Research  
Chicago, IL

Section Specialty: Lipidology

**Jean Davignon, MD, MSc**  
Clinical Research Institute of Montreal  
Montreal (Quebec),  
Canada

Section Specialty: Endocrinology, Metabolism,  
Diabetes, Cardiology

**Robert H. Eckel, MD, FAHA**  
University of Colorado Anschutz Medical  
Campus  
Aurora, CO

Section Specialty: Endocrinology (Lipids)

**Sergio Fazio, MD, PhD**  
Vanderbilt University School of Medicine  
Nashville, TN

Section Specialty: Diabetes

**Ronald B. Goldberg, MD**  
University of Miami School of Medicine  
Miami, FL

Section Specialty: Basic Lipid  
Physiology, Lipolytic Enzymes

**Ira Goldberg, MD**  
Columbia University Medicine  
New York, NY

Section Specialty: Clinical Management

**John R. Guyton, MD**  
Duke University Medical Center  
Durham, NC

Section Specialty: Epidemiology, Disease  
Prevention, Clinical Trials

**Terry A. Jacobson, MD, FACP, FAHA**  
Emory University School of Medicine  
Atlanta, GA

Section Specialty: Lipidology,  
Atherosclerosis

**Peter H. Jones, MD**  
Baylor College of Medicine  
Houston, TX

Section Specialty: Dietetics

**Penny Kris-Etherton, PhD, RD**  
Penn State University  
University Park, PA

Section Specialty: Diabetes,  
Lipidology and Nephrology

**Edgar V. Lerma, MD**  
University of Illinois at Chicago  
College of Medicine/Associates  
in Nephrology, S.C.  
Chicago, IL

Section Specialty: Diabetes, Immunology

**Maria Lopes-Virella, MD, PhD**  
Medical University of SC  
Charleston, SC

Section Specialty: Pharmacology,  
Clinical Trials

**James M. McKenney, PharmD**  
National Clinical Research, Inc.  
Richmond, VA

Section Specialty: Preventive  
Cardiovascular Medicine

**Daniel J. Rader, MD**  
University of Pennsylvania School of Medicine  
Philadelphia, PA

Section Specialty: Cardiovascular  
Disease Epidemiology

**Jennifer G. Robinson, MD, MPH**  
University of Iowa  
Iowa City, IA

Section Specialty: Lipidology, Nutrition

**Frank M. Sacks, MD**  
Harvard School of Public Health  
Boston, MA

Section Specialty: Familial Hypercholesterolemia,  
Imaging in Atherosclerosis, Preventive Cardiology

**Raul D. Santos, MD, MSc, PhD**  
University of São Paulo Medical  
School Hospital  
São Paulo, Brazil

Section Specialty: Endocrinology, Metabolism

**Ernst J. Schaefer, MD**  
Tufts University School of Medicine  
Boston, MA

Section Specialty: Cardiology, Lipidology

**Allan D. Sniderman, MD, FRCP(C), FRSC**  
McGill University Health Centre  
Montreal (Quebec), Canada

Section Specialty: Laboratory Analysis,  
Pediatric Lipidology, Clinical Lipidology

**Evan Stein, MD, PhD**  
Metabolic & Atherosclerosis Research Center  
Cincinnati, OH

Section Specialty: Cardiology, Lipidology  
Clinical Cardiology and Clinical Lipidology

**Neil J. Stone, MD**  
Winnetka, IL

Section Specialty: Endocrinology,  
Epidemiology and Biostatistics

**Robert A. Wild, MD, PhD, MPH**  
Oklahoma University Health Sciences Center  
Oklahoma City, OK

Section Specialty: Pediatric Lipid Management

**Don P. Wilson, MD**  
Phoenix Children's Hospital  
Phoenix, AZ

Section Specialty: Epidemiology

**Peter W. Wilson, MD**  
Emory University School of Medicine  
Atlanta, GA

# Journal of Clinical Lipidology

Official Journal of the National Lipid Association

## EDITORIAL BOARD

Nicola Abate, MD  
Dallas, TX

Eyad Alhaj, MD  
Florence, KY

Mouaz H. Al-Mallah, MD  
Detroit, MI

Billy S. Arant, Jr., MD  
Chattanooga, TN

Kimberly Birtcher, MS, PharmD, BCPS, CDE  
Houston, TX

Michael Bottorff, PharmD  
Cincinnati, OH

Lynne T. Braun, RN APN  
Chicago, IL

Eliot A. Brinton, MD  
Salt Lake City, UT

David M. Capuzzi, MD, PhD  
Wynnewood, PA

Elena Citkowitz, MD, PhD, FACP  
New Haven, CT

John H. Contois, PhD  
Portland, ME

Marshall Ayer Corson, MD  
Seattle, WA

Stephen R. Crespin, MD  
St. Louis, MO

William C. Cromwell, MD  
Raleigh, NC

John R. Crouse, MD  
Winston-Salem, NC

Thomas Darice Dayspring, MD, FACP  
Wayne, NJ

Dave L. Dixon, PharmD  
Winston-Salem, NC

Carlos A. Dujovne, MD  
Mission, KS

Daniel Duprez, MD, PhD, FACC,  
FAHA, FESC  
Minneapolis, MN

James Falko, MD  
Denver, CO

Sergio Fazio, MD, PhD  
Nashville, TN

Gerald Fletcher, MD  
Jacksonville, FL

Jeffrey S. Freeman, DO, FACOI  
Philadelphia, PA

Stephen A. Geraci, MD, FACC, FDDP,  
FAHA, FACP  
Jackson, MS

Edward A. Gill, MD  
Seattle, WA

Douglas Hammer, MD, MPH, DrPH  
Raleigh, NC

Charles R. Harper, MD  
Atlanta, GA

Linda C. Hemphill, MD  
Boston, MA

D. Roger Illingworth, MD  
Portland, OR

Matthew Ito, PharmD, FCCP, BCPS  
Portland, OR

Michael Lee Johnson, PhD  
Houston, TX

Dean G. Karalis, MD, FACC  
Philadelphia, PA

Jack J. Kleid, MD, FACP, FACC, FAHA  
San Diego, CA

Bruce A. Kottke, MD, PhD  
Lakeland, FL

Sandra Kreul, ARNP, MSN  
Valrico, FL

Kevin C. Maki, PhD  
Glen Ellyn, IL

Carol M. Mason, ARNP  
Trinity, FL

Catherine J. McNeal, MD, PhD  
Temple, TX

David G. Meyers, MD, MPH, FACC, FAHA,  
FACPM

Kansas City, KS  
Michael Miller, MD, FACC, FAHA

Baltimore, Maryland  
Patrick M. Moriarty, MD, FACP, FACC

Kansas City, KS  
Anne N. Nafziger, MD, MHS

Albany, NY  
Stephen Nash, MD, FACC, FAHA

Syracuse, NY  
Shailesh B. Patel, BM, ChB, DPhil, FRCP

Milwaukee, WI  
Gregory S. Pokrywka, MD

Towson, MD

Michael Prisant, MD, FACC, FAHA  
Augusta, GA

Vasudevan Raghavan, MBBS, MD,  
MRCP (UK)  
Columbus, OH

Sanjay Rajagopalan, MD  
Columbus, OH

Michael F. Richman, MD, FACS, FCCP  
Los Angeles, CA

Giacomo Ruotolo, MD, PhD  
Milano, Italy

Edward Shahady, MD  
Fernandina Beach, FL

Scott W. Shurmur, MD  
Omaha, NE

Donald A. Smith, MD, MPH  
New York, NY

James H. Stein, MD  
Madison, WI

Mary Ellen Sweeney, MD  
Decatur, GA

David M. Thompson, PhD  
Oklahoma City, OK

Peter P. Toth, MD, PhD FAAFP, FICA, FAHA,  
FCCP, FACC  
Sterling, IL

James A. Underberg, MD  
New York, NY

Ralph M. Vicari, MD  
Melbourne, FL

Yoel Vivas, MD  
Pittsburgh, PA

G. Russell Warnick, MS, MBA  
Alameda, CA

Perry Jay Weinstock, MD, FACC  
Camden, NJ

Robert Allen Wild, MD, PhD, MPH  
Oklahoma City, OK

Michael J. Zema, MD, FACP, FACC, FCCP,  
FCP, FASE, FASNC, FACA, FICA  
Patchogue, NY

Bin Zhang, PhD  
Birmingham, AL

Paul Ziajka, MD, PhD  
Winter Park, FL

Issam Zineh, PharmD  
Gainesville, FL

# Journal of Clinical Lipidology

VOLUME 5, NUMBER 3S, JUNE 2011

Official Journal of the National Lipid Association

## TABLE OF CONTENTS

### Executive Summary

#### **Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients**

**Clinical Guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. . . . . S1**

Anne C. Goldberg, Paul N. Hopkins, Peter P. Toth, Christie M. Ballantyne, Daniel J. Rader, Jennifer G. Robinson, Stephen R. Daniels, Samuel S. Gidding, Sarah D. de Ferranti, Matthew K. Ito, Mary P. McGowan, Patrick M. Moriarty, William C. Cromwell, Joyce L. Ross, Paul E. Ziajka

#### **Familial Hypercholesterolemias: Prevalence, Genetics, Diagnosis and Screening Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia . . . . . S9**

Paul N. Hopkins, Peter P. Toth, Christie M. Ballantyne, Daniel J. Rader

#### **Treatment of Adults with Familial Hypercholesterolemia and Evidence for Treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. . . . . S18**

Jennifer G. Robinson, Anne C. Goldberg

#### **Pediatric Aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. . . . . S30**

Stephen R. Daniels, Samuel S. Gidding, Sarah D. de Ferranti

#### **Management of Familial Hypercholesterolemias in Adult Patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia . . . . . S38**

Matthew K. Ito, Mary P. McGowan, Patrick M. Moriarty

#### **Future Issues, Public Policy, and Public Awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. . . . . S46**

Anne C. Goldberg, Jennifer G. Robinson, William C. Cromwell, Joyce L. Ross, Paul E. Ziajka

---

© 2011 National Lipid Association. All rights reserved.

*Journal of Clinical Lipidology* (ISSN 1933-2874) is published six times a year by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Months of issue are February, April, June, August, October, and December. Periodicals postage paid at New York, NY, and at additional mailing offices.

**POSTMASTER:** Send address changes to *Journal of Clinical Lipidology*, Elsevier, Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043.

**Annual Subscription Rates.** Institutional price: USD 449; Personal price: USD 184; Student price: USD 72; Student price USA: USD 68; Personal price USA: USD 148; Single issue price: USD 75; Institutional price USA: USD 386. Prices include postage and are subject to change without notice.

**Customer Service (orders, claims, online, change of address):** Please contact the Customer Support Department at the Regional Sales Office nearest you: St. Louis: Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Tel: 1-800-654-2452 (U.S. and Canada); 314-447-8871 (outside U.S. and Canada). Fax: 314-447-8029. E-mail: [journalscustomerservice-usa@elsevier.com](mailto:journalscustomerservice-usa@elsevier.com) (for print support); [journalonlinesupport-usa@elsevier.com](mailto:journalonlinesupport-usa@elsevier.com) (for online support). Tokyo: Elsevier Inc., Customer Support Department, 9-15, Hirgashi-Azbu 1-chome, Minatoku, Tokyo 106, Japan; phone: (+3) 5561-5033; fax (+3) 5561-5047; e-mail: [kyf04035@niftyserve.or.jp](mailto:kyf04035@niftyserve.or.jp). Singapore: Elsevier (Singapore) Pte Ltd, No 1 Temasek Avenue, 17-01 Millenia Tower, Singapore 039192; phone (+65) 434-3727; fax (+65) 337-2230; e-mail: [asiainfo@elsevier.com.sg](mailto:asiainfo@elsevier.com.sg). Amsterdam: Elsevier Inc., Customer Support Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands; phone (+31) 20-485-3757; fax (+31) 20-485-3432; e-mail: [nlinfo@elsevier.nl](mailto:nlinfo@elsevier.nl). Rio de Janeiro: Elsevier Inc., Rua Sete de Setembro 111/16 Andar, 20050-02 Centro, Rio de Janeiro-RJ, Brazil; phone (+55) (21) 509-5340; fax (+55) (21) 507-1991; e-mail: [Elsevier@campus.com.br](mailto:Elsevier@campus.com.br) [Note (Latin America): for orders, claims, and help desk information, please contact the Regional Sales Office in Orlando].

**Reprints:** To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710; fax (212) 462-1935; e-mail: [reprints@elsevier.com](mailto:reprints@elsevier.com).

**Photocopying policy:** In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone (978) 750-8400; fax (978) 750-4744. In the UK, users may make payments through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone (+44) 171-436-5931; fax (+44) 171-436-3986. Other countries may have a local reprographic rights agency for payments.

**Advertising orders and inquiries:** Display advertising inquiries in North and South America should be addressed to Aileen Rivera, Elsevier Inc., 360 Park Avenue South, New York, NY 10010; phone (212) 633-3721; fax (212) 633-3820. Inquiries regarding classified advertising (line and display) should be addressed to Brian Vishupad; phone (212) 633-3129. International advertising inquiries should be addressed to Advertising Department, Elsevier Inc., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom; phone (+44) (0) 1865 843565; fax (+44) (0) 1865 843976; e-mail: [media@elsevier.co.uk](mailto:media@elsevier.co.uk). Inquiries in Japan should be directed to the Advertising Department, Elsevier Science Japan, by telephone at (81) (3) 5561 5033 or by fax at (81) (3) 5561 5047.

Although all advertising materials is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such products or claims made of it by its manufacturer.

*Journal of Clinical Lipidology* is indexed in MEDLINE and is in EMBASE/Excerpta Medica and SCOPUS.

This paper meets the requirements of ANSI Standard Z39.48-1992 (Performance of Paper).

**Executive Summary**

# **Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients**

## **Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia**

**Anne C. Goldberg, MD, FNLA, Chair\***, Paul N. Hopkins, MD, MSPH, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA, Jennifer G. Robinson, MD, MPH, FNLA, Stephen R. Daniels, MD, PhD, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH, Matthew K. Ito, PharmD, FNLA, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA

*Washington University Medical School, St. Louis, MO, USA (Dr. Goldberg); Cardiovascular Disease Risk Reduction Clinic, University of Utah School of Medicine, Salt Lake City, UT, USA (Dr. Hopkins); Sterling Rock Falls Clinic, Ltd., CGH Medical Center, University of Illinois School of Medicine, Sterling, IL, USA (Dr. Toth); Section of Atherosclerosis and Vascular Medicine, Center for Cardiovascular Disease Prevention, Baylor College of Medicine, Houston, TX, USA (Dr. Ballantyne); University of Pennsylvania, Philadelphia, PA, USA (Dr. Rader); University of Iowa, Lipid Research Clinic, Prevention Intervention Center, University of Iowa, Iowa City, IA, USA (Dr. Robinson); Department of Pediatrics, University of Colorado School of Medicine, The Children's Hospital, Aurora, CO, USA (Dr. Daniels); Nemours Cardiac Center, A.I. DuPont Hospital for Children, Wilmington, DE, USA (Dr. Gidding); Preventive Cardiology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA (Dr. de Ferranti); Oregon State University/Oregon Health & Science University, Portland, OR, USA (Dr. Ito); Cholesterol Treatment Center, Concord Hospital, Concord, NH, USA (Dr. McGowan); University of Kansas Medical Center, Kansas City, KS, USA (Dr. Moriarty); Lipoprotein and Metabolic Disorders Institute, Wake Forest University School of Medicine, Raleigh, NC, USA (Dr. Cromwell); University of Pennsylvania Health System, Philadelphia, PA, USA (Dr. Ross); and Florida Lipid Institute, Winter Park, FL, USA (Dr. Ziajka)*

---

This article also appears in Volume 5, Issue 3 (May/June 2011) of the *Journal of Clinical Lipidology*.

\* Corresponding author.

E-mail address: agoldber@dom.wustl.edu

Submitted March 2, 2011; revised March 4, 2011. Accepted for publication March 4, 2011.

**KEYWORDS:**

Familial hypercholesterolemia; LDL receptor; Apheresis; Cascade screening; Heterozygous; Heterozygote; Homozygous; Homozygote

**Abstract:** The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD. © 2011 National Lipid Association. All rights reserved.

## Background and rationale

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels. Although the term FH has, in the past, been used to refer specifically to LDL receptor (LDLR) defects, this document will use a broader definition to reflect discoveries of defects in the genes for apolipoprotein (Apo) B, proprotein convertase subtilisin/kexin type 9 (PCSK9), and possibly others yet to be described, which produce severe hypercholesterolemia and increased risk of premature coronary heart disease (CHD). Total cholesterol concentrations in heterozygous FH patients (genetic defect inherited from one parent) are typically in the range of 350 to 550 mg/dL and in homozygotes (genetic defects inherited from both parents) range from 650 to 1000 mg/dL. FH is among the most commonly occurring congenital metabolic disorders. The heterozygous form occurs in approximately 1 in 300 to 500 people in many populations, although this ratio is much higher in certain populations in the U.S. The homozygous form is quite rare, occurring in approximately 1 out of every 1,000,000 individuals. Because FH is due to a genetic defect or defects, hypercholesterolemia is present from childhood, leading to early development of CHD. Of particular concern are FH homozygotes, in whom the severity of hypercholesterolemia usually results in severe atherosclerosis and even cardiovascular disease during childhood and adolescence.

FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. In addition to diet and lifestyle modifications, safe and effective medical therapies are available, including statins and other lipid-lowering drugs, and LDL apheresis, (a method of removing LDL and other Apo B particles from the blood). Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated,

particularly among children. Some estimates suggest that approximately 20% of patients are diagnosed and, of those, only a small minority receive appropriate treatment.

Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. Central to that education is comprehension of the importance of universal screening during childhood and cascade lipid screening of family members of known FH patients. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients (including women of childbearing potential and during pregnancy) developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD. The rationale and supporting evidence for these recommendations are published herein, but are not intended to be a comprehensive examination of the published literature.<sup>1-5</sup>

## 1. Definition, prevalence, genetics, diagnosis and screening

### 1.1 Definition of familial hypercholesterolemias

- 1.1.1 The FH are a group of inherited genetic defects resulting in severely elevated serum cholesterol concentrations.
- 1.1.2 For purposes of this document, FH will refer to the autosomal dominant forms of severe hypercholesterolemia unless otherwise specified. However, causes of inherited high cholesterol are not restricted to autosomal dominant FH.

### 1.2 Prevalence of FH and associated risk

- 1.2.1 The prevalence of FH is 1 in 300 to 500 in many populations, making FH among the most common of serious genetic disorders.

- 1.2.2 There are approximately 620,000 FH patients currently living in the United States.
- 1.2.3 The risk of premature coronary heart disease (CHD) is elevated about 20-fold in untreated FH patients.
- 1.2.4 Approximately 1 in one million persons is homozygous (or compound heterozygous) for *LDLR* mutations and has extreme hypercholesterolemia with rapidly accelerated atherosclerosis when left untreated.
- 1.2.5 In a few populations (such as French Canadians and Dutch Afrikaners), the prevalence of FH may be as high as 1 in 100.

### 1.3 Genetics of FH

- 1.3.1 Currently, known causes of FH include mutations in the LDL receptor (*LDLR*), Apo B (*APOB*), or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) genes.
- 1.3.2 There are over 1600 known mutations of the *LDLR* gene documented to cause FH at the time of this writing, accounting for about 85 to 90% of FH cases.
- 1.3.3 The Arg3500Gln mutation in *APOB* is the most common cause of hypercholesterolemia due to an *APOB* mutation, accounting for 5 to 10% of FH cases in Northern European populations (rare in other populations).
- 1.3.4 Gain-of-function mutations in *PCSK9* cause fewer than 5% of cases in most studies.

### 1.4 Screening for FH

- 1.4.1 Universal screening for elevated serum cholesterol is recommended. FH should be suspected when untreated fasting LDL cholesterol or non-HDL cholesterol levels are at or above the following:
  - Adults ( $\geq 20$  years): LDL cholesterol  $\geq 190$  mg/dL or non-HDL cholesterol  $\geq 220$  mg/dL;
  - Children, adolescents and young adults ( $< 20$  years): LDL cholesterol  $\geq 160$  mg/dL or non-HDL cholesterol  $\geq 190$  mg/dL.
- 1.4.2 For all individuals with these levels, a family history of high cholesterol and heart disease in first-degree relatives should be collected. The likelihood of FH is higher in individuals with a positive family history of hypercholesterolemia or of premature CHD (onset in men before age 55 years and women before age 65 years).
- 1.4.3 Cholesterol screening should be considered beginning at age 2 for children with a family history of premature cardiovascular disease or elevated cholesterol. All individuals should be screened by age 20.
- 1.4.4 Although not present in many individuals with FH, the following physical findings should prompt the clinician to strongly suspect FH

and obtain necessary lipid measurements if not already available:

- Tendon xanthomas at any age (most common in Achilles tendon and finger extensor tendons, but can also occur in patellar and triceps tendons).
  - Arcus corneae in a patient under age 45.
  - Tuberos xanthomas or xanthelasma in a patient under age 20 to 25.
- 1.4.5 At the LDL cholesterol levels listed below the probability of FH is approximately 80% in the setting of general population screening. These LDL cholesterol levels should prompt the clinician to *strongly* consider a diagnosis of FH and obtain further family information:
- LDL cholesterol  $\geq 250$  mg/dL in a patient aged 30 or more;
  - LDL cholesterol  $\geq 220$  mg/dL for patients aged 20 to 29;
  - LDL cholesterol  $\geq 190$  mg/dL in patients under age 20.

### 1.5 Diagnosis

- 1.5.1 Age at onset of CHD, even if approximate, is particularly important to note in the family history.
- 1.5.2 Physical signs of FH are insensitive but can be quite specific. The presence of tendon xanthomas should be sought for by careful palpation (not just visual inspection) of the Achilles tendon and finger extensor tendons. Corneal arcus (partial or complete) is only indicative of FH if present under age 45. Neither xanthelasma nor tuberos xanthomas are specific for FH but, if they are encountered in a younger patient, FH should be considered. Importantly, the absence of any of these physical findings does not rule out FH.
- 1.5.3 Formal clinical diagnosis of FH can be made by applying any one of several validated sets of criteria [U.S. Make Early Diagnosis Prevent Early Death (MEDPED), Dutch Lipid Clinic Network, Simon-Broome Registry]. It should be noted that LDL cholesterol cut points usually vary with age.
- 1.5.4 The clinical diagnosis of FH is most likely when two or more first-degree relatives are found to have elevated LDL cholesterol in the range noted above, when pediatric cases are identified in the family, or when the patient or a close relative has tendon xanthomas.
- 1.5.5 Once a family is diagnosed with FH, somewhat lower LDL cholesterol cut points can be applied to identify additional affected family members.
- 1.5.6 Patients with FH occasionally have elevated triglycerides, and high triglycerides should not exclude the diagnosis of FH.

## 1.6 Genetic screening

- 1.6.1 Genetic screening for FH is generally not needed for diagnosis or clinical management but may be useful when the diagnosis is uncertain.
- 1.6.2 Identification of a causal mutation may provide additional motivation for some patients to implement appropriate treatment.
- 1.6.3 Importantly, a negative genetic test does not exclude FH, since approximately 20% of clinically definite FH patients will not be found to have a mutation despite an exhaustive search using current methods.

## 1.7 Cascade screening

- 1.7.1 Cascade screening involves testing lipid levels in all first-degree relatives of diagnosed FH patients.
- 1.7.2 As cascade screening proceeds, newly identified FH cases provide additional relatives who should be considered for screening.
- 1.7.3 Cascade screening is the most cost-effective means of finding previously undiagnosed FH patients and is also cost-effective in terms of cost per year of life saved. General population screening of a young population (before age 16) is similarly cost-effective in terms of cost per year of life saved, given that effective cholesterol-lowering treatment is begun in all those identified.

## 2. Adult treatment recommendations and evidence for treatment

### 2.1 Rationale for treatment

- 2.1.1 Individuals with FH have a very high lifetime risk of CHD and are at very high risk of premature onset CHD.
- 2.1.2 Early treatment is highly beneficial. Long-term drug therapy of patients with FH can substantially reduce or remove the excess lifetime risk of CHD due to the genetic disorder and can lower CHD event rates in FH patients to levels similar to those of the general population.
- 2.1.3 FH requires lifelong treatment and regular follow-up.

### 2.2 Treatment

- 2.2.1 Both children and adults with LDL cholesterol  $\geq 190$  mg/dL [or non-high-density lipoprotein (HDL) cholesterol  $\geq 220$  mg/dL] after lifestyle changes will require drug therapy.
- 2.2.2 For adult FH patients ( $\geq 20$  years of age), drug treatment to achieve an LDL cholesterol reduction  $\geq 50\%$  should be initiated.
- 2.2.3 Statins should be the initial treatment for all adults with FH.

## 2.3 Intensified drug treatment

- 2.3.1 Higher risk patients may need intensification of drug treatment to achieve more aggressive treatment goals (LDL cholesterol  $< 100$  mg/dL and non-HDL cholesterol  $< 130$  mg/dL).
- 2.3.2 Any of the following places FH patients at higher CHD risk: clinically evident CHD or other atherosclerotic cardiovascular disease, diabetes, a family history of very early CHD (in men  $< 45$  years of age and women  $< 55$  years of age), current smoking, two or more CHD risk factors, or high lipoprotein (a)  $\geq 50$  mg/dL using an isoform insensitive assay.
- 2.3.3 In FH patients without any of the characteristics listed above, intensification of drug therapy may be considered if LDL cholesterol remains  $\geq 160$  mg/dL (or non-HDL cholesterol  $\geq 190$  mg/dL), or if an initial 50% reduction in LDL cholesterol is not achieved.
- 2.3.4 Ezetimibe, niacin, and bile acid sequestrants are reasonable treatment options for intensification of therapy, or for those intolerant of statins.
- 2.3.5 The potential benefit of multidrug regimens for an individual patient should be weighed against the increased cost and potential for adverse effects and decreased adherence.

## 2.4 Risk factors should be aggressively treated

- 2.4.1 Risk factors are the same in FH as in the general population and require aggressive management to reduce CHD risk, with special attention to smoking cessation.
- 2.4.2 Regular physical activity, a healthy diet and weight control should be emphasized.
- 2.4.3 Blood pressure should be treated to  $< 140/90$  mm Hg (or  $< 130/80$  mm Hg in those with diabetes). Low dose aspirin (75-81 mg per day) should be considered in those at high CHD or stroke risk.

## 2.5 Risk stratification algorithms should not be used

- 2.5.1 Individuals with FH are at high CHD risk. The 10-year CHD risk in the FH patient is not adequately predicted by any conventional risk assessment tools. Therefore, assessment of 10-year risk is not recommended.
- 2.5.2 All FH patients require lifestyle management, and very few will not require lipid-lowering drug therapy.

## 2.6 Consider referral to a lipid specialist

- 2.6.1 Consider referral to a lipid specialist with expertise in FH if LDL cholesterol concentrations are not reduced by  $\geq 50\%$  or if patients are at high risk.
- 2.6.2 Cascade testing of first-degree relatives should be offered to all individuals with FH.

### 3. Management issues in pediatrics

#### 3.1 Screening

- 3.1.1 Universal screening at age 9 to 11 years with a fasting lipid profile or nonfasting non-HDL cholesterol measurement is recommended to identify all children with FH. This age identifies individuals at the potential onset of advanced atherosclerosis, and provides the best discrimination between those with and without inherited dyslipidemias by avoiding confounding due to changes in lipid levels associated with puberty.
- 3.1.2 If a nonfasting non-HDL cholesterol concentration of  $\geq 145$  mg/dL is detected, then a fasting lipid profile should be performed.
- 3.1.3 Screening should occur earlier ( $\geq 2$  years of age) in the presence of a positive family history for hypercholesterolemia or premature CHD or the presence of other major CHD risk factors.
- 3.1.4 Identifying FH in someone with other major CHD risk factors is critical for risk stratification.
- 3.1.5 Evaluation (history, physical examination, selected laboratory tests) of possible secondary causes of dyslipidemia should be performed. Secondary causes include hypothyroidism, nephrotic syndrome, and liver disease.

#### 3.2 Diagnosis

- 3.2.1 Untreated fasting lipid levels at which FH may be suspected in children, adolescents and young adults ( $< 20$  years) are LDL cholesterol concentration  $\geq 160$  mg/dL or non-HDL cholesterol  $\geq 190$  mg/dL. These levels are supported by family studies of affected individuals.
- 3.2.2 A second lipid profile should be performed to assess response to diet management, to account for regression to the mean, and to accurately classify those with levels close to classification thresholds.

#### 3.3 Lipid specialists

- 3.3.1 Primary care clinicians should be responsible for screening and diagnosis.
- 3.3.2 For treatment of children with FH, either consultation with or referral to a lipid specialist is recommended. Pediatric lipid specialists include pediatric cardiologists, endocrinologists, or other health care providers with specialized lipidology training. Use of lipid lowering medications is currently not typically part of pediatric training.
- 3.3.3 Homozygous FH should always be managed by a lipid specialist.

#### 3.4 Cardiovascular risk assessment

- 3.4.1 Comprehensive CHD risk assessment [including measurement of lipoprotein (a) levels] and management is critical. The presence of multiple

CHD risk factors is associated with dramatic acceleration of atherosclerosis development.

- 3.4.2 Primordial prevention, which includes counseling for the prevention of risk development (not smoking, low saturated fat diet, appropriate caloric intake and regular physical activity supporting the avoidance of diabetes), is an important component of treatment of patients with FH.

#### 3.5 Treatment in children

- 3.5.1 Statins are preferred for initial pharmacologic treatment in children after initiation of diet and physical activity management.
- 3.5.2 Consideration should be given to starting treatment at the age of 8 years or older. In special cases, such as those with homozygous FH, treatment might need to be initiated at earlier ages.
- 3.5.3 Clinical trials with medium term follow up suggest safety and efficacy of statins in children.
- 3.5.4 The treatment goal of lipid lowering therapy in pediatric FH patients is a  $\geq 50\%$  reduction in LDL cholesterol or LDL cholesterol  $< 130$  mg/dL. There is a need in treatment of pediatric FH for balance between increased dosing and the potential for side effects vs. achieving goals. More aggressive LDL cholesterol targets should be considered for those with additional CHD risk factors.

#### 3.6 Homozygous FH

- 3.6.1 Initiation of therapy early in life and ongoing monitoring of homozygous FH is vital.
- 3.6.2 High dose statins may be effective in some homozygous FH patients, but the majority will require LDL apheresis. Liver transplantation is also being used in some centers.
- 3.6.3 Gene therapy is a potential new treatment in development and may be particularly beneficial for homozygous FH patients.

### 4. Management issues in adults

#### 4.1 Lifestyle modifications

- 4.1.1 Patients with FH should be counseled regarding the following lifestyle modifications:
  - Therapeutic Lifestyle Changes and dietary adjuncts.
    - Reduced intakes of saturated fats and cholesterol: total fat 25-35% of energy intake, saturated fatty acids  $< 7\%$  of energy intake, dietary cholesterol  $< 200$  mg/d.
    - Use of plant stanol or sterol esters 2 g/d.
    - Use of soluble fiber 10-20 g/d.
  - Physical activity and caloric intake to achieve and maintain a healthy body weight.
  - Limitation of alcohol consumption.
  - Emphatic recommendation to avoid use of any tobacco products.

- 4.1.2 Clinicians are encouraged to refer patients to registered dietitians or other qualified nutritionists for medical nutrition therapy.

#### 4.2 Drug treatment of FH

- 4.2.1 For adult FH patients, initial treatment is the use of moderate to high doses of high-potency statins titrated to achieve an LDL cholesterol reduction  $\geq 50\%$  from baseline. Low potency statins are generally inadequate for FH patients.
- 4.2.2 If the initial statin is not tolerated, consider changing to an alternative statin, or every-other-day statin therapy.
- 4.2.3 If initial statin therapy is contraindicated or poorly tolerated, ezetimibe, a bile acid sequestrant (colesevelam), or niacin may be considered.
- 4.2.4 For patients who cannot use a statin, most will require combination drug therapy.

#### 4.3 Additional treatment considerations

- 4.3.1 If the patient is not at LDL cholesterol treatment goal with the maximum available and tolerable dose of statin, then combine with ezetimibe, niacin, or a bile acid sequestrant (colesevelam preferred).
- 4.3.2 Decisions regarding selection of additional drug combinations should be based on concomitant risk factors for myopathy, concomitant medications, and the presence of other disease conditions and lipid abnormalities.

#### 4.4 Candidates for LDL apheresis

- 4.4.1 LDL apheresis is a U.S. Food and Drug Administration approved medical therapy for patients who are not at LDL cholesterol treatment goal or who have ongoing symptomatic disease.
- 4.4.2 In patients who, after six months, do not have an adequate response to maximum tolerated drug therapy, LDL apheresis is indicated according to these guidelines:
- Functional homozygous FH patients with LDL cholesterol  $\geq 300$  mg/dL (or non-HDL-C  $\geq 330$  mg/dL).
  - Functional heterozygous FH patients with LDL cholesterol  $\geq 300$  mg/dL (or non-HDL-C  $\geq 330$  mg/dL) and 0-1 risk factors.
  - Functional heterozygous FH patients with LDL cholesterol  $\geq 200$  mg/dL (or non-HDL-C  $\geq 230$  mg/dL) and high risk characteristics such as  $\geq 2$  risk factors or high lipoprotein (a)  $\geq 50$  mg/dL using an isoform insensitive assay.
  - Functional heterozygotes with LDL cholesterol  $\geq 160$  mg/dL (or non-HDL-C  $\geq 190$  mg/dL) and very high-risk characteristics (established CHD, other cardiovascular disease, or diabetes).

#### 4.5 LDL apheresis referrals

- 4.5.1 Healthcare practitioners should refer candidates for LDL apheresis to qualified sites. Self-referrals are also possible. A list of sites qualified to perform LDL apheresis is in development and will be posted on the National Lipid Association website ([www.lipid.org](http://www.lipid.org)).

#### 4.6 Women of childbearing age

- 4.6.1 Women with FH should receive pre-pregnancy counseling and instructions to stop statins, ezetimibe, and niacin at least four weeks before discontinuing contraception and should not use these medications during pregnancy and lactation.
- 4.6.2 Consultation with her healthcare practitioner regarding continuation of any other lipid medications is recommended.
- 4.6.3 In case of unintended pregnancy, a woman with FH should discontinue statins, ezetimibe, and niacin immediately and should consult with her healthcare practitioner promptly.

#### 4.7 Treatment options during pregnancy

- 4.7.1 Statins, ezetimibe, and niacin should not be used during pregnancy. Use of other lipid lowering medications (e.g., colesevelam) may be considered under the guidance of the healthcare practitioner.
- 4.7.2 Consider LDL apheresis during pregnancy if there is significant atherosclerotic disease or if the patient has homozygous FH.

#### 4.8 Hard to manage patients

- 4.8.1 If other treatment options are inadequate or the FH patient cannot tolerate pharmacotherapy or LDL apheresis, other treatment options include ileal bypass and liver transplantation (both are used rarely), and, potentially, new drugs in development.

### 5. Future issues, public policy, and public awareness

#### 5.1 Screening

- 5.1.1 It is the responsibility of all primary health care providers and relevant specialists to screen all children and adults for hypercholesterolemia, and to initiate therapy in patients with FH and severe hypercholesterolemia.

#### 5.2 Lipid specialists

- 5.2.1 Patients with FH who do not respond adequately to, or are intolerant of, initial statin therapy should be referred to a lipid specialist.
- 5.2.2 For children with FH, either consultation with or referral to a lipid specialist is recommended.
- 5.2.3 Patients who are candidates for more intensive therapy, or who have family histories of very

premature CHD (in men <45 years of age and women <55 years of age), should also be referred to a lipid specialist.

### 5.3 Payers

- 5.3.1 Patients with FH are at high lifetime risk of atherosclerotic cardiovascular disease and appropriate therapy is required.
- 5.3.2 Payers should cover initial screening, initiation of therapy with appropriate medications, and monitoring of response to therapy.
- 5.3.3 Payers should cover appropriate drugs including high potency statins and combination lipid drug therapy. They should also cover other drugs and combinations for patients with statin tolerance problems.
- 5.3.4 LDL apheresis and genetic testing, when appropriate, should be covered by payers.

### 5.4 Public and provider awareness

- 5.4.1 To promote early diagnosis of FH and the prevention, and treatment of CHD, public awareness of FH needs to be increased by a variety of methods.
- 5.4.2 Health care provider awareness needs to be increased through education at all levels and in multiple specialties, through partnering with professional organizations and through local, national and international health agencies.

### 5.5 Responsibility for education

- 5.5.1 Health systems, hospitals, pharmacy benefits management organizations, and insurance companies should contribute to patient and provider education.
- 5.5.2 Governmental agencies and other policy makers at local, state, national and international levels should be engaged in efforts to screen and treat FH.

### 5.6 Research needs

- 5.6.1 Research is needed in the following areas related to FH:
  - Agents to further lower LDL cholesterol;
  - Ways to improve adherence to and persistence with therapy;
  - Cost effective genetic screening;
  - Behavioral management of patients with FH;
  - Cost effectiveness analysis of various approaches to screening and treatment;
  - Cost effectiveness analysis of the benefits of aggressive therapy;
  - Long-term follow-up of patients with FH, including safety of long-term therapy with lipid lowering drugs;
  - Differences in drug metabolism by gender, ethnicity, and age;

- Long-term cardiovascular benefits of combination therapies;
- Management of FH in pregnancy;
- Mechanism and management of statin intolerance;
- Safety and effectiveness of dietary supplements and dietary adjuncts for LDL cholesterol reduction;
- Methods to enhance healthcare provider adherence to guidelines.

### 5.7 Funding

- 5.7.1 Funding for FH education and research should come from multiple sources including government, professional associations, industry, and private donations.

## Concluding statements

FH is a difficult to treat but manageable disease. Primary care clinicians should be aware of the key role they play in the early detection and treatment of FH, and of the availability of additional support and guidance from lipid specialists who have undergone intensive training in the management of lipid disorders. Key elements for control of FH include reducing the LDL cholesterol concentration, management of additional CHD risk factors, such as elevated blood pressure and smoking, and improving adherence to and persistence with lifestyle modifications and pharmacotherapy. Screening first-degree relatives of patients with FH, including siblings, parents and children, facilitates early detection and treatment. Long-term drug therapy of patients with FH significantly reduces or removes the excess lifetime risk of CHD, lowering the level of risk to that of the general population.

## Acknowledgments

The paper, “Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients—Clinical Guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia” has been endorsed by the American Society for Preventive Cardiology, Association of Black Cardiologists, International Cholesterol Foundation, and the Preventive Cardiovascular Nurses Association.

The authors would like to thank Mary R. Dicklin, PhD, and Kevin C. Maki, PhD, for writing and editorial assistance.

## Industry support disclosure

The January 2011 NLA FH recommendations conference was supported by unrestricted grant funding from the following companies: Abbott Laboratories, Aegerion Pharmaceuticals, Daiichi Sankyo, Genzyme, Kaneka Pharma America LLC, and Merck & Co. The National Lipid

Association would like to thank each company for its support of this endeavor. In accordance with the National Lipid Association Code for Interactions with Companies, the NLA maintained full control over the planning, content, quality, scientific integrity, implementation, and evaluation of the recommendations conference and this familial hypercholesterolemia recommendations paper. All related activities are free from commercial influence and bias.

## Author disclosures

Dr. Ballantyne has received honoraria related to consulting from Abbott Laboratories, Adnexus Therapeutics, Amlylin Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Esperion, Genentech, GlaxoSmithKline, Idera Pharmaceuticals, Kowa Pharmaceuticals, Merck & Co., Novartis, Omthera, Resverlogix, Roche/Genentech, Sanofi-Synthelabo, and Takeda Pharmaceuticals. Dr. Ballantyne has received research grants from Abbott Laboratories, American Diabetes Association, American Heart Association, AstraZeneca, Bristol-Myers Squibb, diaDexus, GlaxoSmithKline, Kowa Pharmaceuticals, Merck & Co., National Institutes of Health, Novartis, Roche/Genentech, Sanofi-Synthelabo, and Takeda Pharmaceuticals. Dr. Ballantyne has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, and Merck & Co.

Dr. Cromwell has received honoraria related to consulting from Isis Pharmaceuticals, LabCorp, and Health Diagnostics Laboratory. Dr. Cromwell has received research grants from Isis Pharmaceuticals. Dr. Cromwell has received honoraria related to speaking from Abbott Laboratories, LipoScience Inc., Merck & Co., and Merck Schering Plough.

Dr. Daniels has received honoraria related to consulting from Merck & Co.

Dr. de Ferranti has received research grants from GlaxoSmithKline.

Dr. Gidding has received honoraria related to consulting from Merck & Co. Dr. Gidding has received research grants from GlaxoSmithKline.

Dr. Goldberg has received honoraria related to consulting from Roche/Genentech, ISIS-Genzyme and Merck & Co. Dr. Goldberg has received research grants from Amarin, Abbott Laboratories, GlaxoSmithKline, ISIS-Genzyme Corporation, Merck & Co., Novartis, and Regeneron.

Dr. Hopkins has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, and Merck & Co. Dr. Hopkins has received research grants from Takeda Pharmaceuticals.

Dr. Ito has received honoraria related to consulting from Daiichi Sankyo. Dr. Ito has received honoraria related to speaking from Abbott Laboratories, Kowa Pharmaceuticals, and Merck & Co.

Dr. McGowan has received honoraria related to consulting from Genzyme Corporation and Abbott Laboratories. Dr. McGowan has received honoraria related to speaking from Merck Schering Plough and GlaxoSmithKline.

Dr. Moriarty has received honoraria related to speaking from Abbott Laboratories and Merck & Co. Dr. Moriarty has received honoraria related to consulting from B. Braun USA.

Dr. Rader has received honoraria related to consulting from AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Isis Pharmaceuticals, Novartis, Johnson & Johnson, Eli Lilly and Co., Novartis, Merck & Co., and Resverlogix. Dr. Rader has served on an advisory board for Aegerion.

Dr. Robinson has received research grants from Abbott Laboratories, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Hoffman LaRoche, Merck & Co., Merck Schering Plough, and Spirocor.

Ms. Ross has received honoraria related to consulting from Kaneka America and Genzyme Corporation. Ms. Ross has received honoraria related to speaking from Abbott Laboratories, Kaneka America, Kowa Pharmaceuticals, and Sanofi-Aventis.

Dr. Toth has received honoraria related to consulting from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Kowa Pharmaceuticals, Pfizer Inc., and Merck & Co. Dr. Toth has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer Inc., Merck & Co., and Takeda Pharmaceuticals.

Dr. Ziajka has received honoraria related to speaking from Abbott Laboratories, AstraZeneca and Merck & Co. Dr. Ziajka has received research grants from Genzyme Corporation.

## References

- Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial Hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol.* 2011;5(3 suppl):S9-S17.
- Robinson JG, Goldberg AC. Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol.* 2011;5(3 suppl):S18-S29.
- Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of Familial Hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol.* 2011;5(3 suppl):S30-S37.
- Ito MK, McGowan MP, Moriarty PM. Management of Familial Hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol.* 2011;5(3 suppl):S38-S45.
- Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE. Future issues, public policy, and public awareness of Familial Hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol.* 2011;5(3 suppl):S46-S51.

# Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Paul N. Hopkins, MD, MSPH, FNLA\*, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA

*University of Utah School of Medicine, Salt Lake City, UT, USA (Dr. Hopkins); University of Illinois School of Medicine, Peoria, IL, USA (Dr. Toth); Baylor College of Medicine, Houston, TX, USA (Dr. Ballantyne); and University of Pennsylvania School of Medicine, Philadelphia, PA, USA (Dr. Rader)*

## Introduction

Familial hypercholesterolemia (FH) may be the most common serious genetic condition and is a well-known and frequent cause of premature coronary heart disease (CHD). About 5% of heart attacks under age 60 and as many as 20% under age 45 are due to FH.<sup>1–9</sup> Too often, FH is diagnosed after the occurrence of a major coronary event; hence a population-based approach to identify affected individuals prior to the discovery of atherosclerosis is clearly

warranted.<sup>10</sup> Implementation of appropriate screening can lead to early detection, diagnosis, and treatment of FH and makes a huge impact on the prevention of CHD and related detrimental sequelae.<sup>11,12</sup>

## Definition of Familial Hypercholesterolemias

The FH ([www.ncbi.nlm.nih.gov/sites/GeneTests](http://www.ncbi.nlm.nih.gov/sites/GeneTests)) are defined as a group of inherited genetic defects resulting in severely elevated serum cholesterol concentrations. FH is recognized clinically by an extreme elevation of low-density lipoprotein (LDL) cholesterol, which is characterized by an autosomal dominant or co-dominant transmission pattern with 90% or higher penetrance.<sup>13,14</sup> The vast majority of families show only dominant transmission with heterozygous carriage of the causal gene. FH is, however, a co-dominant trait with the rare low-density lipoprotein receptor (*LDLR*) homozygote or compound heterozygote having extreme elevations in LDL cholesterol. In the Fredrickson classification, FH patients are most often type IIa, but IIb, and even type III hyperlipidemias may be seen.<sup>15–18</sup> Affected subjects are at increased risk for all forms of atherosclerotic disease and premature death secondary to lifelong pathogenic elevations in serum LDL cholesterol.<sup>18</sup>

**National Lipid Association Expert Panel on Familial Hypercholesterolemia:** Anne C. Goldberg, MD, FNLA, Chair, Paul N. Hopkins, MD, MSPH, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA, Jennifer G. Robinson, MD, MPH, FNLA, Stephen R. Daniels, MD, PhD, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH, Matthew K. Ito, PharmD, FNLA, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA.

\* Corresponding author: Paul N. Hopkins, MD, MSPH, FNLA, Professor of Internal Medicine, Co-Director, Cardiovascular Genetics Research, Director, Cardiovascular Disease Prevention Clinic, 420 Chipeta Way, Room 1160, Salt Lake City, UT 84108. Tel: 801-585-5592; Fax: 801-581-6862.

E-mail address: [paul.hopkins@utah.edu](mailto:paul.hopkins@utah.edu)

Submitted March 28, 2011. Accepted for publication March 29, 2011.

## Summary Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

### Definition of Familial Hypercholesterolemias

- The familial hypercholesterolemias are a group of inherited genetic defects resulting in severely elevated serum cholesterol concentrations.
- For purposes of this document, familial hypercholesterolemia (FH) will refer to the autosomal dominant forms of severe hypercholesterolemia unless otherwise specified. However, causes of inherited high cholesterol are not restricted to autosomal dominant FH.

### Prevalence of FH and Associated Risk

- The prevalence of FH is 1 in 300 to 500 in many populations, making FH among the most common of serious genetic disorders.
- There are approximately 620,000 FH patients currently living in the United States.
- The risk of premature coronary heart disease (CHD) is elevated about 20-fold in untreated FH patients.
- Approximately 1 in one million persons is homozygous (or compound heterozygous) for low-density lipoprotein receptor gene (*LDLR*) mutations and has extreme hypercholesterolemia with rapidly accelerated atherosclerosis when left untreated.
- In a few populations (such as French Canadians and Dutch Afrikaners), the prevalence of FH may be as high as 1 in 100.

### Genetics of FH

- Currently, known causes of FH include mutations in the *LDLR*, apolipoprotein (Apo) B (*APOB*), or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) genes.
- There are over 1600 known mutations of the *LDLR* gene documented to cause FH at the time of this writing, accounting for about 85 to 90% of FH cases.
- The Arg3500Gln mutation in *APOB* is the most common cause of hypercholesterolemia due to an *APOB* mutation, accounting for 5 to 10% of FH cases in Northern European populations (rare in other populations).
- Gain-of-function mutations in *PCSK9* cause fewer than 5% of cases in most studies.

### Screening for FH

- Universal screening for elevated serum cholesterol is recommended. FH should be suspected when untreated, fasting LDL cholesterol or non-high-density lipoprotein (HDL) cholesterol levels are at or above the following:
  - Adults ( $\geq 20$  years): LDL cholesterol  $\geq 190$  mg/dL or non-HDL cholesterol  $\geq 220$  mg/dL;
  - Children, adolescents and young adults ( $< 20$  years): LDL cholesterol  $\geq 160$  mg/dL or non-HDL cholesterol  $\geq 190$  mg/dL.
- For all individuals with these levels, a family history of high cholesterol and heart disease in first-degree relatives should be collected. The likelihood of FH is higher in individuals with a positive family history of hypercholesterolemia or of premature CHD (onset in men before age 55 years and women before age 65 years).
- Cholesterol screening should be considered beginning at age 2 for children with a family history of premature cardiovascular disease or elevated cholesterol. All individuals should be screened by age 20.
- Although not present in many individuals with FH, the following physical findings should prompt the clinician to strongly suspect FH and obtain necessary lipid measurements if not already available:
  - Tendon xanthomas at any age (most common in Achilles tendon and finger extensor tendons, but can also occur in patellar and triceps tendons).
  - Arcus corneae in a patient under age 45.
  - Tuberos xanthomas or xanthelasma in a patient under age 20 to 25.
- At the LDL cholesterol levels listed below the probability of FH is approximately 80% in the setting of general population screening. These LDL cholesterol levels should prompt the clinician to *strongly* consider a diagnosis of FH and obtain further family information:
  - LDL cholesterol  $\geq 250$  mg/dL in a patient aged 30 or more;
  - LDL cholesterol  $\geq 220$  mg/dL for patients aged 20 to 29;
  - LDL cholesterol  $\geq 190$  mg/dL in patients under age 20.

### Diagnosis

- Age at onset of CHD, even if approximate, is particularly important to note in the family history.
- Physical signs of FH are insensitive but can be quite specific. The presence of tendon xanthomas should be sought for by careful palpation (not just visual inspection) of the Achilles tendon and finger extensor tendons. Corneal arcus

(partial or complete) is only indicative of FH if present under age 45. Neither xanthelasma nor tuberous xanthomas are specific for FH but, if they are encountered in a younger patient, FH should be considered. Importantly, the absence of any of these physical findings does not rule out FH.

- Formal clinical diagnosis of FH can be made by applying any one of several validated sets of criteria [U.S. Make Early Diagnosis Prevent Early Death (MEDPED), Dutch Lipid Clinic Network, Simon-Broome Registry]. It should be noted that LDL cholesterol cut points usually vary with age.
- The clinical diagnosis of FH is most likely when two or more first-degree relatives are found to have elevated LDL cholesterol in the range noted above, when pediatric cases are identified in the family, or when the patient or a close relative has tendon xanthomas.
- Once a family is diagnosed with FH, somewhat lower LDL cholesterol cut points can be applied to identify additional affected family members.
- Patients with FH occasionally have elevated triglycerides and high triglycerides should not exclude the diagnosis of FH.

### Genetic Screening

- Genetic screening for FH is generally not needed for diagnosis or clinical management but may be useful when the diagnosis is uncertain.
- Identification of a causal mutation may provide additional motivation for some patients to implement appropriate treatment.
- Importantly, a negative genetic test does not exclude FH, since approximately 20% of clinically definite FH patients will not be found to have a mutation despite an exhaustive search using current methods.

### Cascade Screening

- Cascade screening involves testing lipid levels in all first-degree relatives of diagnosed FH patients.
- As cascade screening proceeds, newly identified FH cases provide additional relatives who should be considered for screening.
- Cascade screening is the most cost-effective means of finding previously undiagnosed FH patients and is also cost-effective in terms of cost per year of life saved. General population screening of a young population (before age 16) is similarly cost-effective in terms of cost per year of life saved, given that effective cholesterol-lowering treatment is begun in all those identified.

Heterozygous FH is caused by an inherited mutation from one parent only. Defective LDL receptors have either zero or a reduced capacity for LDL cholesterol uptake, which results in approximately twice the normal concentration of LDL cholesterol. Children of one heterozygote parent carrying the faulty gene have a 50% chance of inheriting it. In this document, use of the term FH refers to autosomal dominant heterozygous FH unless otherwise specified. However, causes of inherited high cholesterol are not restricted to autosomal dominant FH. Genetic defects classified as FH include defects in the LDLR, apolipoprotein B (Apo B), proprotein convertase subtilisin/kexin type 9 (PCSK9), and autosomal recessive hypercholesterolemia.

Children with two heterozygote FH carrier parents have a 25% chance of inheriting both defective genes and therefore developing homozygous FH. There is a gene dosage effect with homozygotes having markedly greater elevations of LDL cholesterol and earlier CHD onset than subjects who are heterozygotes.<sup>19</sup> Homozygous FH is diagnosed when a person inherits exactly the same genetic mutation from both parents, whereas a person who inherits a different mutation from each parent will have compound heterozygous FH. Each of these defects leads to almost no LDL receptor activity, extremely high levels of LDL cholesterol, frequent and large tendon xanthomas, tuberous xanthomas, and a much greater probability of early onset CHD with an unusual

predilection for the coronary ostia, as well as valvular disease caused by xanthoma-like lesions.

### Prevalence of FH and associated risk

According to the Centers for Disease Control and Prevention, based on data from the 2005 to 2008 National Health and Nutrition Examination Survey, there are an estimated 71 million (33.5%) adults in the United States aged  $\geq 20$  years with high LDL cholesterol.<sup>20</sup> These estimates include all persons with LDL cholesterol levels above recommended National Cholesterol Education Program goals, persons who report taking cholesterol-lowering medications, and all etiologies for hypercholesterolemia (e.g., obesity, uncontrolled hypothyroidism). The CDC report states that high LDL cholesterol increases with age with a prevalence of 11.7%, 41.2%, and 58.2% for ages 20 to 39, 40 to 64, and  $\geq 65$  years, respectively.<sup>20</sup>

Heterozygous FH occurs with a frequency of about 1 in every 300 to 500 people and is therefore one of the most commonly occurring congenital metabolic disorders.<sup>2,21,22</sup> Based on this estimate there are approximately 10 million people with FH worldwide. There are some populations with a much higher prevalence of FH, perhaps as high as 1 in 50 to 100 in communities with a 'founder gene',

such as Christian Lebanese, French-Canadians, and three populations in South Africa including Dutch Afrikaner, Ashkenazi Jews, and Asian Indians.<sup>21,23</sup> Because those with heterozygous FH have only one normal gene, resulting in half the normal number of LDL receptors, their hepatocytes take up LDL cholesterol at approximately one-half the rate of those unaffected. Average, untreated LDL cholesterol levels are about 220 mg/dL in those with FH and serum total cholesterol levels are often in the range of 350-550 mg/dL; the risk of premature CHD is elevated about 20-fold without treatment.<sup>10,24</sup> The excess risk for CHD has been estimated to be as high as 100-fold in untreated young men with FH.<sup>23</sup> The CHD risk in women with FH is lower than in FH men, and CHD development usually occurs about ten years later in women compared to men. Approximately 50% of males and at least 30% of females with FH will suffer fatal or non-fatal coronary events before ages 50 and 60 years, respectively.<sup>25</sup>

Homozygous FH occurs in approximately 1 of every 1 million people and, due to a near total or total loss of LDL receptor functionality, cholesterol levels range from 650 to 1000 mg/dL.<sup>21</sup> These patients develop rapidly accelerated atherosclerosis when left untreated. Patients with homozygous FH typically develop CHD by the second decade of life<sup>26</sup>, but death may occur in the first years of life from severe CHD.<sup>22</sup>

## The genetics of Familial Hypercholesterolemias

FH is most commonly attributable to mutations (including deletion, missense, nonsense, and insertion types) in the *LDLR* gene, resulting in LDL receptors having functional reductions (partial to complete) in the capacity to clear LDL cholesterol from the circulation. Patients can be receptor negative, expressing little to no LDL receptor activity, or receptor defective, leading to the expression of *LDLR* isoforms with reduced affinity for LDL on the hepatocyte surface.<sup>27-32</sup> There are five major classes of *LDLR* defects:<sup>30,31</sup>

- Class I: LDL receptor is not synthesized at all.
- Class II: LDL receptor is not properly transported from the endoplasmic reticulum to the Golgi apparatus for expression on the cell surface.
- Class III: LDL receptor does not properly bind LDL on the cell surface because of a defect in either apolipoprotein (Apo) B-100 (R3500Q) or in the LDL receptor.
- Class IV: LDL receptor bound to LDL does not properly cluster in clathrin-coated pits for receptor-mediated endocytosis.
- Class V: LDL receptor is not recycled back to the cell surface.

The gene for *LDLR* resides on the short arm of chromosome 19 (19p13.1-13.3). There are over 1600 mutations of the *LDLR* gene documented to cause FH at the time of this writing. These account for about 85 to 90% of FH cases.<sup>33</sup>

A large number of *LDLR* mutations have been catalogued from around the world and resources listing these are available on the web (see websites at the end of the references).

Hypercholesterolemia due to an *APOB* mutation is referred to as Familial Defective Apo B (FDB).<sup>34-36</sup> FDB is reportedly less severe than typical FH caused by *LDLR* mutations.<sup>37,38</sup> The most common mutation *APOB* mutation is Arg3500Gln, accounting for 5 to 10% of FH cases in northern European populations (rare in other populations).<sup>33</sup>

Another etiology for the FH phenotype is autosomal dominant hypercholesterolemia attributable to increased activity of PCSK9, which increases degradation of the LDL receptor.<sup>39,40</sup> This is the least common cause of FH, accounting for fewer than 5% of cases in most series.<sup>33</sup> The causal gene, whether *LDLR*, *Apo B*, or *PCSK9*, cannot be determined clinically.

Autosomal recessive hypercholesterolemia has been attributed to reduced expression of the LDL receptor accessory protein 1 (*LDLRAP1*) that facilitates the association of LDL receptors with clathrin in cell surface coated pits.<sup>41-43</sup> Other rare forms of autosomal recessive hypercholesterolemia include sitosterolemia due to adenosine triphosphate (ATP)-binding cassette subfamily G member 5 (*ABCG5*) or *ABCG8* deficiency,<sup>44</sup> and deficiency of cholesterol 7- $\alpha$  hydroxylase (*CYP7A1*), which is the enzyme of the first step in bile acid synthesis, resulting in high intrahepatic cholesterol and reduced surface expression of LDL receptors. *CYP7A1* deficiency is the least common of the autosomal recessive conditions that can cause severe hypercholesterolemia.<sup>43</sup>

Inherited high cholesterol may include other forms of hypercholesterolemia such as type III and familial combined hyperlipidemias, as well as polygenic hypercholesterolemia and mutations or variants in genes not yet identified.

## Universal screening

All primary healthcare providers and relevant specialists are responsible for screening all children and adults for hypercholesterolemia and initiating therapy in patients with FH and other forms of severe hypercholesterolemia. Family history of high cholesterol and/or premature history of CHD in first-degree relatives (men <55 years of age and women <65 years of age) warrants suspicion of FH. Asking about early heart attacks or other coronary events in second degree relatives is also helpful, particularly in young patients. Universal screening at ages 9 to 11 years with a fasting lipid profile or non-fasting non-high-density lipoprotein (HDL) cholesterol measurement is recommended to identify all children with FH. At these young ages, LDL cholesterol discriminates those with and without FH particularly well.<sup>45</sup> Non-HDL cholesterol, which is a surrogate marker for Apo B-containing lipoprotein particles, is determined by subtracting HDL cholesterol from total cholesterol. A non-fasting non-HDL cholesterol result  $\geq 145$  mg/dL in a child indicates the need for follow-up and further evaluation of a fasting lipid profile. Screening should

occur earlier ( $\geq 2$  years of age) in the presence of a positive family history for hypercholesterolemia or premature CHD, or the presence of other major CHD risk factors. The importance of identifying FH in children with other CHD risk factors is critical for appropriate risk stratification and treatment. Screening before 2 years of age is not recommended.<sup>46</sup>

FH may be suspected in children, adolescents, or young adults when untreated fasting LDL cholesterol levels are  $\geq 160$  mg/dL or non-HDL cholesterol levels are  $\geq 190$  mg/dL. In adults  $>20$  years, FH is suspected when fasting LDL cholesterol levels are  $\geq 190$  mg/dL or non-HDL cholesterol is  $\geq 220$  mg/dL. In the general population, the probability of FH is approximately 80% when LDL cholesterol levels are  $\geq 250$  mg/dL in patients aged 30 years or more,  $\geq 220$  mg/dL in patients aged 20 to 29 years, and  $\geq 190$  mg/dL in patients younger than 20 years of age.<sup>47</sup>

The following physical findings should prompt the clinician to strongly suspect FH and obtain necessary lipid measurements if not already available:

- Tendon xanthomas at any age (most commonly in the Achilles tendon and finger extensor tendons but possibly in patellar and/or triceps tendons). These clinically detectable nodularities or areas of thickening of the tendons are caused by an infiltration of lipid-laden histiocytes (macrophages in connective tissue).
- Corneal arcus senilis in a patient less than 45 years of age.
- Yellow-orange tuberous xanthomas or xanthelasma in a patient aged 20 to 25 years.

## Diagnosis

When hypercholesterolemia is found, it is initially important to seek and exclude possible secondary causes of the disorder (e.g., undiagnosed diabetes, hypothyroidism, nephrotic syndrome).<sup>48</sup> Patient history should emphasize any prior diagnosis of CHD (with age at onset), current cardiovascular symptoms, use of lipid-altering agents, and presence of other CHD risk factors with particular attention to the family history of cardiovascular disease. Age at onset of CHD in family members, even if approximate, is important to note.

Although this is an area of some controversy, the diagnosis of FH is straightforward in a family with obvious bimodal distribution of LDL cholesterol with unaffected members of the family having LDL cholesterol generally under 130 mg/dL and affected members having levels approximately two-fold higher, typically  $>190$  to 220 mg/dL, depending on age. For any affected member of a pedigree, at least one of the parents will be affected. The diagnosis is certain if one of the family members or close relatives is confirmed to have a tendon xanthoma with high cholesterol.

Physical signs of FH are insensitive but can be quite specific. The presence of tendon xanthomas should be sought by careful palpation, not just visual inspection. They are most

commonly found in the Achilles tendons, less often in finger extensor tendons, and least often in the patellar tendon. Tendon xanthomas are essentially pathognomonic for FH; however, they occur in less than half of FH patients, and this seems to vary between populations. In a large group of Utah FH patients, prevalence was approximately equal to the patient's age minus 10, so that at age 30 years, prevalence is approximately 20 percent.<sup>49</sup> Tendon xanthomas are rare in younger children.<sup>50</sup> Achilles tendon xanthomas may be associated with tendinitis which occurs about six times more frequently among individuals with FH than among those in the general population.<sup>51</sup> Triglyceride-rich lipoprotein remnant accumulation, which occurs in some heterozygotes, infrequently leads to tuberous xanthomas.<sup>15,16</sup> In patients with homozygous FH, remnant accumulation is severe and tuberous xanthomas are frequent.<sup>21,52</sup> It is important to note that cerebrotendinous xanthomatosis, which is said to cause xanthomas, may be mistaken for FH, but does not cause hypercholesterolemia. Sitosterolemia can also cause tuberous and tendon xanthomas.<sup>53</sup> Corneal arcus (partial or complete) is only indicative of FH if present under age 45. Neither xanthelasma nor tuberous xanthomas are specific for FH but if they are encountered in a younger patient, FH should be considered. Importantly, the absence of any of these physical findings does not rule out FH.

The presence of hypertriglyceridemia does not exclude the diagnosis of FH. However, a calculated LDL cholesterol measurement is typically unsuitable for patients with triglycerides  $\geq 400$  mg/dL and a more accurate direct measure of LDL cholesterol may be necessary to ensure proper diagnosis. Furthermore, cholesterol exchange with triglyceride-rich particles may reduce the amount of cholesterol per particle, resulting in decreased sensitivity (under-recognition) for diagnosing FH.

A variety of approaches have been developed for formally diagnosing FH by applying any one of several validated sets of criteria.<sup>24,54</sup> The best characterized are the Simon Broome Register Diagnostic Criteria for FH,<sup>55</sup> the Dutch Lipid Clinic Network Diagnostic Criteria for FH<sup>54</sup> and the US Make Early Diagnosis Prevent Early Death (MEDPED) Program Diagnostic Criteria for FH.<sup>47,56</sup> It should be noted that LDL cholesterol cut points usually vary with age. They may also differ when considering diagnosis of an individual within a previously well-defined FH pedigree as opposed to a new proband without a prior diagnosis of FH in the family. When considering diagnosis in first-degree relatives of a patient with *definite* FH, keep in mind that LDL cholesterol levels are usually about two-fold higher in affected as compared to unaffected family members. Some experts suggest applying age-specific 90 to 95<sup>th</sup> percentile LDL cholesterol cutpoints when diagnosing relatives of known FH patients while other criteria utilize somewhat higher LDL cholesterol cutpoints. Note that in the general population, even if all FH were included among those in the 95<sup>th</sup> percentile for LDL cholesterol, only 1 in 25 would have FH. Random variation, dietary effects, and familial polygenic influences on LDL cholesterol

can cause false-positives and false-negatives when applying any of the clinical criteria.

For a newly identified proband not known to be part of a previously identified FH family, examples of criteria for clinical diagnosis of *definite* FH (consistent with several definitions) are available (See below and Table 1). For example, the US MEDPED rules require multiple affected pedigree members (statistically similar to showing bimodality) with a few exceptions described below. Additional rules for diagnosing *definite* as well as *probable* FH are provided in the formal definitions for each of the different criteria. A website is being planned that will facilitate and automate diagnosis of FH and provide additional information for education and management.

Utilizing LDL categories defined in Table 1, criteria which can be used to diagnose *definite* FH in an individual patient without any additional family information include:

- Presence of a causal mutation for FH by DNA testing together with category 1 to 2 LDL cholesterol levels.
- Presence of a tendon xanthoma with category 2 LDL cholesterol levels.
- Patient age <20 years with category 5 LDL cholesterol levels (no requirement for multiple affected family members). Only *probable* diagnosis of FH is made in older persons with category 5 LDL cholesterol levels without additional family information.

Criteria which can be used to diagnose *definite* FH in a newly identified family requiring data for two or more relatives include:

- Category 4 LDL cholesterol levels in one family member together with category 2 cholesterol levels in a first-degree relative. Only a “probable” diagnosis of FH can be made for category 4 cholesterol levels without additional family information.
- Any two first-degree relatives with category 3 LDL cholesterol levels.
- First-degree relatives of a “definite” FH case with category 2 LDL cholesterol levels.

DNA evidence affirming the presence of a causal mutation in the *LDLR*, *APOB*, or *PCSK9* genes is the gold standard for

diagnosis if, and only if, a mutation has already been identified for the family. Due to incomplete mutation detection in newly identified families, DNA testing may actually be less sensitive than standard clinical criteria.<sup>57</sup>

## Cascade screening

The process of family tracing for identification of people at risk of a genetic condition is called cascade screening and involves screening of family members.<sup>58</sup> Too few FH patients are diagnosed. In any given population it is estimated that approximately 20% of patients with FH are diagnosed and less than 10% of patients with FH receive appropriate treatment.<sup>23,58</sup> The most cost-effective strategy to diagnose patients with FH, initiated by the MEDPED program, is to screen close relatives of patients already diagnosed with FH.<sup>59–61</sup> Cascade screening involves testing lipid levels in all first-degree relatives of diagnosed FH patients. There is a 50% probability of detection in first-degree relatives, 25% probability in second-degree relatives, and a 12.5% probability in third-degree relatives. In families where the disease-causing mutation has been identified, genetic testing may also be a part of cascade screening. This method will help identify new cases of FH among those at highest risk for FH. As cascade screening proceeds, newly identified FH cases provide additional relatives who should be considered for screening. Primary care practitioners are strongly encouraged to use cascade screening.

## Genetic screening

Genetic screening for FH is generally not needed for diagnosis or clinical management but may be useful when the diagnosis is uncertain. Identification of a causal mutation may provide additional motivation for some patients to implement appropriate treatment, with little evidence for psychological harm.<sup>62,63</sup> In families with a previously identified causal mutation, genetic testing clearly provides a gold standard for diagnosis. It may be particularly useful in such a family for a relative with an equivocal or only suggestive

**Table 1** LDL cholesterol categories often used for FH diagnosis\*

Category	Description	LDL cholesterol (mg/dL) <sup>†</sup> by age		
		Age <20	Age 20–29	Age 30+
1	General population 95 <sup>th</sup> percentile	130	160	190
2	80% have FH in first-degree relatives <sup>‡</sup>	150	170	200
3	80% have FH in general population	190	220	260
4	99% have FH in general population	220	240	280
5	99.9% have FH in general population	240	260	300

\*These LDL cholesterol cut points were derived from analyses of Gaussian (normal) distributions in FH and general populations given the conditions in the descriptions. Fasting lipid levels are assumed. For diagnostic criteria, specifying one category implies all higher categories as well.

<sup>†</sup>To convert mg/dL to SI units, divide the results by 38.6.

<sup>‡</sup>This category is relevant for diagnosis of FH patients who are first-degree relatives of a known FH case. At the LDL cholesterol level shown, approximately 80% of first-degree relatives can be expected to have FH.

LDL cholesterol level. Genetic testing may also be reasonable for identifying a causal mutation in newly identified families strongly suspected of having FH. Individuals with no family contacts but who likely have FH may also be good candidates. However, genetic testing does have limitations. Among hypercholesterolemic patients with a diagnosis of *possible* FH, the mutation identification rate is 50% or less, whereas in patients with a more definite phenotypic FH, the mutation identification rate can be as high as 86%.<sup>64–66</sup> However, considerably lower discovery rates have been reported even using current genetic methods.<sup>67</sup> An excellent recent review of genetic screening studies is available.<sup>33</sup> Importantly, a negative genetic test does not exclude FH. Furthermore, persons with high LDL cholesterol remain at high risk and should be treated according to accepted guidelines regardless of the results of genetic testing.

## Acknowledgments

The authors would like to thank Mary R. Dicklin, PhD, Kevin C. Maki, PhD, FNLA, and Lynn Cofer-Chase, MSN, FNLA, from Provident Clinical Research for writing and editorial assistance.

## Industry support disclosure

The January 2011 NLA familial hypercholesterolemia recommendations conference was supported by unrestricted grant funding from the following companies: Abbott Laboratories, Aegerion Pharmaceuticals, Daiichi Sankyo, Genzyme, Kaneka Pharma America LLC, and Merck & Co. The National Lipid Association would like to thank each company for its support of this endeavor. In accordance with the National Lipid Association Code for Interactions with Companies, the NLA maintained full control over the planning, content, quality, scientific integrity, implementation, and evaluation of the recommendations conference and this familial hypercholesterolemia recommendations paper. All related activities are free from commercial influence and bias.

## Author disclosures

Dr. Hopkins has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, and Merck & Co. Dr. Hopkins has received research grants from Takeda Pharmaceuticals.

Dr. Toth has received honoraria related to consulting from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Kowa Pharmaceuticals, Pfizer Inc., and Merck & Co. Dr. Toth has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer Inc., Merck & Co., and Takeda Pharmaceuticals.

Dr. Ballantyne has received honoraria related to consulting from Abbott Laboratories, Adnexus Therapeutics, Amylin

Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Esperion, Genentech, GlaxoSmithKline, Idera Pharmaceuticals, Kowa Pharmaceuticals, Merck & Co., Novartis, Omthera, Resverlogix, Roche/Genentech, Sanofi-Synthelabo, and Takeda Pharmaceuticals. Dr. Ballantyne has received research grants from Abbott Laboratories, American Diabetes Association, American Heart Association, AstraZeneca, Bristol-Myers Squibb, diaDexus, GlaxoSmithKline, Kowa Pharmaceuticals, Merck & Co., National Institutes of Health, Novartis, Roche/Genentech, Sanofi-Synthelabo, and Takeda Pharmaceuticals. Dr. Ballantyne has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, and Merck & Co.

Dr. Rader has received honoraria related to consulting from AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Isis Pharmaceuticals, Novartis, Johnson & Johnson, Eli Lilly and Co., Novartis, Merck & Co., and Resverlogix. Dr. Rader has served on an advisory board for Aegerion.

## References

- Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. *J Clin Invest.* 1973;52:1533–1543.
- Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. *J Clin Invest.* 1973;52:1544–1568.
- Williams RR, Hopkins PN, Hunt SC, et al. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. *Arch Intern Med.* 1990;150:582–588.
- Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. *Circulation.* 1992;85:2025–2033.
- Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. *Lancet.* 1972; 1:393–399.
- Koivisto UM, Hamalainen L, Taskinen MR, Kettunen K, Kontula K. Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. *J Lipid Res.* 1993;34:269–277.
- Gaudet D, Vohl MC, Julien P, et al. Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. *Am J Cardiol.* 1998;82:299–305.
- Rallidis LS, Lekakis J, Panagiotakos D, et al. Long-term prognostic factors of young patients ( $\leq 35$  years) having acute myocardial infarction: the detrimental role of continuation of smoking. *Eur J Cardiovasc Prev Rehabil.* 2008;15:567–571.
- Dorsch MF, Lawrance RA, Durham NP, Hall AS. Familial hypercholesterolemia is underdiagnosed after AMI. *BMJ.* 2001;322:111.
- Hopkins PN. Encouraging appropriate treatment for familial hypercholesterolemia. *Clinical Lipidology.* 2010;5:339–354.
- Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation.* 2006;114:2710–2738.

12. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol.* 2007;27:1803–1810.
13. Goldstein JL, Brown MS. The LDL receptor locus and the genetics of familial hypercholesterolemia. *Annu Rev Genet.* 1979;13:259–289.
14. Benlian P, Turquet A, Carrat F, et al. Diagnosis scoring for clinical identification of children with heterozygous familial hypercholesterolemia. *J Pediatr Gastroenterol Nutr.* 2009;48:456–463.
15. Hopkins PN, Wu LL, Schumacher MC, et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. *Arterioscler Thromb.* 1991;11:1137–1146.
16. Carmena R, Roy M, Roederer G, Minnich A, Davignon J. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. *Atherosclerosis.* 2000;148:113–124.
17. Wu LL, Hopkins PN, Xin Y, et al. Co-segregation of elevated LDL with a novel mutation (D92K) of the LDL receptor in a kindred with multiple lipoprotein abnormalities. *J Hum Genet.* 2000;45:154–158.
18. Civeira F, Jarauta E, Cenarro A, et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. *J Am Coll Cardiol.* 2008;52:1546–1553.
19. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. *Nutr Metab.* 1973;15:132–140.
20. Kuklina EV, Shaw KM, Hong Y. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999–2002 and 2005–200. *MMWR Morb Mortal Wkly Rep.* 2011;60:109–114.
21. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. *The metabolic and molecular bases of inherited disease.* New York: McGraw-Hill, 2001. p. 2863–2913.
22. Moriarty PM. LDL-apheresis therapy. *Curr Treat Options Cardiovasc Med.* 2006;8:282–288.
23. Watts GF, Lewis B, Sullivan DR. Familial hypercholesterolemia: a missed opportunity in preventive medicine. *Nat Clin Pract Cardiovasc Med.* 2007;4:404–405.
24. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. *Am J Epidemiol.* 2004;160:421–429.
25. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis.* 2003;168:1–14.
26. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. *J Clin Endocrinol Metab.* 2008;93:4200–4209.
27. Horsthemke B, Dunning A, Humphries S. Identification of deletions in the human low density lipoprotein receptor gene. *J Med Genet.* 1987;24:144–147.
28. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. *New Engl J Med.* 1987;317:734–737.
29. Hobbs HH, Leitersdorf E, Goldstein JL, Brown MS, Russell DW. Multiple crm-mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions. *J Clin Invest.* 1988;81:909–917.
30. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. *Annu Rev Genet.* 1990;24:133–170.
31. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Hum Mutat.* 1992;1:445–466.
32. Langlois S, Kastelein JJP, Hayden MR. Characterization of six partial deletions in the low-density-lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH). *Am J Hum Genet.* 1988;43:60–68.
33. Varret M, Abifadel M, Rabes JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. *Clin Genet.* 2008;73:1–13.
34. Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. *J Lipid Res.* 1990;31:1337–1349.
35. Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. *J Biol Chem.* 2001;276:9214–9218.
36. Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. *Clin Chem.* 2004;50:1725–1732.
37. Marz W, Ruzicka C, Pohl T, Usadel KH, Gross W. Familial defective apolipoprotein B-100: mild hypercholesterolaemia without atherosclerosis in a homozygous patient [letter]. *Lancet.* 1992;340.
38. Ejarque I, Real JT, Martinez-Hervas S, et al. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. *Transl Res.* 2008;151:162–167.
39. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. *Trends Biochem Sci.* 2007;32:71–77.
40. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. *J Lipid Res.* 2009;50:S172–S177.
41. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science.* 2001;292:1394–1398.
42. He G, Gupta S, Yi M, Michaely P, Hobbs HH, Cohen JC. ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. *J Biol Chem.* 2002;277:44044–44049.
43. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. *Nat Clin Pract Cardiovasc Med.* 2007;4:214–225.
44. Wang J, Joy T, Mymin D, Frohlich J, Hegele RA. Phenotypic heterogeneity of sitosterolemia. *J Lipid Res.* 2004;45:2361–2367.
45. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. *BMJ.* 2007;335:599–603.
46. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. *Pediatrics.* 2008;122:198–208.
47. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol.* 1993;72:171–176.
48. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106:3143–3421.
49. Hopkins PN. Familial hypercholesterolemia. *Current Treatment Options in Cardiovascular Medicine.* 2002;4:121–128.
50. Campagna F, Martino F, Bifulco M, Montali A, et al. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. *Atherosclerosis.* 2008;196:356–364.
51. Beeharry D, Coupe B, Benbow EW, et al. Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis. *Ann Rheum Dis.* 2006;65:312–315.
52. Gibson JC, Goldberg RB, Rubinstein A, et al. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. *Arteriosclerosis.* 1987;7:401–407.
53. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. *Science.* 2000;290:1771–1775.
54. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis.* 2004;173:55–68.
55. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ.* 1991;303:893–896.
56. WHO Familial Hypercholesterolemia Consultation Group. Familial Hypercholesterolemia. Report of a WHO Consultation. Paris: World Health

- Organization; 1998 October 3, 1997. Report No.: WHO/HGN/FH/CONS/98.7.
57. Haddad L, Day INM, Hunt S, Williams RR, Humphries SE, Hopkins PN. Evidence for a third genetic locus causing familial hypercholesterolaemia: a non-LDLR, non-apoB kindred. *J Lipid Res.* 1999; 40:1113–1122.
  58. Herman K, Van Heyningen C, Wile D. Cascade screening for familial hypercholesterolaemia and its effectiveness in the prevention of vascular disease. *Br J Diabet Vasc Dis.* 2009;9:171–174.
  59. Williams RR, Schumacher MC, Barlow GK, et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. *Am J Cardiol.* 1993;72:18D–24D.
  60. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. *BMJ.* 2002;324:1303.
  61. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. *CMAJ.* 2006;174:1124–1129.
  62. Marteau T, Senior V, Humphries SE, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. *Am J Med Genet A.* 2004;128:285–293.
  63. Leren TP. Cascade genetic screening for familial hypercholesterolemia. *Clin Genet.* 2004;66:483–487.
  64. Graham CA, McIlhatton BP, Kirk CW, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. *Atherosclerosis.* 2005;182:331–340.
  65. Pollex RL, Hegele RA. Genomic copy number variation and its potential role in lipoprotein and metabolic phenotypes. *Curr Opin Lipidol.* 2007;18:174–180.
  66. Watts GF, van Bockxmeer FM, Bates T, Burnett JR, Juniper A, O'Leary P. A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. *Heart Lung Circ.* 2010;19:419–422.
  67. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. *Clin Genet.* 2010;77:572–580.

#### Websites:

- <http://www.ncbi.nlm.nih.gov/sites/GeneTests>
- [http://www.ucl.ac.uk/ldlr/Current/search.php?select\\_db=LDLR&srch=all](http://www.ucl.ac.uk/ldlr/Current/search.php?select_db=LDLR&srch=all)
- [http://www.ucl.ac.uk/ldlr/Current/index.php?select\\_db=LDLR](http://www.ucl.ac.uk/ldlr/Current/index.php?select_db=LDLR)
- <http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LDLR>

# Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Jennifer G. Robinson, MD, MPH, FNLA\*, Anne C. Goldberg, MD, FNLA

*University of Iowa, Iowa City, IA, USA (Dr. Robinson); and Washington University, St. Louis, MO, USA (Dr. Goldberg)*

## Rationale for treatment

Patients with familial hypercholesterolemias (FH) are at greatly increased lifetime risk of cardiovascular disease (CVD). If left untreated, most individuals with FH will experience premature coronary heart disease (CHD) and/or stroke. The mean age of onset of a cardiovascular event in men with FH is in the early 40s and in women with FH in the early 50s.<sup>1</sup> Although fewer than 5% of acute myocardial infarctions (AMI) occur in individuals  $\leq 40$  years of age, FH is associated with a 24-fold increase in the risk of myocardial infarction by age 40.<sup>2</sup> In western countries, the prevalence of CVD in middle-aged individuals with FH ranges from 22% to 39%.<sup>3–8</sup> Therefore, all individuals with FH, regardless of age, will require lifestyle and drug

treatment to remove the excess cardiovascular risk due to their genetic disease. Intensification of treatment is indicated in those with FH who already have clinically evident CVD, diabetes, or other cardiovascular risk factors.

Individuals with FH and established CHD or other atherosclerotic CVD are at the very highest risk of future cardiovascular events and death (Table 1).<sup>3,4,7,9–12</sup> In non-FH patients, diabetes is considered a CHD risk equivalent according to current guidelines.<sup>13</sup> The presence of diabetes therefore places individuals with FH at very high risk for CVD. FH patients with CVD or diabetes require more aggressive treatment of LDL cholesterol, non-HDL cholesterol, and other risk factors.

Risk factors for CVD in individuals with FH are similar to the risk factors of those without FH (Table 2).<sup>3,4,7,9–12</sup> However, in the setting of high cholesterol levels, the effect of each risk factor is amplified, resulting in a greater increase in risk than occurs with lower cholesterol levels.<sup>14,15</sup> Individuals with FH who have two or more cardiovascular risk factors are at very high risk of CVD and should receive intensive treatment of their cholesterol as well as the other modifiable cardiovascular risk factors. More intensive cholesterol treatment may be considered in individuals with FH who have only one cardiovascular risk factor, along with treatment of the modifiable risk factor.

Smoking markedly accelerates the atherosclerotic disease process in individuals with FH, and particularly accelerates risk in men. Therefore every effort should be made to encourage smokers to quit. Members of families

**National Lipid Association Expert Panel on Familial Hypercholesterolemia:** Anne C. Goldberg, MD, FNLA, Chair, Paul N. Hopkins, MD, MSPH, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA, Jennifer G. Robinson, MD, MPH, FNLA, Stephen R. Daniels, MD, PhD, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH, Matthew K. Ito, PharmD, FNLA, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA.

\* Corresponding author: Jennifer G. Robinson, MD, MPH, FNLA, Professor, Departments of Epidemiology & Medicine, Director, Lipid Research Clinic, Co-Director, Prevention Intervention Center, University of Iowa, 200 Hawkins Drive SE 223 GH, Iowa City, IA 52242. Office: 319 384 5040, Secretary: 319 384 5003/5062; Fax: 319 384 5004.

E-mail address: jennifer-g-robinson@uiowa.edu

Submitted March 28, 2011. Accepted for publication March 29, 2011.

## Summary Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

### Rationale for Treatment

- Individuals with familial hypercholesterolemias (FH) have a very high lifetime risk of coronary heart disease (CHD) and are at very high risk of premature onset CHD.
- Early treatment is highly beneficial. Long term drug therapy of patients with FH can substantially reduce or remove the excess lifetime risk of CHD due to the genetic disorder and can lower CHD event rates in FH patients to levels similar to those of the general population.
- FH requires lifelong treatment and regular follow-up.

### Treatment

- Both children and adults with low-density lipoprotein (LDL) cholesterol  $\geq 190$  mg/dL [or non-high-density lipoprotein (HDL) cholesterol  $\geq 220$  mg/dL] after lifestyle changes will require drug therapy.
- For adult FH patients ( $\geq 20$  years of age), drug treatment to achieve an LDL cholesterol reduction  $\geq 50\%$  should be initiated.
- Statins should be the initial treatment for all adults with FH.

### Intensified Drug Treatment

- Higher risk patients may need intensification of drug treatment to achieve more aggressive treatment goals (LDL cholesterol  $< 100$  mg/dL and non-HDL cholesterol  $< 130$  mg/dL).
- Any of the following places FH patients at higher CHD risk: clinically evident CHD or other atherosclerotic CVD, diabetes, a family history of very early CHD (in men  $< 45$  years of age and women  $< 55$  years of age), current smoking, two or more CHD risk factors, or high lipoprotein (a)  $\geq 50$  mg/dL using an isoform insensitive assay.
- In FH patients without any of the characteristics listed above, intensification of drug therapy may be considered if LDL cholesterol remains  $\geq 160$  mg/dL (or non-HDL cholesterol  $\geq 190$  mg/dL) or if initial 50% reduction in LDL cholesterol is not achieved.
- Ezetimibe, niacin, and bile acid sequestrants are reasonable treatment options for intensification of therapy, or for those intolerant of statins.
- The potential benefit of multidrug regimens for an individual patient should be weighed against the increased cost and potential for adverse effects and decreased adherence.

### Risk Factors Should be Aggressively Treated

- Risk factors are the same in FH as in the general population and require aggressive management to reduce CHD risk, with special attention to smoking cessation.
- Regular physical activity, a healthy diet and weight control should be emphasized.
- Blood pressure should be treated to  $< 140/90$  mm Hg (or  $< 130/80$  mm Hg in those with diabetes). Low dose aspirin (75-81 mg per day) should be considered in those at high CHD or stroke risk.

### Risk Stratification Algorithms Should not be Used

- Individuals with FH are at high CHD risk. The 10-year CHD risk in the FH patient is not adequately predicted by any conventional risk assessment tools. Therefore, assessment of 10-year risk is not recommended.
- All FH patients require lifestyle management and very few will not require lipid-lowering drug therapy.

### Consider Referral to a Lipid Specialist

- Consider referral to a lipid specialist with expertise in FH if LDL cholesterol concentrations are not reduced by  $\geq 50\%$  or if patients are at high risk.
- Cascade testing of first-degree relatives should be offered to all individuals with FH.

with FH should also be counseled to avoid smoking initiation, and to avoid passive smoke exposure.

Individuals with metabolic syndrome (defined in Table 1) have a  $>2$ -fold increase in cardiovascular risk and a 1.5-fold increased risk of overall mortality.<sup>16</sup> The presence of metabolic syndrome therefore places individuals with FH at higher cardiovascular risk and indicates

the need for more aggressive modification of lifestyle and treatment of risk factors.<sup>13,17</sup>

Recent large epidemiologic and genetic studies have found increased cardiovascular risk with elevated lipoprotein (a) [Lp(a)] levels in the general population and some studies of FH patients.<sup>18</sup> Some evidence suggests the excess risk of high Lp(a) levels may be somewhat ameliorated when

**Table 1** Characteristics placing FH patient at the highest CVD risk

Intensification of treatment and an LDL-C goal <100 mg/dL (non-HDL-C <130 mg/dL) is recommended for FH patients with any of these very high risk characteristics

Established CHD or other CVD	History of acute myocardial infarction, stroke, peripheral arterial disease, resuscitated cardiac arrest, cardiovascular revascularization, stable or unstable angina, transient ischemic attack, carotid artery stenosis >50%, aortic abdominal aneurysm
Smokers	Male current smokers have >2-fold higher risk than female smokers – Encourage smoking cessation to reduce risk
Diabetes mellitus	Lifestyle or drug treated diabetes
Family history of very premature onset CHD	First or second degree male relative onset before age 45 First or second degree female relative onset before age 55
2 or more risk factors	See Table 2

Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

LDL-C levels are <100 mg/dL.<sup>19,20</sup> In extreme cases, LDL-apheresis effectively removes Lp(a), although randomized trials of CVD risk reduction are lacking. The majority of studies have not found an association for C-reactive protein or apolipoprotein (Apo) E genotype.<sup>3</sup> Although genetic testing is not routinely recommended for most individuals with FH, an identified DNA mutation does place an individual at higher risk than when a DNA mutation is not confirmed.<sup>20</sup>

## Evidence drug treatment is beneficial

Treatment recommendations for adults with FH are outlined in Table 3. Evidence supporting these recommendations is discussed below.

All contemporary guidelines recommend using statins as the first line therapy for cardiovascular risk reduction in FH and other patients with hypercholesterolemia.<sup>1,17,20–23</sup> Extensive clinical trial evidence supports the use of statins to reduce cardiovascular events in all patient populations, including those with FH. Moderate and high dose statins have an excellent record of safety.<sup>24–27</sup> Statins also reduce total mortality in high risk populations.

Placebo-controlled CVD endpoint trials have not been performed specifically in individuals with a diagnosis of FH since it is considered unethical to withhold treatment from patients with inborn errors of metabolism.<sup>28,29</sup> Therefore, estimates of the true efficacy of long-term statin treatment of individuals with FH are not available. However, observational data from large cohorts of FH patients in Europe suggest

**Table 2** Cardiovascular risk factors in individuals with FH

Risk factor	Cut-points for risk factors <b>If &gt;2 risk factors present intensification of therapy is recommended</b>
Increasing age	Men >30 years of age Women >40 years of age
Baseline LDL-C level	>250 mg/dL
Male sex	Male sex
Smoking	Current smoker
Family history of premature onset CHD	First degree male relative onset before age 55 First degree female relative onset before age 65
Metabolic syndrome	3 of 5 characteristics: <ul style="list-style-type: none"> <li>• Increased waist circumference: <ul style="list-style-type: none"> <li>Men &gt;40" (&gt;37" in some populations) and women &gt;35"</li> </ul> </li> <li>• Blood pressure <math>\geq</math>130 mm Hg/or <math>\geq</math>80 mm Hg or drug treatment</li> <li>• Triglycerides <math>\geq</math>150 mg/dL or drug treatment</li> <li>• Low HDL-C: <ul style="list-style-type: none"> <li>Men &lt;40 mg/dL and women &lt;50 mg/dL</li> </ul> </li> <li>• Elevated glucose <math>\geq</math>100 mg/dL or drug treatment</li> </ul>
Low HDL-C level	HDL-C <40 mg/dL
Hypertension	Blood pressure >140/or >90 mm Hg or drug treatment
High lipoprotein (a)	$\geq$ 50 mg/dL using an isoform insensitive assay
Physical findings	Tendon xanthoma

Abbreviations: CHD, coronary heart disease; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

**Table 3** Adult FH treatment recommendations

1. **All** adult FH patients should receive long-term cholesterol-lowering therapy to reduce LDL-C by >50%
  - Almost all will require a high dose statin
2. Intensification of cholesterol-lowering therapy should be considered in higher risk FH patients (see Table 1)
  - Clinically evident CHD or other cardiovascular disease
  - Diabetes
  - Family history of very premature onset CHD (first degree relative male <45 years or female <55 years)
  - Current smoking (strongly encourage smoking cessation)
  - Two or more cardiovascular risk factors other than smoking (see Table 2)
  - Most will require ezetimibe or another drug in combination with a high dose statin
  - The potential benefit for an individual patient should be weighed against the potential for adverse effects, cost, and decreasing adherence with multidrug regimens.
3. Intensification of therapy may be considered in lower risk FH patients after the initial >50% reduction in LDL-C
4. Treat other cardiovascular risk factors
  - Emphasize a healthy diet, regular physical activity and weight control
  - Avoid tobacco
  - Control blood pressure <140/<90 mm Hg (Diabetes: <130/<80 mm Hg)
  - Low-dose aspirin for those with cardiovascular disease or diabetes; consider for those with  $\geq 2$  risk factors
5. Consider referral to a lipid specialist
  - More aggressive lipid management
  - Cascade testing to identify relatives with FH

Abbreviations: CHD, coronary heart disease; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

long-term statin treatment removes the excess lifetime risk of CVD disease due to FH to a level similar to that of the general population. A Dutch study evaluating a cohort of over 2100 FH patients who did not have CVD in 1990 (prior to availability of the first statin) found that in those who later took statin therapy, the risk of myocardial infarction was reduced by 76% over the next 8+ years to a rate similar to that of an age-matched general population.<sup>30</sup> Similarly, an analysis of the U.K. Simon Broome database (n = 3382) of asymptomatic FH patients who used statins had rates of CHD death similar to the general population. Moreover, all-cause mortality was 33% lower than in the general population, primarily due to a 37% lower risk of fatal cancer.<sup>31</sup>

Although no randomized cardiovascular outcomes trials of exclusively FH patients are available, several outcomes trials in populations of severely hypercholesterolemic persons have been performed. Two placebo-controlled statin trials in populations with severely elevated LDL cholesterol levels >170 mg/dL found moderate dose simvastatin or pravastatin reduced the risk of nonfatal coronary events and CVD death.<sup>32,33</sup> The Scandinavian Simvastatin Survival Study, performed in a secondary prevention population, found a significant 30% reduction in both stroke and total mortality over five years of treatment.<sup>32</sup> The West of Scotland trial of a largely primary prevention population also found a trend toward reduced total mortality (-22%; p = 0.051).<sup>33</sup> The MEGA Study was the only trial in a severely hypercholesterolemic population performed outside the US and Europe. This five-year primary prevention trial of hypercholesterolemic Japanese, primarily female, patients found a lower statin dose (pravastatin 10 to 20 mg) combined with diet reduced cardiovascular risk by 25% over diet alone.<sup>34</sup>

An individual-level meta-analysis of 14 randomized placebo-controlled trials of statin therapy (n > 90,000) found that individuals with baseline LDL cholesterol >175 mg/dL (>4.5 mmol/L) experienced the same 23% relative risk reduction as those with lower LDL cholesterol levels.<sup>35</sup> It should be noted that individuals with high LDL cholesterol levels are at higher risk of CVD, and therefore have a greater reduction in the absolute risk of CVD. A subsequent individual-level meta-analysis that included an additional 12 trials further found that high dose statins reduce risk more than moderate dose statins regardless of LDL cholesterol level.<sup>36</sup>

Non-statin treatments have also been found to reduce CVD events in severely hypercholesterolemic populations, although none have been shown to reduce CVD deaths or total mortality. Individually, each of four small dietary trials (three evaluated polyunsaturated fats), in men with CHD failed to show a significant reduction in CVD events, but overall the reduction in CVD events was proportionate to the fairly modest reductions in LDL cholesterol level of <20%.<sup>37-40</sup> Two larger placebo-controlled trials of the bile acid sequestrants, colestipol and cholestyramine, also found reductions in CVD over a five-year period proportionate to the degree of LDL cholesterol lowering of 13 to 21% in primary prevention and CHD populations.<sup>41,42</sup> A placebo-controlled trial of niacin (2 grams) in men with CHD also found a reduction in CHD events (17%) proportionate to the magnitude of non-HDL cholesterol reduction (17%).<sup>43,44</sup> A trial of ileal bypass surgery in CHD patients lowered LDL cholesterol by 38% and CVD events by 30%.<sup>45</sup> A placebo-controlled primary prevention trial of gemfibrozil found a significant 34% reduction in CHD events in hypertriglyceridemic men, which was somewhat

greater than that expected from the magnitude of non-HDL cholesterol (16%) or LDL cholesterol (10%) lowering.<sup>44,46</sup> However, an ancillary study to this trial, that evaluated men with CHD, found no benefit from gemfibrozil compared to placebo.<sup>47</sup>

No cardiovascular event outcomes trials of ezetimibe or a fibrate in combination with statin therapy have been performed in severely hypercholesterolemic populations, nor are any planned at this time. The results of cardiovascular endpoint trials evaluating statins used in combination with other drugs in less severely hypercholesterolemic populations are discussed below.

### Evidence for >50% LDL cholesterol reduction

High dose statins reduce cardiovascular risk more than moderate dose statins, regardless of the baseline LDL cholesterol level.<sup>36</sup> Two trials using a non-invasive endpoint of carotid intimal thickness (CIMT) have been performed in FH patients. The first trial, [Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP)], found more aggressive LDL cholesterol lowering with atorvastatin 80 mg (54%) resulted in regression of CIMT over two years compared to progression of CIMT in those receiving less aggressive treatment with simvastatin 40 mg (42% LDL cholesterol lowering).<sup>48</sup> Regression in the atorvastatin group occurred despite a mean on-treatment LDL cholesterol level of 150 mg/dL. After the simvastatin group had been switched to atorvastatin 80 mg for two more years of treatment, CIMT progression was arrested although no regression was observed.<sup>49</sup> The second CIMT trial [Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerotic Regression (ENHANCE)] in FH patients evaluated the addition of ezetimibe 10 mg to simvastatin 80 mg.<sup>50</sup> Despite the 27% lower LDL cholesterol level with the addition of ezetimibe, no difference in CIMT was observed after two years of treatment. Since 80% of ENHANCE participants had received long-term statin therapy prior to trial entry, these findings were not surprising given the results of the four-year follow-up of patients switched to atorvastatin 80 mg in the earlier ASAP trial.<sup>49</sup> Notably the 20% of ENHANCE participants who were not receiving statins at study entry did have evidence of CIMT progression. The most important finding of ENHANCE was that long-term statin therapy had normalized the CIMT at study entry for the ENHANCE participants (who were on average 46 years old at baseline), to the level of a 32 year old male with an LDL cholesterol of 134 mg/dL.<sup>51</sup> Another Dutch study observed similar results in FH patients treated with LDL cholesterol lowering medication for at least five years.<sup>52</sup> These patients experienced 59% reductions in LDL cholesterol from baseline and had both LDL cholesterol levels (145 mg/dL) and CIMT similar to their spouses. A second drug (predominantly ezetimibe) was used in addition to a moderate to high dose statin in 25% of FH patients in this study.

Taken together, these findings suggest long-term reductions in LDL cholesterol of >50% essentially normalizes the adverse consequences of this genetic disorder to the level of the general population and therefore should be the initial goal of therapy in all adult FH patients. However, the general population still has significant cardiovascular risk. U.S. guidelines have identified an LDL cholesterol goal <100 mg/dL (and non-HDL cholesterol <130 mg/dL) for individuals at moderately high to very high cardiovascular risk.<sup>17</sup> Therefore, it is reasonable to intensify therapy in FH patients who are at particularly high risk due to the presence of clinical or subclinical CVD, diabetes, 2 or more cardiovascular risk factors, or are smokers (Table 2). Although it is also reasonable to attempt to achieve an LDL cholesterol <100 mg/dL in many of these high risk FH patients, it may be very difficult. The potential benefit for an individual patient should be weighed against the potential for adverse effects, cost, and decreasing adherence with multidrug regimens. It should be noted that no clinical trial data are yet available on the long-term efficacy and safety of high dose statins used in combination with other drugs.

### Statin combination therapy

No large cardiovascular endpoint trials of statins used in combination with another drug have been performed in FH or severely hypercholesterolemic populations. However, several of the completed trials of a statin combined with ezetimibe, niacin, fibrates and omega-3 fatty acids have implications for the treatment of FH patients.

The primary actions of ezetimibe are LDL cholesterol and non-HDL cholesterol lowering. Used as monotherapy or in addition to a statin, ezetimibe lowers LDL cholesterol and non-HDL cholesterol on average by 15–20%.<sup>53</sup> Two cardiovascular endpoint trials have been completed, and a third is underway. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial was a placebo-controlled trial performed in a primary prevention population of individuals with aortic stenosis and baseline LDL cholesterol levels of 140 mg/dL.<sup>54</sup> After 4.4 years of treatment with simvastatin 40 mg/ezetimibe 10 mg, the 22% reduction in ischemic CVD events was less than expected based on the 50% reduction in LDL cholesterol, based on a previous meta-analysis of statin trials.<sup>35</sup> However, a subsequent *post hoc* analysis did find the expected magnitude of CVD event reduction in the lowest two tertiles of aortic stenosis severity.<sup>55</sup> The Study of Heart and Renal Protection (SHARP) compared simvastatin 20 mg/ezetimibe 10 mg to placebo in a primary prevention population of individuals with chronic kidney disease and a mean LDL cholesterol of 108 mg/dL.<sup>56</sup> Major CVD events were reduced by 17% in the simvastatin/ezetimibe group, a degree of risk reduction predicted by the 32 mg/dL reduction in LDL cholesterol.<sup>35,57</sup> In a prespecified analysis of the approximately two-thirds of participants who were not receiving dialysis, CVD risk was significantly reduced by 20%. Therefore, there is some evidence that the addition of

ezetimibe to moderate dose statin therapy provides additional risk reduction benefit in patients without other severe or end-stage diseases. Given its record of tolerability and apparent safety when used in combination with statins,<sup>53,58</sup> it is reasonable to consider the addition of ezetimibe to a maximal dose of statin in FH patients who require intensification of therapy, or who are intolerant of statins.

Several very small surrogate endpoint trials have evaluated niacin used in combination with a moderate dose statin in populations without severe hypercholesterolemia. Unfortunately, although meta-analyses of niacin trials overall show cardiovascular risk reduction benefit, no definitive conclusions can be drawn regarding the additional cardiovascular event reduction benefit of niacin added to statin therapy, or the benefit of HDL cholesterol and triglyceride alterations *per se*.<sup>59,60</sup> The results of the ongoing cardiovascular endpoint trials Niacin Plus Statin to Prevent Vascular Events (AIM-HIGH) and Treatment of HDL to Reduce the Incidence of Vascular Events (HPS-2 THRIVE) are needed to address these questions.<sup>61,62</sup> No trials evaluating the safety and efficacy of niacin combined with the highest doses of statins are anticipated.<sup>63</sup>

The only trial of statin plus fibrate, Action to Control Cardiovascular Risk in Diabetes (ACCORD), did not find any additional cardiovascular risk reduction benefit in the trial as a whole when fenofibrate was added to simvastatin therapy in diabetic patients.<sup>64</sup> Subgroup analyses did find a trend toward benefit with the addition of fenofibrate in those with triglycerides  $\geq 204$  mg/dL and HDL cholesterol  $\leq 34$  mg/dL, whereas no benefit was found in the large majority not meeting these conditions (interaction  $p = 0.06$ ). On the other hand, the addition of fenofibrate *increased* cardiovascular risk in women (interaction  $p = 0.01$ ). ACCORD has several important implications for the treatment of FH patients for the reduction of cardiovascular risk. First, treatment of diabetes with lifestyle and hypoglycemic drugs is an excellent strategy for lowering LDL cholesterol and triglycerides in diabetic patients. Both the usual care and aggressive diabetes treatment groups had improvements in both lipid parameters over the course of the trial. Second, on the basis of extensive evidence, high dose statins are preferable to a low or moderate dose statin used in combination with a fibrate for cardiovascular prevention. Although ACCORD did suggest benefit in high triglyceride/low HDL cholesterol patients, no benefit was observed in the rest of the study participants. This is in contrast to high dose statins, which reduce cardiovascular risk in all subgroups of individuals regardless of concomitant triglyceride or HDL cholesterol abnormalities or LDL cholesterol levels.<sup>36</sup> Therefore, fibrates are not indicated in FH patients with genetic disorders manifested primarily as increased LDL cholesterol levels, without elevated triglyceride levels. However, severely hypertriglyceridemic FH patients, such as those with Familial Combined Hyperlipidemia, may need treatment with a triglyceride-lowering agent in addition to lifestyle and statin therapy.

Omega-3 fatty acids in pharmacologic doses are primarily used to lower triglycerides rather than LDL cholesterol. The largest trial ( $n > 18,000$ ) of omega-3 fatty acid supplementation was performed in Japan, where fish consumption is high. This trial found an additional 20% reduction in CHD events with eicosapentaenoic acid (EPA) 1800 mg in statin treated hypercholesterolemic patients with and without CVD.<sup>65</sup> EPA did not influence LDL cholesterol level in this population without significant HDL cholesterol (58 mg/dL) or triglyceride (153 mg/dL) abnormalities. Interestingly, the main effect of EPA was to decrease nonfatal CHD events without decreasing the risk of sudden death. The most recent trials of omega-3 supplementation in US and European countries have not found evidence of cardiovascular benefits from moderate doses of either marine omega-3 fatty acid (EPA and docosahexaenoic acid) or plant omega-3 (alpha-linolenic) supplementation in high-risk patients with high levels of utilization of lipid-modifying, antihypertensive, and antithrombotic therapies.<sup>66-68</sup> For FH patients, it is therefore reasonable to emphasize aggressive risk factor treatment and reserve omega-3 fatty acids for the treatment of severely hypertriglyceridemic patients.

## Other treatments

Plasma exchange has been shown to prolong the lives of children with homozygous FH.<sup>69</sup> Plasma exchange has been largely replaced with LDL apheresis. LDL apheresis lowers LDL cholesterol similarly to maximal lipid-lowering drug therapy, and is the only treatment that substantially lowers Lp(a). No randomized trials of LDL apheresis have been performed, but it is reasonable to assume reductions in CVD events are proportional to the degree of LDL cholesterol lowering.<sup>70,71</sup> LDL apheresis should be considered in high risk adult FH patients, such as those with overt CVD who are refractory to therapy and in those who are intolerant to drug therapy.<sup>72</sup>

## Cost-effectiveness

Long-term high dose statin therapy in adult FH patients is cost-effective for both primary and secondary prevention of CVD well below the threshold of \$50,000 per quality adjusted life year (QALY). An analysis performed for the U.K. National Institute for Health and Clinical Excellence (NICE) found simvastatin 80 mg, atorvastatin 80 mg, or rosuvastatin 40 mg were cost-effective over simvastatin 40 mg (£13,500/QALY or \$21,000 in 2011 US dollars) in FH patients without clinical CVD.<sup>29</sup> The cost-effectiveness models were sensitive to age in the case of asymptomatic FH *diagnosed after* age 60, with atorvastatin 80 mg becoming less cost-effective over simvastatin 40 mg (£26,250/QALY or \$40,400 in 2011 US dollars). It should be noted that atorvastatin 80 mg will become more cost-effective when it becomes generic in the U.S. in late 2011. In general, statins used for secondary prevention are about twice as

**Table 4** National and international guidelines for the treatment of FH patients

U.S. Guidelines	European Guidelines	United Kingdom Guidelines	Canadian Guidelines
ATP III (2002,2004) <sup>13,17</sup> AHA/ACC (2006) <sup>78</sup>	4 <sup>th</sup> European Cardiovascular Prevention Guidelines (2007) <sup>22</sup>	UK NICE Familial Hypercholesterolemia Guidelines (2008) <sup>1,20</sup>	Canadian Dyslipidemia Guidelines (2009) <sup>23</sup>
No specific treatment recommendations for FH patients	<b>FH patients:</b> Aggressive statin treatment starting at a young age	<b>Offer lifestyle advice, especially on smoking cessation</b>	<b>Low risk (FRS&lt;10%)</b>
<b>Very high risk</b> (CVD + diabetes, multiple risk factors)	<b>High Clinical Priority</b> includes:	<b>Start treatment with high intensity statin to achieve a &gt;50% reduction in LDL-C</b> (such as simvastatin 80 mg or appropriate doses of atorvastatin or rosuvastatin)	<b>Drug therapy recommended:</b>
• LDL-C goal <100 mg/dL & optional LDL-C goal <70 mg/dL	• Patients with established CVD	• Increase to maximum dose if necessary	• LDL-C 5.0 mmol/L (>190 mg/dL)
	• Asymptomatic patients with:		<b>usually reflecting a genetic lipoprotein disorder</b> (class I, level C)
	- Multiple risk factors and ≥5% 10-year risk CVD death		• TC/HDL-C ratio >6.0 (class IIb, level C), especially with severe hypertriglyceridemia to prevent pancreatitis
	- Diabetes type 2 and type 1 with microalbuminuria	<b>Consider ezetimibe</b>	• Goal: ≥50% ↓ LDL-C (Class IIa, level A)
	- Markedly increased single risk factor, especially if associated with end-organ damage	• As monotherapy if statin use is limited by intolerance	
	• Close relatives of individuals with premature CVD or at particularly high risk	• As combination therapy if LDL-C not appropriately controlled	
<b>High risk</b> (CHD risk equivalent)	• LDL-C goal <100 mg/dL		<b>Moderate risk</b> (FRS 10-19%)
• LDL-C goal <100 mg/dL	• Optional LDL-C goal <80 mg/dL	<b>Refer patients to a specialist with expertise in FH if</b>	• Initiate treatment if LDL-C > 3.5 mmol/L (130 mg/dL); TC/HDL-C > 5.0; hs-CRP > 2 mg/dL in men >50 or women >60 years; family history or elevated CRP (RRS)
• Optional/reasonable* LDL-C goal <70 mg/dL		At high risk (established CHD, family history of early disease, or ≥risk factors)	• Goal: LDL-C <77 mg/dL or ≥50% ↓ LDL-C [alternate Apo B <0.80 g/L] (Class IIa, level A)
<b>Moderately high risk</b> (≥2 RF & 10-20% CHD risk*)	<b>Objectives of CVD prevention</b>	<b>Offer referral to a cardiologist</b> for evaluation of CHD if family history early CHD or ≥risk factors	<b>High risk</b> (CHD, other CVD, most patients with diabetes, FRS ≥20%, RRS ≥20%)
• LDL-C goal <130 mg/dL	• Maintain or achieve low lifetime CVD risk	<b>Do NOT use risk estimation tools</b> (such as Framingham Risk Score, Reynolds Risk Score, SCORE or others)	• Consider drug treatment for all high risk patients
Optional LDL-C goal <100 mg/dL	• No smoking		• Goal LDL-C <77 mg/dL or ≥50% ↓ LDL-C [alternate Apo B <0.80 g/L] (Class I, level A)
	• Healthy food choices		
	• Physical activity 30 min moderate activity daily		

<p><b>Low risk</b> (0-1 risk factor &amp; &lt;10% CHD risk*)</p> <ul style="list-style-type: none"> <li>• Add drugs if LDL-C &gt; 190 mg/dL (optional &gt; 160 mg/dL)</li> </ul> <p><b>LDL-C goal &lt;160 mg/dL</b></p> <p><b>Non-HDL-C goal is 30 mg/dL higher than LDL-C goal</b> when triglycerides 200-500 mg/dL</p> <p><b>Treat other cardiovascular risk factors</b></p>	<ul style="list-style-type: none"> <li>• BMI &lt;25 kg/m<sup>2</sup> and avoidance of central obesity</li> <li>• Blood pressure &lt;140/90 mm Hg</li> <li>• Total cholesterol &lt;5 mmol/L (190 mg/dL) LDL-C &lt;3 mmol/L (115 mg/dL)</li> <li>• Fasting blood glucose &lt;6 mmol/L (110 mg/dL)</li> </ul> <p><b>Achieve more rigorous risk factor control in high risk individuals, if feasible</b></p> <ul style="list-style-type: none"> <li>• Blood pressure &lt;130/80 mm Hg</li> <li>• Total cholesterol &lt;4.5 mmol/L (175 mg/dL); option &lt;4 mmol/L (155 mg/dL)</li> <li>• LDL-C &lt; 2.5 mmol/L (100 mg/dL); option &lt;2 mmol/L (80 mg/dL)</li> <li>• Fasting blood glucose &lt;6 mmol/L and HbA1c &lt;6.5%</li> </ul>	<p><b>Encourage healthy behaviors</b></p> <ul style="list-style-type: none"> <li>• Smoking cessation</li> <li>• Diet (reduced saturated fats and refined sugars)</li> <li>• Weight reduction and maintenance</li> <li>• Exercise (daily)</li> <li>• Stress management</li> </ul>
<p><b>Metabolic syndrome</b></p> <ul style="list-style-type: none"> <li>• Intensify lifestyle therapy</li> </ul>	<p><b>Consider cardioprotective drug therapy in high risk individuals,</b> especially those with established atherosclerotic CVD</p>	<p><b>See report for additional recommendations</b> for FH diagnosis, referral, specialist care, and special considerations for women and children</p>
<p><b>Offer referral for cascade testing</b> to identify relatives with FH</p> <p><b>Offer a structured review at least annually</b></p> <ul style="list-style-type: none"> <li>• Measure fasting lipid profile</li> <li>• Assess for symptoms of CHD and smoking status</li> <li>• Discuss medication adherence &amp; possible side effects</li> <li>• Update family pedigree with CHD events &amp; cascade testing</li> <li>• Use a low threshold for urgent referral for evaluation of sign &amp; symptoms of CHD</li> </ul>	<p><b>Offer referral for cascade testing</b> to identify relatives with FH</p> <p><b>Offer a structured review at least annually</b></p> <ul style="list-style-type: none"> <li>• Measure fasting lipid profile</li> <li>• Assess for symptoms of CHD and smoking status</li> <li>• Discuss medication adherence &amp; possible side effects</li> <li>• Update family pedigree with CHD events &amp; cascade testing</li> <li>• Use a low threshold for urgent referral for evaluation of sign &amp; symptoms of CHD</li> </ul>	<p><b>Encourage healthy behaviors</b></p> <ul style="list-style-type: none"> <li>• Smoking cessation</li> <li>• Diet (reduced saturated fats and refined sugars)</li> <li>• Weight reduction and maintenance</li> <li>• Exercise (daily)</li> <li>• Stress management</li> </ul>

Abbreviations: Apo, apolipoprotein; BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; CVD, cardiovascular disease; FRS, Framingham Risk Score; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RF, risk factor; RRS, Reynolds Risk Score; TC, total cholesterol.

\*No specific mention about whether or not to perform Framingham Risk Scoring (FRS) in FH patients; FRS or other risk stratification algorithms are NOT recommended in FH patients due to their very high short and long-term cardiovascular risk due to elevated LDL-C and/or non-HDL-C levels.

cost-effective as when used for primary prevention.<sup>73</sup> Cost-effectiveness evaluations of the addition of other drugs to statin therapy have not yet been performed. Nor has the cost-effectiveness of LDL-apheresis been formally evaluated.<sup>20</sup>

## Targets of treatment

FH is a condition characterized by elevated LDL cholesterol concentrations. Those with Familial Combined Hyperlipidemia may also have elevations in non-HDL cholesterol as well as abnormalities in triglycerides and HDL cholesterol. Evidence supports the recommendation to use LDL cholesterol as the primary target of therapy and non-HDL cholesterol as the second target of therapy in those with elevated triglyceride levels.<sup>13,36,44,74</sup> However, there is insufficient evidence at this time for drug treatment targeting triglycerides or HDL cholesterol for cardiovascular prevention in FH or other patient populations.<sup>60</sup> Nor is there yet evidence that further targeting Apo B, after LDL cholesterol or non-HDL cholesterol, improves cardiovascular outcomes.<sup>74</sup>

Aggressive lipid lowering to achieve >50% LDL cholesterol reduction is recommended for FH patients.<sup>1</sup> High dose statins reduce CVD risk more than moderate dose statins regardless of LDL cholesterol level and are therefore appropriate for almost all FH patients.<sup>36</sup> Lower doses of statins may be more appropriate for some FH patients, such as those of Japanese or other Asian ancestry, due to safety concerns with higher doses.<sup>75–77,78</sup>

International guidelines have identified LDL cholesterol and, in some cases, non-HDL cholesterol or Apo B as targets for therapy (Table 4).<sup>1,13,17,20,23,78</sup> The U.K. NICE Familial Hypercholesterolemia Guidelines are the most comprehensive guidelines addressing the diagnosis and treatment of FH patients and were based on an extensive evidence review.<sup>1,20</sup> Evidence supports drug treatment of lower risk patients with or without FH when LDL cholesterol is >190 mg/dL with a >50% reduction in LDL cholesterol recommended. Those with established CHD, other atherosclerotic CVD, diabetes, or multiple risk factors should be more aggressively treated to achieve LDL cholesterol <100 mg/dL. More aggressive optional LDL cholesterol goals <70–80 mg/dL are suggested for the highest risk patients, although this level of LDL cholesterol is very difficult to achieve in patients with FH.

Attainment of an LDL cholesterol <100 mg/dL is a problem for FH patients unless high dose statins and/or statin combination therapy is used. In a recent Dutch study of three academic and two regional medical centers (n = 1249), 96% were on a statin and 47% achieved >50% LDL cholesterol reduction.<sup>79</sup> However, only 21% had LDL cholesterol <100 mg/dL (2.5 mmol/L). Of those with LDL cholesterol ≥100 mg/dL, 27% were on maximum statin dose plus ezetimibe. Physician reluctance to intensify therapy was reported in 32% of those with LDL cholesterol ≥100 mg/dL. Another report on a Spanish

cohort (n = 881) with FH (mean age of 47 years and 22% with clinical CVD) also identified underutilization of intensive therapy.<sup>3</sup> Baseline mean LDL cholesterol was 336 mg/dL and non-HDL cholesterol was 365 mg/dL. Over 80% reported statin use at the time of the study but <30% were receiving the highest dose of simvastatin or atorvastatin alone or in combination with a resin.

## Non-invasive testing

Noninvasive testing in asymptomatic middle-aged (45–50 years) individuals with FH reveals a substantial burden of subclinical atherosclerosis, related to cholesterol level and risk factor burden.<sup>12</sup> In one study, approximately half had plaques on coronary CT angiography (CTCA) compared to 14% of age and sex-matched controls; 19% had stenosis >50% on CTCA compared to 3% in age and sex-matched controls. Mean calcium scores were also higher in FH patients (55 vs. 38 in age/sex-matched controls). However, about 50% of those with FH had a zero calcium score. Similarly, when present, Achilles tendon xanthomas may indicate a greater atherosclerotic burden<sup>12,80</sup> and are associated with a three-fold greater CVD risk.<sup>81</sup> However, most FH patients will not have xanthomas, xanthelasma, or corneal arcus despite being at high cardiovascular risk. Carotid IMT does not correlate well with the presence of coronary plaque or stenosis and so is less useful in FH patients for whom CHD is usually the first manifestation.<sup>12,20,82</sup>

Therefore, although subclinical atherosclerosis is common even in young adult FH patients, routine noninvasive screening of FH patients is not recommended. All FH patients should receive lifestyle and drug therapy to reduce cardiovascular risk. In the few highly selected FH patients who undergo non-invasive testing, a negative non-invasive test should not determine the intensity of therapy. Other considerations such as smoking, family history, severity of LDL cholesterol elevation, and the presence of other cardiovascular risk factors should determine intensity of therapy. The same considerations should also guide intensity of therapy in those with a positive non-invasive test. Since assessment of noninvasive imaging in drug-treatment trials does not predict cardiovascular events, these tests should not be used for monitoring response to treatment.<sup>83,84</sup>

## Acknowledgments

The authors would like to thank Mary R. Dicklin, PhD, Kevin C. Maki, PhD, FNLA, and Lynn Cofer-Chase, MSN, FNLA, from Provident Clinical Research for editorial assistance.

## Industry support disclosure

The January 2011 NLA FH recommendations conference was supported by unrestricted grant funding from the

following companies: Abbott Laboratories, Aegerion Pharmaceuticals, Daiichi Sankyo, Genzyme, Kaneka Pharma America LLC, and Merck & Co. The National Lipid Association would like to thank each company for its support of this endeavor. In accordance with the National Lipid Association Code for Interactions with Companies, the NLA maintained full control over the planning, content, quality, scientific integrity, implementation, and evaluation of the recommendations conference and this FH recommendations paper. All related activities are free from commercial influence and bias.

## Author disclosures

Dr. Robinson's institution has received research grants from Abbott Laboratories, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Hoffman LaRoche, Merck & Co., Merck Schering Plough, and Spirocor.

Dr. Goldberg has received honoraria related to consulting from Roche/Genentech, ISIS-Genzyme and Merck & Co. Dr. Goldberg has received research grants from Amarin, Abbott Laboratories, GlaxoSmithKline, ISIS-Genzyme Corporation, Merck & Co., Novartis, and Regeneron.

## References

1. Wierzbicki AS, Humphries SE, Minhas R, on behalf of the Guideline Development G. Familial hypercholesterolaemia: summary of NICE guidance. *BMJ*. 2008;337:a1095.
2. Wiesbauer F, Blessberger H, Azar D, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors ( $\leq 40$  years of age). *Eur Heart J*. 2009;30:1073–1079.
3. Alonso R, Mata N, Castillo S, et al. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. *Atherosclerosis*. 2008;200:315–321.
4. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. *Circulation*. 1995;92:290–295.
5. Jansen ACM, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. *Journal of Internal Medicine*. 2004;256:482–490.
6. Neil HAW, Seagroatt V, Betteridge DJ, et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. *Heart*. 2004;90:1431–1437.
7. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. *Journal of Medical Genetics*. 2006;43:943–949.
8. Bertolini S, Cantafora A, Averna M, et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. *Arterioscler Thromb Vasc Biol*. 2000;20:e41–e52.
9. Real JT, Chaves FJ, Martnez-Usa I, Garca-a-Garca-a AB, Ascaso JF, Carmena R. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. *European Heart Journal*. 2001;22:465–471.
10. Hill J, Hayden M, Frohlich J, Pritchard P. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. *Arterioscler Thromb*. 1991;11:290–297.
11. Junyent M, Gilabert R, Jarauta E, et al. Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. *Atherosclerosis*. 2009;208:437–441.
12. Miname MH, Ribeiro Ii MS, Filho JP, et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. *Atherosclerosis*. 2010;213:486–491.
13. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. *Circulation*. 2002;106:3143–3421.
14. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: The risk curve concept. *Am J Cardiol*. 2006;98:1405–1408.
15. Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham Heart Study general cardiovascular risk profile. *Circulation*. 2009;120:384–390.
16. Mottillo S, Filion KB, Genest J, et al. The Metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;56:1113–1132.
17. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227–239.
18. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31:2844–2853.
19. Kamstrup PR. Lipoprotein(a) and ischemic heart disease—A causal association? A review. *Atherosclerosis*. 2010;211:15–23.
20. DeMott K, Nherera L, Shaw E, et al. Clinical Guidelines and Evidence Review for Familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
21. Watts G, van Bockxmeer F, Bates T, Burnett J, Juniper A, O'Leary P. A new model of care for familial hypercholesterolaemia from Western Australia: Closing a major gap in preventive cardiology. *Heart, Lung and Circ*. 2010;19:419–422.
22. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2007;28:2375–2414.
23. Genest J, McPherson RF, J, Anderson T, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. *Can J Cardiol*. 2009;25:567–579.
24. Law M, Rudnicka AR. Statin safety: A systematic review. *Am J Cardiol*. 2006;97:S52–S60.
25. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol*. 2006;97: S89–S94.
26. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. London: Technology Appraisal 94; 2006.
27. Davidson M, Robinson JG. Safety of aggressive lipid management. *J Am Coll Cardiol*. 2007;49:1753–1762.
28. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis*. 2003;168:1–14.
29. Minhas R, Humphries SE, Qureshi N, Neil HAW, on behalf of the NICE Guideline Development Group. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. *Heart*. 2009;95:584–587.

30. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ*. 2008;337:a2423.
31. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. *Eur Heart J*. 2008;29:2625–2633.
32. Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383–1389.
33. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med*. 1995;333:1301–1307.
34. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet*. 2006;368:1155–1163.
35. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267–1278.
36. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
37. Report of a Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. *Lancet*. 1968;2:693–700.
38. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. *J Am Coll Cardiol*. 2005;46:1855–1862.
39. Woodhill J, Palmer A, Leelathaepin B, McGilchrist C, Blacket R. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. *Adv Exp Med Biol*. 1978;109:317–330.
40. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. *Acta Med Scand*. 1966;466:5–92.
41. Dorr A, Gundersen K, Schneider J Jr., Spencer T, Martin W. Colestipol hydrochloride in hypercholesterolemic patients – effect on serum cholesterol and mortality. *J Chron Dis*. 1978;31:5–14.
42. Lipid Research Clinics. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA*. 1984;251:351–364.
43. Coronary Drug Project. Clofibrate and niacin in coronary heart disease. *JAMA*. 1975;231:360–380.
44. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. *J Am Coll Cardiol*. 2009;53:316–322.
45. Buchwald H, Varco R, Matts J, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). *N Engl J Med*. 1990;323:946–955.
46. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. *JAMA*. 1988;260:641–651.
47. Frick M, Heinonen O, Huttenen J, Koskinen P, Manttari M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. *Ann Med*. 1993;25:41–45.
48. Smilde TJ, van Wissen S, Awollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. *Lancet*. 2001;357:577–581.
49. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AFH, Kastelein JJP. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. *Am J Cardiol*. 2005;95:264–266.
50. Kastelein JJP, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. *American Heart Journal*. 2005;149:234–239.
51. Robinson JG, Davidson M. Is it over for ezetimibe? *Exp Rev Cardiovasc Ther*. 2008;6:781–783.
52. Sivapalaratnam S, van Loendersloot LL, Hutten BA, Kastelein JJP, Trip MD, de Groot E. Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness. *Atherosclerosis*. 2010;212:571–574.
53. Iijoma N, Robinson J. Current and emerging therapies in hypercholesterolemia: Focus on colesevelam. *Clin Med Rev Vasc Health*. 2010;2:21–40.
54. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med*. 2008;359:1343–1356.
55. Holme I, Boman K, Brudi P, et al. Observed and Predicted Reduction of Ischemic Cardiovascular Events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial. *The American Journal of Cardiology*. 2010;105:1802–1808.
56. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J*. 2010;160:785–794.e10.
57. Baigent C, Landray M, Investigators obotS. The results of the Study of Heart and Renal Protection (SHARP). Presentation at the American Society Nephrology Scientific Sessions. Denver, Co, 2010.
58. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. *N Engl J Med*. 2008;359:1357–1366.
59. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. *Atherosclerosis*. 2010;210:353–361.
60. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. *BMJ*. 2009;338:b92.
61. National Heart L, and Blood Institute., AIM-HIGH: Niacin plus statin to prevent vascular events (NCT00120289). National Heart Lung and Blood Institute. 2010.
62. University of Oxford. Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). 2010.
63. Robinson J. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. *Vasc Health Risk Man*. 2009;5:31–43.
64. The Accord Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *N Engl J Med*. 2010;362:1563–1574.
65. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*. 2007;369:1090–1098.
66. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. *New Engl J Med*. 2010;363:2015–2026.
67. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation*. 2010;122:2152–2159.
68. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ*. 2010;341.
69. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. *Am J Cardiol*. 2008;102:1199–1204.

70. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. *Am J Cardiol.* 1998;82:1489–1495.
71. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. *Atherosclerosis.* 2009;208:317–321.
72. Thompson GR. Recommendations for the use of LDL apheresis. *Atherosclerosis.* 2008;198:247–255.
73. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statin for the prevention of coronary events. *Health Technol Assess.* 2007;11.
74. Kastelein JJP, van der Stieg W, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation.* 2008;117:3002–3009.
75. AstraZeneca Pharmaceuticals. Crestor (rosuvastatin calcium) [prescribing information]. Wilmington, DE, 2010.
76. US Food and Drug Administration. FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. 2010.
77. Liao JK. Safety and efficacy of statins in Asians. *Am J Cardiol.* 2007;99:410–414.
78. Smith JSC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol.* 2006;47:2130–2139.
79. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. *Atherosclerosis.*;209: 189-194.
80. Oosterveer DIM, Versmissen J, Yazdanpanah M, Defesche JC, Kastelein JJP, Sijbrands EJG. The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway. *European Heart Journal.* 2010;31:1007-1012.
81. Oosterveer DM, Versmissen J, Yazdanpanah M, Hamza TH, Sijbrands EJG. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: A systematic review and meta-analysis. *Atherosclerosis.* 2009;207:311–317.
82. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. *Arterioscler Thromb Vasc Biol*;30:177-181.
83. Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events?: A meta-analysis of 41 randomized trials. *J Am Coll Cardiol.* 2010;56:2006–2020.
84. McCullough PA, Chinnaiyan KM. Annual progression of coronary calcification in trials of preventive therapies. *Arch Intern Med.* 2009;169: 2064–2070.

# Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Stephen R. Daniels, MD, PhD\*, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH

University of Colorado School of Medicine, Aurora, CO, USA (Dr. Daniels); Nemours Foundation, Wilmington, DE, USA (Dr. Gidding); and Children's Hospital Boston, Boston, MA, USA (Dr. de Ferranti)

## Introduction

Cardiovascular disease is a leading cause of death and morbidity in the United States.<sup>1</sup> Results from autopsy studies of children and young adults (2 to 39 years of age), including the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study<sup>2,3</sup> and the Bogalusa Heart Study,<sup>4,5</sup> show that the process of atherosclerosis begins in childhood with the development of the fatty streak.<sup>2,3,4–6</sup> A fatty streak is an accumulation of lipid-filled macrophages within the arterial intima.<sup>7</sup> Continued accumulation of lipid-filled macrophages combined with smooth muscle cell proliferation can eventually progress to an atherosclerotic lesion or fibrous plaque.<sup>7</sup> Rupture of the plaque or blockage of the arterial lumen by the fibrous plaque, usually with an overlying

thrombus, leads to the clinical outcomes seen in cardiovascular disease: myocardial infarction and stroke.

The PDAY and Bogalusa Heart Study investigators showed that elevated plasma/serum cholesterol concentrations during childhood and adolescence, specifically low-density lipoprotein (LDL) and non-high-density lipoprotein (HDL) cholesterol, were associated with increased fatty streaks and plaques.<sup>2,3,5,6,8–10</sup> The Cardiovascular Risk in Young Finns Study investigators<sup>11</sup> examined the association between LDL cholesterol concentration measured during childhood and adolescence and carotid intima-media thickness, a marker of subclinical atherosclerosis, measured in adulthood. LDL cholesterol levels in boys aged 12 to 18 years were positively associated with adult carotid intima media thickness.<sup>11</sup>

In addition to the association between lipid levels during childhood and the development of cardiovascular disease, epidemiologic evidence indicates that total and LDL cholesterol concentrations during childhood are strong predictors of adult cholesterol concentrations.<sup>12–20</sup> In the Bogalusa Heart Study, 50% of the children with elevated cholesterol (>75<sup>th</sup> percentile) during childhood had hypercholesterolemia as adults.<sup>14–16</sup> This is more than twice the proportion that would be predicted to have hypercholesterolemia by chance alone.<sup>21</sup>

The familial hypercholesterolemias (FH) are defined as a group of inherited genetic defects resulting in severely elevated serum cholesterol concentrations. FH is one of the two most frequently diagnosed lipid disorders in children and adolescents (the other is familial combined hyperlipidemia).

---

**National Lipid Association Expert Panel on Familial Hypercholesterolemia:** Anne C. Goldberg, MD, FNLA, Chair, Paul N. Hopkins, MD, MSPH, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA, Jennifer G. Robinson, MD, MPH, FNLA, Stephen R. Daniels, MD, PhD, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH, Matthew K. Ito, PharmD, FNLA, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA.

\* Corresponding author: Stephen R. Daniels, MD, PhD, Professor and Chairman, Department of Pediatrics, University of Colorado School of Medicine, Pediatrician-in-Chief and L. Joseph Butterfield Chair of Pediatrics The Children's Hospital, Denver, 13123 E. 16th Avenue, B065, Aurora, CO 80045, Tel: 720-777-2766, Fax: 720-777-7278.

E-mail address: Daniels.Stephen@tchden.org

Submitted March 30, 2011. Accepted for publication March 30, 2011.

**Summary Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia****Screening**

- Universal screening at age 9 to 11 years with a fasting lipid profile or nonfasting non-high-density lipoprotein (HDL) cholesterol measurement is recommended to identify all children with familial hypercholesterolemias (FH). This age identifies individuals at the potential onset of advanced atherosclerosis, and provides the best discrimination between those with and without inherited dyslipidemias by avoiding confounding due to changes in lipid levels associated with puberty.
- If a nonfasting non-HDL cholesterol concentration of  $\geq 145$  mg/dL is detected, then a fasting lipid profile should be performed.
- Screening should occur earlier ( $\geq 2$  years of age) in the presence of a positive family history for hypercholesterolemia or premature coronary heart disease (CHD) or the presence of other major CHD risk factors.
- Identifying FH in someone with other major CHD risk factors is critical for risk stratification.
- Evaluation (history, physical examination, selected laboratory tests) of possible secondary causes of dyslipidemia should be performed. Secondary causes include hypothyroidism, nephrotic syndrome, and liver disease.

**Diagnosis**

- Untreated fasting lipid levels at which FH may be suspected in children, adolescents and young adults (<20 years) are low-density lipoprotein (LDL) cholesterol concentration  $\geq 160$  mg/dL or non-HDL cholesterol  $\geq 190$  mg/dL. These levels are supported by family studies of affected individuals.
- A second lipid profile should be performed to assess response to diet management, to account for regression to the mean, and to accurately classify those with levels close to classification thresholds.

**Lipid Specialists**

- Primary care clinicians should be responsible for screening and diagnosis.
- For treatment of children with FH, either consultation with or referral to a lipid specialist is recommended. Pediatric lipid specialists include pediatric cardiologists, endocrinologists, or other health care providers with specialized lipidology training. Use of lipid lowering medications is currently not typically part of pediatric training.
- Homozygous FH should always be managed by a lipid specialist.

**Cardiovascular Risk Assessment**

- Comprehensive CHD risk assessment [including measurement of lipoprotein (a) levels] and management is critical. The presence of multiple CHD risk factors is associated with dramatic acceleration of atherosclerosis development.
- Primordial prevention, which includes counseling for the prevention of risk development (not smoking, low saturated fat diet, appropriate caloric intake and regular physical activity supporting the avoidance of diabetes), is an important component of treatment of patients with FH.

**Treatment**

- Statins are preferred for initial pharmacologic treatment in children after initiation of diet and physical activity management.
- Consideration should be given to starting treatment at the age of 8 years or older. In special cases, such as those with homozygous FH, treatment might need to be initiated at earlier ages.
- Clinical trials with medium term follow up suggest safety and efficacy of statins in children.
- The treatment goal of lipid lowering therapy in pediatric FH patients is a  $\geq 50\%$  reduction in LDL cholesterol or LDL cholesterol  $< 130$  mg/dL. There is a need in treatment of pediatric FH for balance between increased dosing and potential for side effects vs. achieving goals. More aggressive LDL cholesterol targets should be considered for those with additional CHD risk factors.

**Homozygous FH**

- Initiation of therapy early in life and ongoing monitoring of homozygous FH is vital.
- High dose statins may be effective in some homozygous FH patients, but the majority will require LDL apheresis. Liver transplantation is also being used in some centers.
- Gene therapy is a potential new treatment in development and may be particularly beneficial for homozygous FH patients.

The genetic defects in FH arise from mutations affecting the LDL receptor,<sup>22</sup> apolipoprotein B (Apo B)<sup>23</sup> or proprotein convertase subtilisin kexin type 9 (PCSK9; an enzyme involved in LDL receptor degradation).<sup>24</sup> Heterozygous FH affects approximately one of every 500 persons in the United States, whereas homozygous FH is rare with a prevalence of one of every million individuals in the United States.<sup>22,25</sup> Throughout this document, the term FH refers to the heterozygous (autosomal dominant) form of FH, unless otherwise indicated. Children with FH, particularly the homozygous form, are at extremely high risk for developing premature coronary heart disease (CHD). This document provides the rationale for the consensus reached by the National Lipid Association Familial Hypercholesterolemia Panel with regards to recommendations for the treatment of FH in pediatric patients.

## Screening

Screening for hypercholesterolemia in childhood allows for early and accurate identification of FH. Because FH confers lifelong risk of atherosclerosis beginning in childhood, and is associated with premature CHD, early screening is justified. Previous national guidelines have recommended targeted screening for children who either 1) have a family history of premature cardiovascular disease or high blood cholesterol concentrations, or 2) have unknown family history or have other risk factors for cardiovascular disease such as obesity, hypertension or diabetes mellitus.<sup>21,26–28</sup> Because FH is a genetic disorder, acknowledging the role that family history may have in the development of disease is important; however, reliance on family history as the basis for screening decisions has several limitations. Methods for collecting family history information are not standardized, and often family history and/or family members' cholesterol levels are unknown.<sup>21,29</sup> Furthermore, a negative family history of premature CHD should not rule out a diagnosis of FH. It has been reported that application of targeted screening approaches may fail to indicate screening for 30 to 60% of children and adolescents with elevated cholesterol concentrations.<sup>21,30–32</sup>

Due to the lack of sensitivity and specificity of targeted screening for detecting elevated cholesterol in children, we recommend universal screening of all children between the ages of 9 and 11 years to identify children with FH. This screening measurement should include a fasting lipid profile or a non-fasting non-high-density lipoprotein (HDL) cholesterol assessment, which is an estimate of the cholesterol content of all Apo B-containing lipoproteins calculated by subtracting HDL cholesterol from total cholesterol. If a non-fasting non-HDL cholesterol concentration  $\geq 145$  mg/dL is reported, then a fasting lipid profile should be obtained. The age range between 9 and 11 years was selected in order to allow the best discrimination between those with and without FH at the potential onset of advanced atherosclerosis, while avoiding confounding by pubertal-related unstable lipid levels. Lipid levels, particularly levels of LDL cholesterol, are reduced during pubertal development and then increase in

late adolescence and early adulthood.<sup>19,33</sup> Screening should occur earlier ( $\geq 2$  years of age) in the presence of a positive family history for hypercholesterolemia or premature CHD or the presence of other major CHD risk factors, including obesity, hypertension and diabetes. The cut point of  $\geq 2$  years is suggested because serum lipids and lipoprotein levels increase during the first two years of life, becoming stable around age 2.<sup>34–36</sup>

Although cholesterol screening has been recommended for several decades in children and adolescents, there is significant under-screening, based on family history or the presence of other risk factors, and lack of adherence by practitioners in prescribing recommended treatments in children identified with lipid disorders.<sup>21</sup> The importance of adherence to dietary and drug management of hypercholesterolemia should be strongly emphasized to parents and young patients identified with FH.

Hypercholesterolemia can be secondary to other diseases that affect lipoprotein metabolism. An important part of the screening process is to rule out possible secondary causes of dyslipidemia (e.g., diabetes, hypothyroidism, hepatic disease, or renal disease or dysfunction) through evaluation of history, physical examination or selected laboratory tests. Identifying FH in someone with other major CHD risk factors is also critical for risk management as described in greater detail in the Risk Management section below.

## Diagnosis

Childhood and adolescent levels of total, LDL and non-HDL cholesterol categorized according to acceptable, borderline, and high classifications from Bogalusa Heart Study data,<sup>37</sup> as described by the National Cholesterol Education Program Expert Panel on Cholesterol Levels in Children and Lipid Research Clinics Prevalence Study<sup>12</sup> are shown in Table 1.

Several standardized criteria for the diagnosis of FH are used clinically, including the Simon Broome Criteria,<sup>38</sup> Dutch Lipid Clinic Network Criteria,<sup>39</sup> and Make Early Diagnosis Prevent Early Deaths (MEDPED) criteria.<sup>40</sup> These diagnostic criteria are described in detail elsewhere in this supplement. Genetic testing is an important element for making a diagnosis according to these criteria. Because confirmation of the presence of a genetic mutation is not necessary to identify individuals with hypercholesterolemia, and is unlikely to modify the approach to management in the current state of knowledge, a simplified approach to FH diagnosis can be taken (Table 2). FH may be suspected in a child, adolescent, or young adult ( $< 20$  years of age) if he/she has an untreated fasting LDL cholesterol level  $\geq 160$  mg/dL (or non-HDL cholesterol  $\geq 190$  mg/dL). These levels are substantially above the 95th percentile as supported by population studies and family studies of affected individuals.<sup>41</sup> A second lipid profile (following dietary counseling) should be performed to assess response to diet management, account for regression to the mean, and confirm classification for those with levels close to

**Table 1** Levels of plasma lipid concentrations (mg/dL)\* in children, adolescents and young adults

	Acceptable	Borderline High	High
<b>Children and Adolescents<sup>†</sup></b>			
Total Cholesterol	<170	170–199	≥200
LDL Cholesterol	<110	110–129	≥130
Non-HDL Cholesterol	<120	120–144	≥145
<b>Young Adults<sup>‡</sup></b>			
Total Cholesterol	<190	190–224	≥225
LDL Cholesterol	<120	120–159	≥160
Non-HDL Cholesterol	<150	150–189	≥190

\*To convert mg/dL to SI units, divide the results by 38.6.

<sup>†</sup>Values for plasma lipid levels are in agreement with the National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children.<sup>26</sup> Non-HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cut-points for LDL cholesterol.<sup>37</sup> The cut-points for high and borderline-high represent approximately the 95<sup>th</sup> and 75<sup>th</sup> percentiles, respectively.<sup>26,37</sup>

<sup>‡</sup>Values provided are from the Lipid Research Clinics Prevalence Study.<sup>12</sup> The cut points for total, LDL and non-HDL cholesterol represent the 95<sup>th</sup> percentile for subjects aged 20–24 years and are not identical with the cut points used in the most recent NCEP ATP III<sup>42</sup> which are derived from combined data on adults of all ages. The age-specific cut-points given here are provided for pediatric care providers to use in managing this young adult age group. For total, LDL, and non-HDL cholesterol, borderline high values are between the 75<sup>th</sup> and 94<sup>th</sup> percentiles, whereas acceptable values are <75<sup>th</sup> percentile.

thresholds. Decisions regarding the need for prescription lipid drug therapy should be based on the average of results from at least two fasting lipid profiles. The amount of time between initial dietary counseling and decisions to start lipid drug therapy may vary between patients, depending on age, family history and baseline LDL cholesterol levels.

## Lipid specialists

Primary care clinicians are at the front line of responsibility for the screening and diagnosis of FH in the pediatric population. However, because the use of lipid lowering medications is not typically part of pediatric medical training, if heterozygous FH is suspected or diagnosed, the primary care clinician should either consult a lipid specialist for guidance in treatment or refer the child directly to the lipid specialist. A pediatric patient with homozygous FH should always be managed by a lipid specialist. Pediatric lipid specialists include pediatric cardiologists, endocrinologists, or other health care providers with specialized lipidology training (see [www.learnyourlipids.com/resources.php](http://www.learnyourlipids.com/resources.php) for a lipid specialist locator).

## Cardiovascular risk assessment

Hypercholesterolemia is an established risk factor for the development of atherosclerosis.<sup>42,43</sup> Other major CHD risk

factors and risk equivalents include family history of premature heart disease, increased age, male sex, hypertension, diabetes, smoking, and reduced high-density lipoprotein (HDL) cholesterol concentration. Children with chronic kidney disease, Kawasaki disease with coronary aneurysms, and possibly other chronic inflammatory conditions such as lupus are at risk for coronary artery disease as young adults.<sup>44</sup> The presence of additional CHD risk factors is associated with a dramatic acceleration of atherosclerosis in the FH patient, and should therefore be assessed comprehensively. When other CHD risk factors are present, they should be treated aggressively. If other CHD risk factors are not present, lifestyle intervention should be initiated to prevent the development of other risk factors. CHD risk assessment, including measurement of lipoprotein (a), and management of identified risk factors is integral to the treatment of FH.

## Treatment

Primordial prevention, which includes counseling for the prevention of risk development (not smoking, low saturated fat diet, appropriate caloric intake, and regular physical activity supporting the avoidance of diabetes), is an important component of the treatment of patients with FH.<sup>42</sup> All FH patients require primordial prevention, but it is unlikely that diet and lifestyle changes alone will be enough to achieve the target of ≥50% reduction in LDL cholesterol or LDL cholesterol <130 mg/dL. More aggressive LDL cholesterol targets should be considered for those with additional CHD risk factors.<sup>44</sup> Almost all FH patients, including children and adolescents, will ultimately require lipid-lowering drug therapy to achieve LDL cholesterol treatment goal, but diet and lifestyle modifications, which may reduce LDL cholesterol by 10 to 15%,<sup>45,46</sup> should not be abandoned with the initiation of drug therapy. These are important in long-term management, may affect non-cholesterol and cardiovascular disease risk factors, and may lower the required pharmacotherapy dose.<sup>42</sup>

After initiation of diet (including dietary adjuncts of plant sterols/stanols and soluble fiber),<sup>42</sup> statins are the

**Table 2** Recommended screening indicators and treatment targets for pediatric FH

<b>Screening</b>	
Non-fasting non-HDL cholesterol ≥145 mg/dL	→ Perform fasting lipid profile
Fasting LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL	→ Suspect FH in patients <20 years of age
<b>Treatment</b>	
Target for FH patients	≥50% ↓ LDL cholesterol or LDL cholesterol <130 mg/dL

preferred initial pharmacologic treatment in children with FH. Consideration should be given to starting medical treatment at the age of 8 years or older. In special cases, such as those with homozygous FH, treatment might need to be initiated at earlier ages. Six statins (rosuvastatin, atorvastatin, simvastatin, pravastatin, lovastatin, and fluvastatin) are FDA approved as an adjunct to diet to lower markedly elevated LDL cholesterol levels in children 10 years of age and older (ages 8 years and older for pravastatin).<sup>47,48</sup> Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate limiting enzyme for endogenous synthesis of cholesterol, and by doing so lower hepatocyte cholesterol concentration leading to LDL receptor upregulation and improved clearance of circulating LDL cholesterol.

Numerous clinical trials of the safety and efficacy of statins for lowering LDL cholesterol have been conducted in children and adolescents with severe dyslipidemia or FH.<sup>49–60</sup> Although these clinical trials had short- to medium-term follow up, all suggested that statins are well tolerated, safe and efficacious for lowering LDL cholesterol in young people with hypercholesterolemia. While there have been no randomized clinical trials designed to address whether treating FH with drugs in children and adolescents will reduce cardiovascular disease events later in life, there is evidence from non-invasive vascular endothelial function testing and carotid intima-media thickness measurements that lipid-lowering with statins may delay the atherosclerotic disease process.<sup>57,61,62</sup> In general, statins reduce LDL cholesterol levels in children with FH by 23 to 40%.<sup>60</sup> Adverse event profiles for statins in youth are similar to those reported in adult studies<sup>63</sup> and include rare instances of myopathy and hepatic enzyme elevation.<sup>60</sup> Routine monitoring of liver and muscle enzymes and symptoms of muscle toxicity, according to the timing described by the Scientific Statement from the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing<sup>64</sup> is strongly recommended for children and adolescents receiving statin therapy.

Children who are not able to reach the LDL cholesterol treatment goal with the initial statin dose, or who have additional CHD risk factors, may require intensification of statin therapy, or the addition of a second lipid medication under the guidance of a lipid specialist. Therapeutic management of FH in the pediatric population requires a careful balance between increased dosing and potential side effects vs. achieving treatment goals.

Bile acid sequestrants (colesevelam, cholestyramine, colestipol) bind bile salts in the intestinal lumen preventing their enterohepatic recirculation. This depletion of hepatic bile acids signals the need for increased production of bile acids from cholesterol. Bile acid sequestrants lower LDL cholesterol by 10 to 20%, but cholestyramine and colestipol are associated with significant gastrointestinal side effects (constipation) and low palatability, which reduce their tolerability.<sup>65,66</sup> Although bile acid sequestrants are

generally considered safe in childhood (despite being poorly tolerated), cholestyramine and colestipol do not have pediatric indications. Colesevelam is indicated for use in pediatric populations (boys and postmenarchal girls aged 10 to 17 years with FH) as monotherapy or combined with a statin. This agent is available as a tablet or powder and is associated with only relatively minor side effects.<sup>67</sup>

Ezetimibe is a cholesterol absorption inhibitor that acts to specifically inhibit cholesterol absorption in the intestine. Although ezetimibe is absorbed, most remains within the enterohepatic circulation. Ezetimibe has been shown to reduce LDL cholesterol by an additional 20% when added to a statin,<sup>68</sup> and recent studies support its use as monotherapy or in combination with a statin in children and adolescents.<sup>69,70</sup> Currently, ezetimibe is not approved by the FDA for use in children with hypercholesterolemia.

There is limited published experience in children with the use of niacin or fibrates,<sup>48,71,72</sup> and neither is used routinely for the treatment of pediatric FH. Niacin can be effective in lowering LDL cholesterol, lipoprotein (a), and triglycerides while increasing HDL cholesterol. However, its adverse effects make it difficult to use in pediatric clinical practice (flushing, hepatic dysfunction, myopathy, glucose intolerance, and hyperuricemia). The primary actions of fibric acid derivatives (gemfibrozil and fenofibrate) are to lower triglycerides and raise HDL cholesterol, and they do not reliably lower LDL cholesterol. Furthermore fibrates (particularly gemfibrozil) may increase the risk of statin-induced myositis.<sup>73</sup> Therefore, fibrates are not recommended for routine use in pediatric patients with FH, unless triglyceride levels are elevated, and then they should be used with caution.

Children should receive at least three nutrition counseling sessions in the six months after initial diagnosis, and then have clinic visits every one to two years until the age at which statins are recommended, unless lifestyle issues indicate that more frequent nutrition/lifestyle behavior visits are necessary. After lipid medication is initiated, clinic visits should occur every 3 to 6 months with a fasting lipid profile and comprehensive assessment by history and laboratory testing for side effects (hepatic enzyme elevation and muscle toxicity), other cardiovascular risk factors, and to reassess lifestyle behaviors.

## Homozygous FH

Homozygous FH is very rare, with a prevalence of approximately one in every one million persons in the United States.<sup>22,25</sup> It is associated with extremely high LDL cholesterol levels (650 to 1000 mg/dL). Homozygous FH most commonly manifests in infancy and early childhood as a history of skin lesions (xanthomas). In fact, initial identification of homozygous FH is often made by a dermatologist or by an astute family member. Initiation of therapy in childhood and ongoing monitoring is vital because patients with homozygous FH often develop cardiovascular disease in their 20s, or even earlier in severe cases.<sup>25</sup>

A pediatric patient with homozygous FH should always be managed by a lipid specialist. A complete cardiologic investigation, including an electrocardiogram and echocardiogram or vascular imaging, at the time of diagnosis is useful for assessment of ongoing cardiovascular disease and may be beneficial for further educating the homozygous FH patient and parents regarding their disease risk. However, these findings do not typically alter decisions regarding treatment. Thus, there are no specific recommendations for performing these tests in children. The follow up of patients with homozygous FH is also not standard, and there are no generally accepted guidelines. Repeat echocardiograms to evaluate supravalvular aortic stenosis are useful and stress testing using nuclear medicine or stress echocardiography may be indicated. Regular assessment of coronary arteries for plaque formation may be important. This can be accomplished by coronary artery angiography sometimes accompanied by intracoronary ultrasound, or computed tomography angiogram using lower radiation protocols in experienced institutions. Significant atherosclerosis may develop outside the coronary system, including renal artery stenosis and carotid disease.

There are no randomized controlled trials of treatment for homozygous FH (for ethical reasons). Despite severely reduced LDL cholesterol receptor level/activity in homozygous FH patients, high doses of statins may be somewhat effective for lowering LDL cholesterol concentrations.<sup>25</sup> However, the majority will require LDL apheresis, which is an FDA-approved process of selectively removing Apo B-containing particles from the circulation through extracorporeal precipitation.<sup>74</sup> The procedure is performed at medical centers with this expertise and must be repeated every 1 to 2 weeks. A listing of sites qualified to perform LDL apheresis is in development and will be posted on the National Lipid Association website ([www.lipid.org](http://www.lipid.org)). Liver transplantation may also be considered, and is being performed in some centers. The surgery is associated with considerable risks, but because a new liver provides functional LDL receptors, it can dramatically decrease LDL cholesterol concentrations. Gene therapy is a potential new treatment in development that may be particularly beneficial for patients with homozygous FH who require lifelong therapy and monitoring yet remain at significant risk for the development of cardiovascular disease.<sup>75–77</sup>

## Acknowledgments

The authors would like to thank Mary R. Dicklin, PhD, Kevin C. Maki, PhD, FNLA, and Lynn Cofer-Chase, MSN, FNLA, from Provident Clinical Research for writing and editorial assistance.

## Industry support disclosure

The January 2011 NLA familial hypercholesterolemia recommendations conference was supported by unrestricted

grant funding from the following companies: Abbott Laboratories, Aegerion Pharmaceuticals, Daiichi Sankyo, Genzyme, Kaneka Pharma America LLC, and Merck & Co. The National Lipid Association would like to thank each company for its support of this endeavor. In accordance with the National Lipid Association Code for Interactions with Companies, the NLA maintained full control over the planning, content, quality, scientific integrity, implementation, and evaluation of the recommendations conference and this familial hypercholesterolemia recommendations paper. All related activities are free from commercial influence and bias.

## Author disclosures

Dr. Daniels has received honoraria related to consulting from Merck & Co.

Dr. de Ferranti has received research grants from GlaxoSmithKline.

Dr. Gidding has received honoraria related to consulting from Merck & Co. Dr. Gidding has received research grants from GlaxoSmithKline.

## References

1. American Heart Association. Executive Summary: Heart Disease and Stroke Statistics 2011 Update: A Report from the American Heart Association. American Heart Association Heart Disease and Stroke Statistics Writing Group. *Circulation*. 2011;123:459–463.
2. McGill HC Jr., McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Arterioscler Thromb Vasc Biol*. 2000;20:836–845.
3. McGill HC Jr., McMahan CA, Zieske AW, et al. Effect of nonlipid risk factors on atherosclerosis in youth with favorable lipoprotein profile. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Circulation*. 2001;103:1546–1550.
4. Newman WP III, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. *N Engl J Med*. 1986;314:138–144.
5. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med*. 1998;338:1650–1656.
6. McGill HC Jr., McMahan CA, Malcom GT, Oalmann MS, Strong JP. Effects of serum lipoproteins of smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. *Arterioscler Thromb Vasc Biol*. 1997;17:95–106.
7. Sary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol*. 1995;15:1512–1531.
8. Rainwater DL, McMahan CA, Malcom GT, et al. Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. *Arterioscler Thromb Vasc Biol*. 1999;19:753–761.
9. McMahan CA, Gidding SS, Fayad ZA, et al. Risk scores predict atherosclerotic lesions in young people. *Arch Intern Med*. 2005;165:883–890.

10. McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC Jr. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. *Pediatrics*. 2006;118:1447–1455.
11. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. *JAMA*. 2003;290:2277–2283.
12. LaRosa JC, Chambless LE, Criqui MH, et al. Patterns of dyslipoproteinemia in selected North American populations: The Lipid Research Clinical Program Prevalence Study. *Circulation*. 1986;73:112–129.
13. Stuhldreher WL, Orchard TJ, Donahue RP, Kuller LH, Gloninger MF, Drash AL. Cholesterol screening in childhood: sixteen year Beaver County Lipid Study experience. *J Pediatr*. 1991;119:551–556.
14. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. *Am J Epidemiol*. 1991;133:884–899.
15. Porkka KV, Vilkari JS, Taimlea S, Dahl M, Akerblom HK. Tracking and predictiveness of serum lipid and lipoprotein measures in childhood: a 12-year follow-up. The Cardiovascular Risk in Young Finns study. *Am J Epidemiol*. 1994;140:1096–1110.
16. Bao W, Srinivasan SR, Wattigney WA, Bao W, Berenson GS. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study. *Arch Intern Med*. 1996;155:190–196.
17. Srinivasan SR, Ehnholm C, Wattigney WA, Berenson GS. The relation of apolipoprotein E polymorphism to multiple cardiovascular risks in children: the Bogalusa Heart Study. *Atherosclerosis*. 1996;123:33–42.
18. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. *JAMA*. 2003;290:2271–2276.
19. Friedman LA, Morrison JA, Daniels SR, McCarthy WF, Sprecher DL. Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. *Pediatrics*. 2006;118:165–172.
20. Magnussen CG, Raitakari OT, Thomson R, et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study. *Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study*. *Circulation*. 2008;117:32–42.
21. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systemic evidence review for the US Preventive Services Task Force. *Pediatrics*. 2007;120:e189–e214.
22. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. *The metabolic and molecular bases of inherited disease*. New York: McGraw-Hill, 2001. p. 2863–2913.
23. Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the Apo B gene. *Clin Chem*. 2004;50:1725–1732.
24. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. *J Lipid Res*. 2009;50:S172–S177.
25. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. *J Clin Endocrinol Metab*. 2008;93:4200–4209.
26. Expert Panel of Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. *Pediatrics*. 1992;89:495–501.
27. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. *Pediatrics*. 1998;101:141–147.
28. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. *Pediatrics*. 2008;122:198–208.
29. Dennison BA, Jenkins PL, Pearson TA. Challenges to implementing the current pediatric cholesterol screening guidelines into practice. *Pediatrics*. 1994;94:296–302.
30. Griffin TC, Chritoffel KK, Binns HJ, McGuire PA. Family history evaluation as a predictive screen for childhood hypercholesterolemia. Pediatric Practice Research Group. *Pediatrics*. 1989;84:365–373.
31. Diller PM, Huster GA, Leach AD, Laskarzewski PM, Sprecher DL. Definition and application of the discretionary screening indicators according to the National Cholesterol Education Program for Children and Adolescents. *J Pediatr*. 1995;126:345–352.
32. Rifai N, Neufeld E, Ahlstrom P, Rimm E, D'Angelo L, Hicks JM. Failure of current guidelines for cholesterol screening in urban African-American adolescents. *Pediatrics*. 1996;98(3 pt 1):383–388.
33. Hickman TB, Briefel RR, Carroll MD, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. *Prev Med*. 1998;27:879–890.
34. Kwiterovich PO Jr, Levy RI, Fredrickson DS. Neonatal diagnosis of familial type-II hyperlipoproteinemia. *Lancet*. 1973;1:118–121.
35. Freedman DS, Srinivasan SR, Cresanta JL, Webber LS, Berenson GS. Cardiovascular risk factors from birth to 7 years of age: the Bogalusa Heart Study. Serum lipids and lipoproteins. *Pediatrics*. 1987;80(5 Pt 2):789–796.
36. Tamir L, Heiss G, Glueck CJ, Christensen B, Kwiterovich P, Rifkind B. Lipid and lipoprotein distributions in white children ages 6–19 years: the Lipid Research Clinics Program Prevalence Study. *J Chronic Dis*. 1981;34:27–39.
37. Srinivasan SR, Myers L, Berenson GS. Distribution and correlates of non-high-density lipoprotein cholesterol in children: the Bogalusa Heart Study. *Pediatrics*. 2002;110:e29.
38. Scientific steering committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. *BMJ*. 1991;303:893–896.
39. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis*. 2004;173:55–68.
40. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol*. 1993;72:171–176.
41. Ose L. Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children. *Semin Vasc Med*. 2004;4:51–57.
42. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143–3421.
43. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227–239.
44. Kavey RE, Allada V, Daniels SR, et al. American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science: the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney and Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation*. 2006;114:2710–2738.
45. Gidding SS, Dennison BA, Birch LL, et al. American Heart Association; American Academy of Pediatrics. Dietary recommendations for children and adolescents: a guide for practitioners: consensus

- statement from the American Heart Association. *Circulation*. 2005;112:2061–2075.
46. Bruckert E, Rosenbaum D. Lowering LDL cholesterol through diet: potential role in the statin era. *Curr Opin Lipidol*. 2011;22:43–48.
  47. Stein EA. Statins and children. Whom do we treat and when? *Circulation*. 2007;116:594–595.
  48. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2010;55:1121–1126.
  49. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children. *Lancet*. 1992;338:1488.
  50. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of Pravastatin in 72 children with familial hypercholesterolemia. *Pediatr Res*. 1996;39:867–871.
  51. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. *Pediatrics*. 1996;97:619–628.
  52. Stein EA, Illingworth DR, Kwiterovich PO Jr., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. *JAMA*. 1999;281:137–144.
  53. Firth JC, Marais AD, Byrnes P, Fusco RA, Bonnici F. Fluvastatin in heterozygous familial hypercholesterolemia. *Cardiol Young*. 2000;10(suppl 2):35.
  54. de Jongh S, Ose L, Szamosi T, et al. Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. *Circulation*. 2002;106:2231–2237.
  55. McCrindle BW, Heldon E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. *Pediatr Res*. 2002;51:715–721.
  56. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. *J Pediatr*. 2003;143:74–80.
  57. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *JAMA*. 2004;292:331–337.
  58. Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. *Pediatrics*. 2005;116:682–688.
  59. van der Graaf A, Nierman MC, Firth JC, Wolmarens KH, Marais AD, de Groot E. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia. *Acta Paediatr*. 2006;95:1461–1466.
  60. Vuorino A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev*. 2010;7:CD006401.
  61. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2002;40:2117–2121.
  62. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger the better. *Circulation*. 2007;116:664–668.
  63. McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Task Force Liver Expert Panel. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol*. 2006;89C–94C.
  64. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents. A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. *Circulation*. 2007;115:1948–1967.
  65. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. *J Pediatr*. 1996;129:42–49.
  66. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. *J Pediatr*. 1997;130:266–273.
  67. Perry CM. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. *Paediatr Drugs*. 2010;12:133–140.
  68. Gagne C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation*. 2002;105:2469–2475.
  69. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. *J Am Coll Cardiol*. 2008;52:1421–1429.
  70. Yeste D, Chacon P, Clemente M, Albus MA, Gussinye M, Carracosa A. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. *J Pediatr Endocrinol Metab*. 2009;22:487–492.
  71. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. *Pediatrics*. 1993;92:78–82.
  72. Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. *Arch Dis Child*. 1985;60:34–37.
  73. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. *Nat Rev Endocrinol*. 2009;5:507–518.
  74. Moriarty PM. LDL-apheresis therapy. *Curr Treat Options Cardiovasc Med*. 2006;8:282–288.
  75. Hansson GK. Vaccination against atherosclerosis: science or fiction? *Circulation*. 2002;106:1599–1601.
  76. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. *Molec Ther*. 2007;15:1233–1247.
  77. Goldberg AC. NLA Symposium on Familial Hypercholesterolemia. Novel therapies and new targets of treatment familial hypercholesterolemia. *J Clin Lipidol*. 2010;4:350–356.

# Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Matthew K. Ito, PharmD, FNLA\*, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD

*Oregon State University/Oregon Health & Science University, Portland, OR, USA (Dr. Ito); Cholesterol Treatment Center, Concord Hospital, Concord, NH, USA (Dr. McGowan); and The University of Kansas Hospital, Kansas City, KS, USA (Dr. Moriarty)*

## Introduction

Cardiovascular disease is the leading cause of morbidity and mortality in the United States.<sup>1</sup> Hypercholesterolemia, specifically elevated level of low-density lipoprotein (LDL) cholesterol, is a major coronary heart disease (CHD) risk factor.<sup>2</sup> While environmental factors such as diet and physical activity have important roles in determining an individual's level of circulating cholesterol, there is also a genetic component. The familial hypercholesterolemias (FH) are a group of inherited genetic defects resulting in severely elevated serum cholesterol concentrations. The genetic defects in FH arise from mutations affecting the LDL receptor,<sup>3</sup> apolipoprotein (Apo) B<sup>4</sup> or proprotein convertase subtilisin kexin type 9

(PCSK9; an enzyme involved in LDL receptor degradation)<sup>5</sup>. Heterozygous FH is a common genetic defect affecting approximately one of every 500 persons in the United States, although this ratio is much higher in certain subpopulations in the U.S. Homozygous FH is quite rare, affecting one of every one million individuals in the United States.<sup>6–9</sup> Throughout this document, the term FH refers to the heterozygous form of FH, unless otherwise indicated.

FH is associated with a high risk for premature coronary heart disease (>50% risk in men by age 50 and >30% in women by age 60).<sup>8,9</sup> In untreated individuals, symptoms of coronary disease may manifest in men in their 40s and in women 10 to 15 years later. There is a substantial body of evidence from large-scale clinical trials supporting the benefit of lowering LDL cholesterol with statins to reduce cardiovascular disease morbidity and mortality.<sup>2,10</sup> Although no randomized placebo-controlled outcome trials of statin therapy have been conducted in FH cohorts (for ethical reasons) due to their high LDL cholesterol levels and associated cardiovascular disease risk, observational studies provide compelling evidence that statins alter the clinical course of the disease.<sup>11</sup> Thus, aggressive lipid management in men and women with FH is vital in order to prevent or slow the progression of coronary atherosclerosis. This document provides the rationale for the consensus reached by the National Lipid Association Familial Hypercholesterolemia Panel with regards to recommendations for the treatment of FH in adult patients.

---

**National Lipid Association Expert Panel on Familial Hypercholesterolemia:** Anne C. Goldberg, MD, FNLA, Chair, Paul N. Hopkins, MD, MSPH, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA, Jennifer G. Robinson, MD, MPH, FNLA, Stephen R. Daniels, MD, PhD, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH, Matthew K. Ito, PharmD, FNLA, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA.

\* Corresponding author: Matthew K. Ito, PharmD, FNLA, Professor of Pharmacy Practice, Oregon State University/Oregon Health & Science University, College of Pharmacy Portland Campus at OHSU, Tel: 503-494-3657.

E-mail address: itom@ohsu.edu

Submitted March 31, 2011. Accepted for publication April 4, 2011.

**Summary Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia****Lifestyle Modifications**

- Patients with familial hypercholesterolemias (FH) should be counseled regarding the following lifestyle modifications:
  - Therapeutic Lifestyle Changes and dietary adjuncts.
    - Reduced intakes of saturated fats and cholesterol: total fat 25-35% of energy intake, saturated fatty acids <7% of energy intake, dietary cholesterol <200 mg/d.
    - Use of plant stanol or sterol esters 2 g/d.
    - Use of soluble fiber 10-20 g/d.
  - Physical activity and caloric intake to achieve and maintain a healthy body weight.
  - Limitation of alcohol consumption.
  - Emphatic recommendation to avoid use of any tobacco products.
- Clinicians are encouraged to refer patients to registered dietitians or other qualified nutritionists for medical nutrition therapy.

**Drug Treatment of FH**

- For adult FH patients, initial treatment is the use of moderate to high doses of high-potency statins titrated to achieve low-density lipoprotein (LDL) cholesterol reduction  $\geq 50\%$  from baseline. Low potency statins are generally inadequate for FH patients.
- If the initial statin is not tolerated, consider changing to an alternative statin, or every-other-day statin therapy.
- If initial statin therapy is contraindicated or poorly tolerated, ezetimibe, a bile acid sequestrant (colesevelam) or niacin may be considered.
- For patients who cannot use a statin, most will require combination drug therapy.

**Additional Treatment Considerations**

- If the patient is not at LDL cholesterol treatment goal with the maximum available and tolerable dose of statin, then combine with ezetimibe, niacin, or a bile acid sequestrant (colesevelam preferred).
- Decisions regarding selection of additional drug combinations should be based on concomitant risk factors for myopathy, concomitant medications, and the presence of other disease conditions and lipid abnormalities.

**Candidates for LDL Apheresis**

- LDL apheresis is a U.S. Food and Drug Administration approved medical therapy for patients who are not at LDL cholesterol treatment goal or who have ongoing symptomatic disease.
- In patients who, after six months, do not have an adequate response to maximum tolerated drug therapy, LDL apheresis is indicated according to these guidelines:
  - Functional homozygous FH patients with LDL cholesterol  $\geq 300$  mg/dL (or non-HDL cholesterol  $\geq 330$  mg/dL).
  - Functional heterozygous FH patients with LDL cholesterol  $\geq 300$  mg/dL (or non-HDL cholesterol  $\geq 330$  mg/dL) and 0-1 risk factors.
  - Functional heterozygous FH patients with LDL cholesterol  $\geq 200$  mg/dL (or non-HDL cholesterol  $\geq 230$  mg/dL) and high risk characteristics such as  $\geq 2$  risk factors or high lipoprotein (a)  $\geq 50$  mg/dL using an isoform insensitive assay.
  - Functional heterozygotes with LDL cholesterol  $\geq 160$  mg/dL (or non-HDL cholesterol  $\geq 190$  mg/dL) and very high-risk characteristics (established CHD, other cardiovascular disease, or diabetes).

**LDL Apheresis Referrals**

- Healthcare practitioners should refer candidates for LDL apheresis to qualified sites. Self-referrals are also possible. A listing of sites qualified to perform LDL apheresis is in development and will be posted on the National Lipid Association website ([www.lipid.org](http://www.lipid.org)).

**Women of Childbearing Age**

- Women with FH should receive pre-pregnancy counseling and instructions to stop statins, ezetimibe, and niacin at least four weeks before discontinuing contraception and should not use them during pregnancy and lactation.
- Consultation with her healthcare practitioner regarding continuation of any other lipid medications is recommended.
- In case of unintended pregnancy, a woman with FH should discontinue statins, ezetimibe, and niacin immediately and should consult with her healthcare practitioner promptly.

### Treatment Options During Pregnancy

- Statins, ezetimibe, and niacin should not be used during pregnancy. Use of other lipid lowering medications (e.g., colesvelam) may be considered under the guidance of the healthcare practitioner.
- Consider LDL apheresis during pregnancy if there is significant atherosclerotic disease or if the patient has homozygous FH.

### Hard to Manage Patients

- If other treatment options are inadequate or the FH patient cannot tolerate pharmacotherapy or LDL apheresis, other treatment options include ileal bypass and liver transplantation (both are used rarely), and, potentially, new drugs in development.

## Lifestyle modifications

The goal of treatment for patients with FH is to achieve an LDL cholesterol reduction of at least 50% from baseline.<sup>8,9</sup> In patients with FH, lifestyle modifications should always be instituted, but usually these changes alone are insufficient to achieve the LDL cholesterol treatment goal.<sup>12,13</sup> The degree of LDL cholesterol reduction with dietary and lifestyle changes is quite variable, depending on the patient's original diet, compliance, and genetic responsiveness. A decrease of 10 to 15% is achievable in many individuals.<sup>13,14</sup>

Clinicians are encouraged to refer FH patients to registered dietitians or other qualified nutritionists for medical nutrition therapy and counseling in order to achieve the maximum possible diet-mediated reduction in LDL cholesterol. The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) Therapeutic Lifestyle Changes (TLC) diet, which restricts intakes of total fat (25 to 35% of energy intake), saturated fatty acids (<7% of energy intake), and cholesterol (<200 mg/d) is recommended for patients with FH.<sup>2</sup> Patients should also be instructed to incorporate dietary adjuncts including 2 g/d of plant stanol or sterol esters and 10 to 20 g/d of soluble fiber, both of which decrease cholesterol absorption.<sup>2,15,16</sup>

In addition to following the TLC diet, patients with FH should be encouraged to achieve and maintain a healthy body weight through physical activity and appropriate caloric intake.<sup>2</sup> If an individual is overweight or obese, significant weight loss will improve lipid levels. Each kilogram of weight loss produces a reduction of about 0.8 mg/dL in the LDL cholesterol concentration.<sup>17</sup> Limiting alcohol consumption and avoiding or stopping tobacco use (smoking cessation has been shown to increase HDL cholesterol levels<sup>18</sup>) is recommended in order to reduce the burden of additional cardiovascular risk factors among FH patients who are already at high risk by virtue of their severe hypercholesterolemia. Assistance in stopping smoking should be offered.

Dietary modifications should not be discounted in FH patients undergoing pharmacological therapy, because the effects on LDL cholesterol reduction are directly additive to those of lipid-lowering medications.<sup>19-22</sup> The importance

of complying with dietary management of hypercholesterolemia should be strongly emphasized during counseling of patients with FH, and the added negative effects of smoking should be thoroughly explained.

## Drug treatment of FH

Management of FH in women of childbearing potential and in breastfeeding women requires specific guidance, due to the risks to the child of certain types of drug therapies during pregnancy and breastfeeding (see sections below for Women of Childbearing Age and Treatment During Pregnancy). The recommendations for drug treatment of FH in the present section refer to women who are using contraception or who are not of childbearing potential.

After a confirmatory diagnosis of FH (excluding secondary causes of hypercholesterolemia), adult FH patients should receive initial treatment with higher potency statins (atorvastatin, rosuvastatin, pitavastatin, simvastatin) titrated to achieve an LDL cholesterol reduction  $\geq 50\%$  from baseline (pitavastatin and simvastatin have lower probability of achieving a 50% reduction from baseline).<sup>8,9,23</sup> Low potency statins (fluvastatin, lovastatin, pravastatin) are generally inappropriate as initial therapy for FH patients. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting enzyme in cholesterol synthesis, causing a reduction in hepatic cholesterol and leading to upregulation of hepatic LDL receptors. Increased LDL receptor activity results in a reduction in circulating LDL cholesterol concentration. With 50% functional LDL receptors, heterozygous FH patients typically have an excellent response to statins. Even some FH homozygotes who have LDL receptor defective mutations have sufficient LDL receptor activity to respond favorably to statin therapy, although generally to a degree insufficient to achieve their LDL cholesterol goal.<sup>24,25</sup> In individuals with hypercholesterolemia (not necessarily FH), statins have been shown to reduce LDL cholesterol concentrations by 50 to 60% at their maximum approved doses.<sup>26-29</sup> Many randomized, placebo-controlled trials have demonstrated that lowering LDL cholesterol with statins reduces coronary morbidity and mortality.<sup>2,10</sup>

Statins are generally well tolerated and have an excellent safety profile.<sup>30–32</sup> The potential adverse effects of statins in FH patients are the same as in other treated patients, notably myopathy and elevated liver enzymes. Certain low potency statins, such as fluvastatin and pravastatin, may be less likely to cause severe myopathy,<sup>32</sup> but they are not the preferred choice for patients with FH due to their lower ability to reduce LDL cholesterol levels.<sup>27,28,33</sup>

Some patients do not tolerate statin therapy. In these cases, possible alternatives include changing to a different statin, instituting every-other-day statin therapy, or using very low dose statin therapy in combination with other LDL cholesterol lowering medications. Alternative lipid-lowering medications to consider, if initial statin therapy is either contraindicated or poorly tolerated, include ezetimibe (cholesterol absorption inhibitor), a bile acid sequestrant, most often colestevlam, or niacin.<sup>8,9,29</sup> For patients who cannot use a statin, combination therapy of these other LDL cholesterol lowering agents will likely be required. Even among patients who tolerate the maximum doses of the higher efficacy statins, the addition of one or more non-statin cholesterol-lowering medications is often necessary to achieve the recommended LDL cholesterol reduction of  $\geq 50\%$ .

Ezetimibe specifically inhibits cholesterol and phytosterol absorption by binding to intestinal enterocytes and interfering with the activity of the Niemann-Pick C1-Like 1 sterol transporter. The reduced flow of cholesterol from the intestine to the liver leads to a compensatory increase in the hepatic LDL receptor resulting in increased uptake of circulating LDL and other lipoprotein particles. Ezetimibe reduces LDL cholesterol by approximately 15 to 20% when given alone or when combined with a statin. It can be administered in combination with other lipid medications in FH patients who do not tolerate statins.<sup>34–39</sup>

Bile acid sequestrants (colesevelam, cholestyramine, colestipol) are anion-exchange compounds that prevent reabsorption of bile acids in the intestine. They have been shown to decrease LDL cholesterol concentrations by up to 20%<sup>40</sup> and can be added to statin therapy in FH patients requiring additional LDL cholesterol lowering.<sup>41</sup> Because they are not absorbed systemically, they are generally considered safer than other lipid-lowering drugs. Cholestyramine and colestipol are associated with significant adverse gastrointestinal side effects, particularly constipation and multiple drug-drug interactions; and patient compliance is often an issue. The newest bile acid sequestrant on the market is colestevlam, a polymer available as a tablet or as a powder for oral suspension. Compared with cholestyramine and colestipol, colestevlam has fewer gastrointestinal side effects and drug-drug interactions and is effective at a lower dose. Its use may be associated with improved adherence compared with cholestyramine and colestipol. Colestevlam is also approved by the U. S. Food and Drug Administration for improving glycemic control in patients with type 2 diabetes mellitus. Colestevlam is therefore the recommended bile acid sequestrant for

use in patients with FH. Colesevelam can produce up to 20% further LDL cholesterol reductions when added to a statin.<sup>41</sup>

Niacin or nicotinic acid is available in immediate-release, extended-release, and sustained-release forms. The extended-release prescription product is preferred and most sustained-release non-prescription forms are not recommended due to increased potential for liver toxicity. Niacin is a water-soluble B vitamin which lowers very low-density lipoprotein and LDL cholesterol while raising HDL cholesterol, but its use is typically associated with troublesome side effects of flushing or hot flashes due to vasodilatation.<sup>42–44</sup> Extended-release niacin, dosing not to exceed 2 g/d, when added to a stable dose of statin therapy has been shown to be effective in lowering LDL cholesterol.<sup>45–46</sup>

Fibric acid derivatives (gemfibrozil, fenofibric acid, and fenofibrate) primarily act to lower triglycerides and raise HDL cholesterol, but do not reliably lower LDL cholesterol. Furthermore, fibrates (particularly gemfibrozil) may increase the risk of statin-induced myositis.<sup>47</sup> Therefore, fibrates should be used with caution. However, fenofibric acid is FDA approved for use in combination with low to moderate doses of statins. Prescription omega-3 fatty acid esters can also be used if concurrent high triglyceride levels are present.

## Additional treatment considerations

As described above, if an individual with FH is not at LDL cholesterol treatment goal with the maximum available and tolerable dose of statin, then the statin should be combined with ezetimibe, niacin, or a bile acid sequestrant (colesevelam preferred). The risk for myopathy with statin therapy appears to be positively associated with the dose and potency of the statin.<sup>32</sup> Because doubling the dose of a statin further lowers LDL cholesterol by only 6 to 7%,<sup>28</sup> addition of another agent (such as ezetimibe, niacin, or colestevlam) is often necessary to achieve the amount of LDL cholesterol reduction required in FH patients. However, the risk for myopathy is also increased by certain drug combinations, such as that of a fibrate (particularly gemfibrozil) with a statin.<sup>32,47</sup> Decisions regarding the selection of drug combinations should be based on concomitant risk factors for myopathy. Polypill forms of simvastatin combined with extended-release niacin (Simcor) and simvastatin combined with ezetimibe (Vytorin) are attractive options for patients with FH, reducing the number of pills required, which lowers cost and may improve adherence.

Another important factor to consider in the selection of combination drug therapies is potential concomitant medication interactions. Drug interactions with statins are primarily related to cytochrome P450 metabolism, drug transporters, and glucuronidation. Thus, caution should be used with a statin in combination with fibrates (mainly gemfibrozil), antifungals (except terbinafine which can be used with a statin), macrolide antibiotics,

antiarrhythmics, cyclosporine, protease inhibitors, or in patients who routinely drink grapefruit juice. Because it is not metabolized by cytochrome 3A4, rosuvastatin, unlike atorvastatin and simvastatin, may be less likely to produce interactions with other medications. Bile acid sequestrants may decrease the absorption of some medications, and the timing of dosing in conjunction with other medications is important, particularly with cholestyramine and colestipol. Ezetimibe, on the other hand, has a specific mechanism of action to inhibit cholesterol absorption, and therefore does not interfere with the absorption of other drugs.

Other major considerations when selecting drug combinations for treating FH are the presence of additional lipid abnormalities and other disease conditions, particularly hypertension, diabetes (type 1 or 2), and obesity, which also increase CHD risk. In addition to treating hypercholesterolemia, other cardiovascular risk factors should be identified and treated aggressively in patients with FH. The prognosis of FH patients depends heavily on the amount of LDL cholesterol reduction that can be achieved, but treatment of other modifiable risk factors such as hypertension, diabetes, and smoking, further decreases the risk of heart disease.

### Candidates for LDL apheresis

In patients where LDL cholesterol reduction has been inadequate despite diet and maximum drug therapy (after 6 months), or if drug therapy is not tolerated or contraindicated, LDL apheresis may be considered for the following individuals: 1) functional homozygous FH patients with LDL cholesterol  $\geq 300$  mg/dL (or non-HDL cholesterol  $\geq 330$  mg/dL), 2) functional heterozygous FH patients with LDL cholesterol  $\geq 300$  mg/dL (or non-HDL cholesterol  $\geq 330$  mg/dL) and 0-1 risk factors, 3) functional heterozygous FH patients with LDL cholesterol  $\geq 200$  mg/dL (or non-HDL cholesterol  $\geq 230$  mg/dL) and high risk characteristics such as  $\geq 2$  risk factors or high lipoprotein (a)  $\geq 50$  mg/dL using an isoform insensitive assay, and 4) functional heterozygotes with LDL cholesterol  $\geq 160$  mg/dL (or non-HDL cholesterol  $\geq 190$  mg/dL) and very high risk characteristics (established CHD, other cardiovascular disease, or diabetes).

LDL apheresis is a U.S. FDA-approved process of selectively removing Apo B-containing particles from the circulation through extracorporeal precipitation with either dextran sulphate cellulose or heparin.<sup>48-51</sup> The procedure must be repeated every 1 to 2 weeks. In a single procedure, LDL apheresis typically removes at least 60% of the Apo B-containing lipoproteins.<sup>50</sup> Higher baseline lipid levels appear to exhibit a greater response to LDL apheresis treatment. Due to the cyclical nature of Apo B synthesis and circulation, recurrent hypercholesterolemia occurs in approximately 12 to 13 days with a rebound to pre-treatment levels of Apo B particles.<sup>52</sup> Concomitant treatment with a statin enhances the efficacy of LDL apheresis.<sup>53</sup> Long-term therapy has been shown to result in a 20 to 40%

reduction in LDL cholesterol from pre-treatment levels.<sup>54,55</sup> Few adverse effects are associated with LDL apheresis, mostly noncritical episodes of hypotension.

Several clinical trials have confirmed the benefits of LDL apheresis for prevention and slowing the progression of cardiovascular disease,<sup>50,56-62</sup> and for other cardiovascular effects such as improvements in endothelial function,<sup>63</sup> coronary vasodilation,<sup>64</sup> microvascular flow,<sup>65</sup> and myocardial perfusion.<sup>66</sup> LDL apheresis has also been shown to promote regression of xanthomas<sup>50</sup> and modify a number of markers associated with vascular disease, including lipoprotein (a), an atherothrombotic marker.<sup>67</sup> LDL apheresis is the only treatment shown to consistently reduce lipoprotein (a) levels by more than 50%.<sup>68</sup> Although LDL apheresis is effective for retarding the development of atherosclerosis, and is often the only viable option for certain patients such as those with homozygous FH, the procedure is time consuming (more than 3 hours every 1 to 2 weeks) and expensive.<sup>62,69</sup>

### LDL apheresis referrals

Physicians should refer candidates for LDL apheresis to qualified sites. Self-referrals are also possible. A listing of sites qualified to perform LDL apheresis is in development and will be posted on the National Lipid Association website ([www.lipid.org](http://www.lipid.org)). Currently, there are more than 400 patients in North America receiving LDL apheresis therapy at more than 40 centers. While new facilities are added regularly, there is a significant gap between the number of patients receiving LDL apheresis therapy and the number that, according to FDA guidelines,<sup>70</sup> may qualify for LDL apheresis.

### Women of childbearing age

Statins, ezetimibe, and niacin are not approved for use by pregnant or breastfeeding women. Women with FH should receive pre-pregnancy counseling and instructions to stop use of statins, ezetimibe, and niacin at least four weeks prior to discontinuing contraception, and should not use these drugs during pregnancy and lactation. It is recommended that a woman of childbearing age consult her physician regarding continuation of any other lipid medications. In cases of unintended pregnancy, a woman with FH should discontinue statins, ezetimibe, and niacin immediately, and she should consult with her physician promptly.

### Treatment options during pregnancy

LDL cholesterol concentrations increase during the course of pregnancy due to hormonal changes.<sup>71-73</sup> This is considered beneficial in non-FH patients because cholesterol is necessary for embryonic and fetal nervous system development. However, in women with FH, the hormonal

increase in cholesterol combined with the need to stop taking statins (category X), ezetimibe (category C), and niacin (category C) in order to prevent potential birth defects, may put them at increased cardiovascular risk. Colesevelam is a pregnancy category B lipid-lowering medication indicating that it can be used during pregnancy when the need is clearly established. However, controlled trials during pregnancy have not been conducted. LDL apheresis should be considered during pregnancy if there is significant atherosclerotic disease or if the patient has homozygous FH. Although not specifically recommended, case studies have provided evidence supporting the safety of LDL apheresis for pregnant women with FH.<sup>74</sup>

## Hard to manage patients

In the general population of hypercholesterolemic patients, a subset fails to achieve their NCEP ATP III LDL cholesterol goal.<sup>75,76</sup> Many of these are patients with FH and patients who are resistant to lipid-lowering therapies. These hard-to-manage patients, particularly those with homozygous FH, cannot achieve target LDL cholesterol levels with currently available medications and will require alternative methods for cholesterol reduction.<sup>77</sup> For those who cannot tolerate drug therapy or LDL apheresis, other potential treatment options include partial ileal bypass and liver transplantation. Liver transplantation is beneficial because it can provide normal LDL receptors and often leads to a significant lowering of LDL cholesterol, but it is rarely used because of the risks associated with transplant surgery. Partial ileal bypass is also rarely used to treat FH. Gene therapy is another potential treatment option, but it is still in the investigational stage, as issues regarding potential side effects and long-term safety need to be resolved.<sup>78–81</sup>

Investigation into better methods to treat patients with FH in order to decrease the morbidity and mortality associated with this inherited disorder is ongoing. Several other potential approaches to LDL cholesterol lowering are currently in development, including Apo B antisense oligonucleotides (prevent the production of Apo B-containing particles from the liver), microsomal triglyceride transfer protein inhibitors (inhibit the transfer of nascent Apo B to very low-density lipoprotein and chylomicrons), PCSK9 inhibitors (prevent the degradation of the LDL receptor), and thyroid hormone analogues (which like natural thyroid hormone, would regulate cholesterol metabolism).<sup>81</sup>

In addition to plant sterols/stanols and soluble fiber, which are recommended as adjuncts to the TLC diet, use of other non-pharmacologic lipid-altering substances may be helpful for some individuals with hypercholesterolemia.<sup>14,82,83</sup> The following herbal products and supplements may have modest effects on LDL cholesterol levels, but these products should be used with caution, particularly in FH patients receiving multi-drug therapy: soy (has an FDA approved labeling health claim for cholesterol reduction, but recent studies suggest the effect may be quite small), red yeast rice

(some products may contain the active ingredient lovastatin, and should be treated as lovastatin and should never be used in conjunction with a statin), and green tea (suggestive epidemiologic data, but inconclusive clinical trial data, of its cholesterol lowering ability).<sup>84</sup>

## Acknowledgments

The authors would like to thank Mary R. Dicklin, PhD, Kevin C. Maki, PhD, FNLA, and Lynn Cofer-Chase, MSN, FNLA, from Provident Clinical Research for writing and editorial assistance.

## Industry support disclosure

The January 2011 NLA familial hypercholesterolemia recommendations conference was supported by unrestricted grant funding from the following companies: Abbott Laboratories, Aegerion Pharmaceuticals, Daiichi Sankyo, Genzyme, Kaneka Pharma America LLC, and Merck & Co. The National Lipid Association would like to thank each company for its support of this endeavor. In accordance with the National Lipid Association Code for Interactions with Companies, the NLA maintained full control over the planning, content, quality, scientific integrity, implementation, and evaluation of the recommendations conference and this familial hypercholesterolemia recommendations paper. All related activities are free from commercial influence and bias.

## Author disclosures

Dr. Ito has received honoraria related to consulting from Daiichi Sankyo. Dr. Ito has received honoraria related to speaking from Abbott Laboratories, Kowa Pharmaceuticals, and Merck & Co.

Dr. McGowan has received honoraria related to consulting from Genzyme Corporation and Abbott Laboratories. Dr. McGowan has received honoraria related to speaking from Merck Schering Plough and GlaxoSmithKline.

Dr. Moriarty has received honoraria related to speaking from Abbott Laboratories and Merck & Co. Dr. Moriarty has received honoraria related to consulting from B. Braun USA.

## References

1. American Heart Association. Executive Summary: Heart Disease and Stroke Statistics 2011 Update: A Report from the American Heart Association. American Heart Association Heart Disease and Stroke Statistics Writing Group. *Circulation*. 2011;123:459–463.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143–3421.

3. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver Cr, Beaudet AL, Sly WS, Valle D, editors. *The Metabolic and molecular basis of inherited disease*. New York: McGraw Hill, 2001. p. 2863–2913.
4. Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the Apo B gene. *Clin Chem*. 2004;50:1725–1732.
5. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. *J Lipid Res*. 2009;50:S172–S177.
6. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. *J Clin Endocrinol Metab*. 2008;93:4200–4209.
7. Rees A. Familial hypercholesterolemia: underdiagnosed and undertreated. *Eur Heart J*. 2008;29:2583–2584.
8. National Institute for Health and Clinical Excellence. Clinical guidelines and evidence review for familial hypercholesterolemias: the identification and management of adults and children with familial hypercholesterolemia. 2008 (Clinical guidelines 71) [www.nice.org.uk/CG71](http://www.nice.org.uk/CG71).
9. Wierzbicki AS, Humphries SE, Minhas R, on behalf of the Guidance Development Group. Familial hypercholesterolemia: summary of NICE guidance. *BMJ*. 2008;337:509–510.
10. Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227–239.
11. Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. *J Atheroscler Thromb*. 2010;17:667–674.
12. Illingworth DR. Management of hypercholesterolemia. *Med Clin North Am*. 2000;84:23–42.
13. Lichtenstein AH, Ausman LM, Jalbert SM, et al. Efficacy of Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. *J Lipid Res*. 2002;43:264–273.
14. Bruckert E, Rosenbaum D. Lowering LDL cholesterol through diet: potential role in the statin era. *Curr Opin Lipidol*. 2011;22:43–48.
15. Brown L, Roener B, Willett WW, Sacks FM. Cholesterol lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*. 1999;69:30–42.
16. Demonty I, Ras RT, van der Knaap HCM, et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phyto-sterol intake. *J Nutr*. 2009;139:271–284.
17. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992;56:320–328.
18. Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH. Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial. *Am Heart J*. 2011;161:145–151.
19. Connor WE, Connor SL. Dietary treatment of familial hypercholesterolemia. *Arteriosclerosis*. 1989;9(1Suppl):I91–I105.
20. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesvelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. *Clin Cardiol*. 2001;24:467–474.
21. Castro Cabezas M, de Vries JH, Van Oostrom AJ, Iestra J, van Staveren WA. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. *J Am Diet Assoc*. 2006;106:1564–1569.
22. Goldberg AC, Ostlund RE Jr, Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. *Am J Cardiol*. 2006;97:376–379.
23. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. *Atherosclerosis*. 2003;168:1–14.
24. Feher MD, Webb JC, Patel DD, et al. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolemia. *Atherosclerosis*. 1993;103:171–180.
25. Goldammer A, Wiltschnig S, Heinz G, et al. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. *Metabolism*. 2002;51:976–980.
26. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383–1389.
27. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). *Am J Cardiol*. 1998;81:582–587.
28. Jones PH, Davidson MH, Stein EA. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR\* Trial). *Am J Cardiol*. 2003;92:152–160.
29. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med*. 2001;345:1583–1592.
30. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. *Am J Cardiol*. 2006;97:77C–81C.
31. Thompson PD, Clarkson PM, Rosenson RS. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by muscle experts. *Am J Cardiol*. 2006;97:69C–76C.
32. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. National Lipid Association Statin Safety Task Force Liver Expert Panel. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol*. 2006;97:94C–94C.
33. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. *Am Heart J*. 2006;151:273–281.
34. van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH5825, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. *J Pharmacol Exp Ther*. 1997;283:157–163.
35. Gagne C, Gauder D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation*. 2002;105:2469–2475.
36. Zema MJ. Colesevelam HCL and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. *Am J Ther*. 2005;12:306–310.
37. Kastelein JJP, Adkim F, Stroes ESG, et al; for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*. 2008;358:1431–1443.
38. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. *Vasc Health Risk Manag*. 2010;6:1023–1037.
39. Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. *Int Angiol*. 2010;29:514–524.
40. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results, I: reduction in the incidence of coronary heart disease. *JAMA*. 1984;251:351–364.
41. Huijgen R, Abbink EJ, Bruckert E, et al. Trip Study Group. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind controlled trial. *Clin Ther*. 2010;32:615–625.
42. Dhood JM, Zimetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. *J Clin Pharmacol*. 1991;31:641–650.
43. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. *Am J Cardiol*. 1998;82:35U–38U.
44. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. *Am J Cardiol*. 1998;82:29U–34U.
45. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. *Am J Cardiol*. 1998;82:82U–84U.
46. Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. *Am J Cardiol*. 2001;87:476–479.
47. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. *Nat Rev Endocrinol*. 2009;5:507–518.

48. de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. Homozygous cutaneo-tendinous forms of hypercholesterolemic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment. *Bull Mem Soc Med Hop Paris*. 1967;118:1377–1402.
49. Schettler V, Wieland E, Armstrong VW, Kleinoeder T, Grunewald RW, Muller GA. Participants of the Gottingen Consensus Conferences. First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. *Ther Apher*. 2002;6:381–383.
50. Thompson GR. LDL apheresis. *Atherosclerosis*. 2003;167:1–13.
51. Moriarty PM. LDL-apheresis therapy. *Curr Treat Options Cardiovasc Med*. 2006;8:282–288.
52. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL apheresis. Kinetics and estimation of mean lipoprotein levels. *Atherosclerosis*. 2000;152:519–526.
53. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. *J Lipid Res*. 1997;38:2071–2078.
54. Pfohl M, Naoumova RP, Klass C, et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG CoA reductase inhibitor therapy. *J Lipid Res*. 1994;35:1946–1955.
55. Gordon DR, Kelsey SF, Dau PC, et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. *Am J Cardiol*. 1998;81:407–411.
56. Tatami R, Inove N, Itoh H, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. *Atherosclerosis*. 1992;95:1–13.
57. Waidner T, Franzen D, Voelker W, et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. *Clin Investig*. 1994;72:858–863.
58. Schuff-Werner P, Gohike H, Bartmann U, et al. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL cholesterol plasma concentration and the course of coronary heart disease. *Eur J Clin Invest*. 1994;24:724–732.
59. Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. *Lancet*. 1995;345:811–816.
60. Kroon AA, Aengevaeren WR, van den Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment of coronary atherosclerosis. *Circulation*. 1996;93:1826–1835.
61. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. *Am J Cardiol*. 1998;82:1489–1495.
62. Ritcher WO, Donner MG, Hoffing B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. *Metabolism*. 1998;47:863–868.
63. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. *Circulation*. 1997;95:76–82.
64. Igarashi K, Tsuji M, Nishimura M, Horimoto M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. *J Clin Apher*. 2004;19:11–16.
65. Sato M, Amano I. Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. *Ther Apher Dial*. 2003;7:419–424.
66. Kobayashi K, Yamashita K, Tasaki H, et al. Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis. *Ther Apher Dial*. 2004;8:383–389.
67. Keller C. Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management. *Ther Apher Dial*. 2007;11:2–8.
68. Bambauer R. Is lipoprotein(a)-apheresis useful? *Ther Apher Dial*. 2005;9:142–147.
69. Thompson J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. *Atherosclerosis*. 2006;189:31–38.
70. U.S. Food and Drug Administration (FDA). PMA final decisions rendered for September 1997. H.E.L.P. Accessed February 8, 2011. Available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/p940016.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/p940016.pdf)
71. Loke DF, Viegas OA, Kek LP, Rauff M, Thai AC, Ratnam SS. Lipid profiles during and after normal pregnancy. *Gynecol Obstet Invest*. 1991;32:144–147.
72. Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? *Clin Sci (Lond)*. 1999;96:421–425.
73. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. *Atherosclerosis*. 2006;189:451–457.
74. Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R. Differential indication of lipoprotein apheresis during pregnancy. *Ther Apher Dial*. 2003;7:359–364.
75. Grundy SM. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. *Am J Cardiol*. 2001;88:23J–27J.
76. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. *Am J Cardiol*. 2005;96:53E–59E.
77. Stein EA. Other therapies for reducing low-density lipoprotein cholesterol: medications in development. *Endocrinol Metab Clin North Am*. 2009;38:99–119.
78. Hansson GK. Vaccination against atherosclerosis: science or fiction? *Circulation*. 2002;106:1599–1601.
79. Ito MK. ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense? *Ann Pharmacother*. 2007;41:1669–1678.
80. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. *Molec Ther*. 2007;15:1233–1247.
81. Goldberg AC. NLA Symposium on Familial Hypercholesterolemia. Novel therapies and new targets of treatment familial hypercholesterolemia. *J Clin Lipidol*. 2010;4:350–356.
82. Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. *Pharmacotherapy*. 2001;21:481–487.
83. Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. *Cardiovasc Ther*. 2010;28:202–215.
84. McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? *Curr Atheroscler Rep*. 2009;11:470–476.

# Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Anne C. Goldberg, MD, FNLA\*, Jennifer G. Robinson, MD, FNLA, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA

Washington University School of Medicine, St. Louis, MO, USA (Dr. Goldberg); University of Iowa, Iowa City, IA, USA (Dr. Robinson); Wake Forest University School of Medicine, Winston–Salem, NC, USA (Dr. Cromwell); University of Pennsylvania Health System, Philadelphia, PA, USA (J.L. Ross); and Florida Lipid Institute, Winter Park, FL, USA (Dr. Ziajka)

## Introduction

Heterozygous familial hypercholesterolemia (FH) occurs with a frequency of about 1 in every 300 to 500 people and is therefore one of the most commonly occurring congenital metabolic disorders.<sup>1–3</sup> It is estimated that at least 620,000 Americans are affected with FH.<sup>2,4</sup> Unfortunately, large numbers of the populace with FH are undiagnosed and consequently remain at increased risk for coronary heart disease (CHD).<sup>5</sup> Furthermore, even though

highly effective lipid-lowering drugs are available, FH is often inadequately treated.<sup>4</sup>

In order to prevent premature CHD, avoid early death, and reduce costs to patients and society, there is a need to increase public and provider awareness, foster research, and develop national policies to improve diagnostic and treatment services for those with FH. The following discussion reflects the opinion of the members of the National Lipid Association's Expert Panel on Familial Hypercholesterolemia based on their experience as lipid specialists and evaluation of scientific evidence. It is intended to describe, from a clinical perspective, the current procedures for screening, diagnosis, and management of FH and areas for improvement. The panel acknowledges that policy statements such as these are not simply a matter of the scientific evidence, but also have political and social implications, particularly since FH is a genetic disorder.

---

**National Lipid Association Expert Panel on Familial Hypercholesterolemia:** Anne C. Goldberg, MD, FNLA, Chair, Paul N. Hopkins, MD, MSPH, Peter P. Toth, MD, PhD, FNLA, Christie M. Ballantyne, MD, FNLA, Daniel J. Rader, MD, FNLA, Jennifer G. Robinson, MD, MPH, FNLA, Stephen R. Daniels, MD, PhD, Samuel S. Gidding, MD, Sarah D. de Ferranti, MD, MPH, Matthew K. Ito, PharmD, FNLA, Mary P. McGowan, MD, FNLA, Patrick M. Moriarty, MD, William C. Cromwell, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, Paul E. Ziajka, MD, PhD, FNLA.

\* Corresponding Author: Anne C. Goldberg, MD, FNLA, Associate Professor of Medicine, Washington University School of Medicine, St. Louis, Missouri, Tel: 312-462-4332.

E-mail address: agoldber@dom.wustl.edu

Submitted April 1, 2011. Accepted for publication April 4, 2011.

## Screening

Because it is a relatively common, but treatable, disorder associated with high risk for CHD, FH meets the World

**Summary Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia****Screening**

- It is the responsibility of all primary health care providers and relevant specialists to screen all children and adults for hypercholesterolemia, and to initiate therapy in patients with familial hypercholesterolemias (FH) and severe hypercholesterolemia.

**Lipid Specialists**

- Patients with FH who do not respond adequately to, or are intolerant of, initial statin therapy should be referred to a lipid specialist.
- For children with FH, either consultation with or referral to a lipid specialist is recommended.
- Patients who are candidates for more intensive therapy, or who have family histories of very premature coronary heart disease (in men <45 years of age and women <55 years of age), should also be referred to a lipid specialist.

**Payers**

- Patients with FH are at high lifetime risk of atherosclerotic cardiovascular disease and appropriate therapy is required.
- Payers should cover initial screening, initiation of therapy with appropriate medications, and monitoring response to therapy.
- Payers should cover appropriate drugs including high potency statins and combination lipid drug therapy. They should also cover other drugs and combinations for patients with statin tolerance problems.
- Low-density lipoprotein (LDL) apheresis and genetic testing, when appropriate, should be covered by payers.

**Public and Provider Awareness**

- To promote early diagnosis of FH and the prevention, and treatment of CHD, public awareness of FH needs to be increased by a variety of methods.
- Health care provider awareness needs to be increased through education at all levels and in multiple specialties, through partnering with professional organizations and through local, national and international health agencies.

**Responsibility for Education**

- Health systems, hospitals, pharmacy benefits management organizations, and insurance companies should contribute to patient and provider education.
- Governmental agencies and other policy makers at local, state, national and international levels should be engaged in efforts to screen and treat FH.

**Research Needs**

- Research is needed in the following areas related to FH:
  - Agents to further lower LDL cholesterol;
  - Ways to improve adherence to and persistence with therapy;
  - Cost effective genetic screening;
  - Behavioral management of patients with FH;
  - Cost effectiveness analysis of various approaches to screening and treatment;
  - Cost effectiveness analysis of the benefits of aggressive therapy;
  - Long-term follow-up of patients with FH, including safety of long-term therapy with lipid lowering drugs;
  - Differences in drug metabolism by gender, ethnicity and age;
  - Long-term cardiovascular benefits of combination therapies;
  - Management of FH in pregnancy;
  - Mechanism and management of statin intolerance;
  - Safety and effectiveness of dietary supplements and dietary adjuncts for LDL cholesterol reduction;
  - Methods to enhance healthcare provider adherence to guidelines.

**Funding**

- Funding for FH education and research should come from multiple sources including government, professional associations, industry, and private donations.

Health Organization criteria for systematic screening.<sup>6</sup> Various FH screening approaches have been implemented in different countries. In the United States, screening for FH involves assessment of blood cholesterol concentrations, accompanied by an inspection for physical signs of FH such as xanthomas, and evaluation of family history. After an individual has been diagnosed with FH, cascade screening should be implemented where possible, which involves testing lipid levels in all available first-degree relatives of the index case.

Although several U.S. national health organizations encourage screening for FH beginning in childhood,<sup>7–10</sup> a widespread universal screening initiative has not been implemented. This panel believes it is the responsibility of primary healthcare providers and relevant specialists to screen all children and adults for hypercholesterolemia, and to initiate therapy in patients with FH and severe hypercholesterolemia. Individuals with FH have a mortality risk, particularly as young adults, that is disproportionately higher than that which would be predicted for individuals with the same cholesterol level, but without FH.<sup>11</sup> This increased risk is due to the exposure of people with FH to very high low-density lipoprotein (LDL) cholesterol concentrations from birth.<sup>11</sup> Without treatment, more than half of all men with FH and 30% of women with FH are expected to have a myocardial infarction before 60 years of age.<sup>12</sup> Early detection of FH is paramount to the successful treatment of the disease.

The late professor Roger Williams at the University of Utah recognized the importance of a systematic approach to identify individuals with FH more than 20 years ago.<sup>4,13–15</sup> His commitment and worldwide activism for this cause led to the development of the Make Early Diagnosis Prevent Early Death (MEDPED, [www.medped.org/index.html](http://www.medped.org/index.html)) program, a non-profit humanitarian organization to help diagnose and treat children and adults with high cholesterol disorders. MEDPED is supported internationally by over 40 countries.

Typically, FH is diagnosed on the basis of clinical and biological signs, but another aspect to diagnosis is identifying the causal genetic mutation.<sup>16</sup> Genetic testing is generally not needed for clinical management or diagnosis, but may be useful when the diagnosis is uncertain. Identification of the causal mutation may also provide additional motivation for some patients to adhere to treatment. Population-based genetic screening for FH is generally impractical due to the large number of possible causal mutations (over 1600 known mutations of the LDL receptor gene alone at the time of this writing). The cost of genetic testing may also limit its use, but since the test is performed once in a lifetime and multiple affected relatives can then be identified, the benefits might outweigh the cost.<sup>17–19</sup> The use of genetic information may also raise ethical concerns.<sup>20</sup> So, in cases where genetic testing is undertaken, the implications of the test results should be carefully explained to the patient. Another important point to note is that a negative genetic test does not necessarily exclude a diagnosis of FH, since about 20% of patients who have

been diagnosed as having definite FH do not have an identifiable mutation when tested with current methods.

In some countries, currently the Netherlands, Spain, and Wales, national screening programs exist which include genetic cascade screening.<sup>21–23</sup> Records from the Lipid Clinic Network in the Netherlands indicate that with the use of the genetic cascade screening approach, 4500 to 6000 relatives of FH patients can be contacted yearly, resulting in identification of 1500 to 2000 new cases of FH per year.<sup>4</sup> A long-term follow-up study of patients identified using this program also provided compelling evidence for the benefits of statin treatment.<sup>24</sup> In this follow-up (mean 8.5 years) study of 2146 patients with FH, statin use reduced CHD risk by approximately 80%, to a level similar to that of an age-matched sample from the general population. This suggests that statin treatment may substantially reduce or eliminate the CHD risk associated with FH.

Not only are cascade screening programs (both those that incorporate genetic testing and those that do not) effective in reducing disease risk, they have been shown to be cost-effective.<sup>6,25–30</sup> Cascade screening is the most cost-effective means of finding a previously undiagnosed FH patient, particularly in children.<sup>31</sup> Cost effectiveness will continue to improve as drug costs for certain statins, the drugs of choice for FH treatment, decrease due to the expiration of patents. Furthermore, as DNA diagnostic technology advances, the cost of genetic testing may also decrease.

## Role of the front line provider

Primary care practitioners are on the front line of identifying individuals with hypercholesterolemia and FH, and in some cases successfully diagnose and manage the lipid treatment for FH patients. Primary care practitioners include family practitioners, internists, pediatricians, obstetrician-gynecologists, and nurse practitioners, physician assistants, pharmacists and others providing primary care. Cardiologists and neurologists may overlook a potential FH diagnosis in a person who has had a cardiovascular or cerebrovascular event, due to their focus on the acute event and the rapid discharge of the patient from the hospital.<sup>32</sup> Achilles tendon xanthomas and premature corneal arcus are often overlooked during a routine physical examination. Unfortunately, there are many cases when patients with FH are not given an accurate diagnosis unless they visit a physician interested in lipid disorders.<sup>15</sup>

## Role of the lipid specialist

Some FH patients require specialized care and should be referred to a lipid specialist. These include patients with FH who do not respond adequately to or are intolerant of initial statin therapy; children with FH (consultation with or referral to a lipid specialist is always recommended); and patients who are candidates for more intensive therapy

because of higher CHD risk, or who have family histories of very premature CHD (in men <45 years of age and women <55 years of age). Lipid specialists include physicians and other healthcare providers who have received specialized lipidology training. Such training has been recognized by the American Board of Clinical Lipidology or the Accreditation Council for Clinical Lipidology. An important part of the lipid specialists' approach to the management of FH, which may be different from the approach of the general practitioner, is the awareness of the familial nature of the condition and implementation of cascade screening of first-degree relatives of index cases.<sup>11,31</sup>

## Payers

Patients with FH are at very high lifetime risk of atherosclerotic cardiovascular disease and appropriate therapy is required. It is the opinion of this panel that initial screening, initiation of therapy with appropriate medications, and follow up monitoring should be covered by payers. It is understood that support for this proposition may be difficult to achieve. With no cure for FH on the horizon, long-term coverage of lipid-altering agents, including high potency statins and combination therapy, should be covered by payers. Other, non-statin, lipid altering agents for FH patients with statin intolerance or those refractory to statin therapy should also be covered. Patients with severe forms of FH may require coverage of LDL apheresis, and coverage of this procedure should not be denied for patients who meet criteria for LDL apheresis.

Although genetic testing is not recommended as a universal screening measure, and is not generally needed for clinical management or diagnosis, there are cases when genetic testing has an important role, such as when the diagnosis of FH is uncertain. The panel recommends that genetic testing should be covered by payers under those circumstances. Genetic testing has social implications and is an important policy issue.<sup>4,16,20,33,34</sup> Issues regarding its use and impact on eligibility for health insurability have to be addressed.<sup>33-35</sup> Patients who do have genetic testing for FH need to have legal safeguards in place to protect them from discriminatory practices. In the Netherlands and U.K. there has been preliminary research into the ethical, legal, and social issues related to genetic testing, but research in the U.S. is needed.<sup>33,36,37</sup>

## Public and provider awareness and education

FH is a significant, but poorly identified and underestimated, problem in the U.S. For early diagnosis of FH and for prevention and treatment of CHD, increased public awareness is necessary. Awareness by the general public is lacking, and even patients diagnosed with FH often have limited understanding of the nature of the condition.

According to an examination of 74 patients with FH who were administered a questionnaire about knowledge of FH, most patients knew about cholesterol, prevention, and the reason for drug treatment, but had very little knowledge about the risk of genetic transmission and the importance of family history.<sup>38</sup> The public needs to know the signs of FH, and that FH is a treatable condition with therapies that can markedly reduce the risk of early CHD, premature death, and other complications from atherosclerotic disease. Furthermore, FH patients and their families need to understand that this is a genetic disorder that is typically passed down from one generation to the next as a dominant trait. A variety of methods, including news media stories and public service announcements should be utilized to increase public and patient awareness. Also useful might be an FH patient/family organization or support group to assist in the dissemination of educational information.

Not only is there an apparent lack of awareness among the general public and FH patients, but also healthcare providers have often had limited training regarding the importance of screening and of appropriate treatment of FH. A follow-up study of the Netherlands genetic cascade screening program indicated that even after diagnosis of FH, patients who were receiving cholesterol-lowering medication(s) and being followed by their physicians were undertreated, and a minority reached their treatment goal.<sup>4,22,39</sup> This indicates that not only should the importance of screening be emphasized in provider education, but also the need for aggressive therapy. Primary healthcare practitioners and relevant specialists should receive education regarding screening of all children and adults for hypercholesterolemia and the appropriate management of patients with FH and severe hypercholesterolemia. This education needs to be provided initially in medical and allied health professional schools, internship, residency, and fellowship programs, and thereafter through continuing education, in multiple specialties, through partnering of professional organizations and through local, national, and international health agencies. Furthermore, government agencies and other policy makers at local, state, national, and international levels should all be engaged in efforts to screen and treat patients with FH appropriately. Healthcare systems, hospitals, pharmacy benefits management organizations, and insurance companies should contribute to the education of both the public and healthcare practitioners.

## Research

Since the development of MEDPED over 20 years ago, there have been great strides in the identification of FH through genetic testing and publication of diagnostic criteria and the treatment of high cholesterol with the development of safe, high potency statins. However, several areas in the field of FH require further research. In the United States, better data are needed regarding the percentage of individuals in the general population who are diagnosed

with and treated for FH, as well as information on CHD risk status and event rates for patients with FH; the cost effectiveness of various approaches to screening and treatment, including genetic screening; and the benefits and risks of aggressive therapy. Several areas of study are important in order to improve the care of FH patients including:

- behavioral management of patients with FH;
- patient adherence to medications and ways to improve adherence to therapy;
- adherence to guidelines by healthcare practitioners;
- long term follow up of patients with FH, including safety of long term therapy with lipid lowering drugs and long-term cardiovascular benefits of combination therapies;
- additional agents/methodologies for further lowering of LDL cholesterol;
- differences in drug metabolism by gender, ethnicity, and age;
- management of FH in pregnancy;
- mechanisms and treatment of statin intolerance; and
- safety and effectiveness of over-the-counter preparations and dietary adjuncts for lowering LDL cholesterol.

## Funding

It has been the experience of this panel, that funding for FH education and research is obtainable from multiple sources, including government agencies such as the National Institutes of Health, professional associations like the American Heart Association, various industries, and non-profit foundations. Together, fiscal support from multiple donors for public awareness campaigns, education, and research can greatly facilitate the implementation of appropriate screening, which can then lead to early detection and treatment of FH and make an enormous impact on the prevention of CHD and other atherosclerotic sequelae.<sup>40,41</sup>

## Acknowledgments

The authors would like to thank Mary R. Dicklin, PhD, Kevin C. Maki, PhD, FNLA, and Lynn Cofer-Chase, MSN, FNLA, from Provident Clinical Research for writing and editorial assistance.

## Industry support disclosure

The January 2011 NLA FH recommendations conference was supported by unrestricted grant funding from the following companies: Abbott Laboratories, Aegerion Pharmaceuticals, Daiichi Sankyo, Genzyme, Kaneka Pharma America LLC, and Merck & Co. The National Lipid Association would like to thank each company for its support of this endeavor. In accordance with the National Lipid Association Code for Interactions with Companies, the NLA

maintained full control over the planning, content, quality, scientific integrity, implementation, and evaluation of the recommendations conference and this FH recommendations paper. All related activities are free from commercial influence and bias.

## Author disclosures

Dr. Goldberg has received honoraria related to consulting from Roche/Genentech, ISIS-Genzyme and Merck & Co. Dr. Goldberg has received research grants from Amarin, Abbott Laboratories, GlaxoSmithKline, ISIS-Genzyme Corporation, Merck & Co., Novartis, and Regeneron.

Dr. Robinson has received research grants from Abbott Laboratories, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Hoffman LaRoche, Merck & Co., Merck Schering Plough, and Spirocor.

Dr. Cromwell has received honoraria related to consulting from Isis Pharmaceuticals, LabCorp, and Health Diagnostics Laboratory. Dr. Cromwell has received research grants from Isis Pharmaceuticals. Dr. Cromwell has received honoraria related to speaking from Abbott Laboratories, LipoScience Inc., Merck & Co., and Merck Schering Plough.

Ms. Ross has received honoraria related to consulting from Kaneka America and Genzyme Corporation. Ms. Ross has received honoraria related to speaking from Abbott Laboratories, Kaneka America, Kowa Pharmaceuticals, and Sanofi-Aventis.

Dr. Ziajka has received honoraria related to speaking from Abbott Laboratories, AstraZeneca and Merck & Co. Dr. Ziajka has received research grants from Genzyme Corporation.

## References

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. *J Clin Invest.* 1973;52:1544-1568.
2. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver Cr, Beaudet AL, Sly WS, Valle D, editors. *The Metabolic and Molecular Basis of Inherited Disease.* New York: McGraw Hill, 2001. p. 2863-2913.
3. Moriarty PM. LDL-apheresis therapy. *Curr Treat Options Cardiovasc Med.* 2006;8:282-288.
4. Defesche JC. NLA Symposium on Familial Hypercholesterolemia: Defining the challenges of FH screening for familial hypercholesterolemia. *J Clin Lipidol.* 2010;4:338-341.
5. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis.* 2004;173:55-68.
6. World Health Organization. Human Genetics Programme. Report of a second WHO Consultation, Geneva, 4 September 1998. Available at: [http://whqlibdoc.who.int/hq/1999/WHO\\_HGN\\_FH\\_CONS\\_99.2.pdf](http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdf).
7. Expert Panel of Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. *Pediatrics.* 1992;89:495-501.
8. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. *Pediatrics.* 1998;101:141-147.
9. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children

- and adolescents: systemic evidence review for the US Preventive Services Task Force. *Pediatrics*. 2007;120:e189–e214.
10. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. *Pediatrics*. 2008;122:198–208.
  11. Mant D. Commentary: What's so special about familial hypercholesterolemia? *Br J Gen Pract*. 2009;59:777–778.
  12. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. *Atherosclerosis*. 1999;142:105–112.
  13. Hopkins PN, Williams RR, Kuida H, et al. Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah. *Am J Cardiol*. 1988;62:703–707.
  14. Williams RR, Schumacher MC, Barlow GK, et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. *Am J Cardiol*. 1993;72:18D–24D.
  15. Tomlinson B, Lan IW, Hamilton-Craig I. Screening for familial hypercholesterolaemia. Funding is difficult to obtain but screening can be international. *BMJ*. 2001;322:1061–1062.
  16. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. *Eur J Hum Genet*. 2003;11(Suppl 2):S49–S87.
  17. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JJP. The molecular basis of familial hypercholesterolemia in The Netherlands. *Hum Genet*. 2001;109:602–615.
  18. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. *Semin Vasc Med*. 2004;4:67–74.
  19. Alves AC, Medeiros AM, Francisco V, Gaspar IM, Rato Q, Bourbon M. Molecular diagnosis of familial hypercholesterolemia: an important tool for cardiovascular risk stratification. *Rev Port Cardiol*. 2010;29:907–921.
  20. Gaudet D, Gagné C, Perron P, Couture P, Tonstad S. Ethical issues in molecular screening for heterozygous familial hypercholesterolemia: The complexity of dealing with genetic susceptibility to coronary artery disease. *Community Genet*. 1999;2:2–8.
  21. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. *BMJ*. 2000;321:1497–1500.
  22. Umans-Eckenhausen MAW, Defesche JC, Van Dam MJ, Kastelein JJP. Long term compliance to lipid lowering medication after genetic screening for Familial Hypercholesterolemia. *Arch Intern Med*. 2003;163:65–68.
  23. National Institute for Health and Clinical Excellence. Clinical guidelines and evidence review for familial hypercholesterolemias: the identification and management of adults and children with familial hypercholesterolemia. 2008 (Clinical guidelines 71). Available at: [www.nice.org.uk/CG71](http://www.nice.org.uk/CG71).
  24. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ*. 2008;337:a2423.
  25. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. *Am J Cardiol*. 1993;72:75D–79D.
  26. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. *BMJ*. 2002;324:1303–1308.
  27. Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, Bonsel GJ, Klazinga NS. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the Netherlands. *Eur Heart J*. 2002;23:1922–1930.
  28. Leren TL. Cascade genetic screening for familial hypercholesterolemia. *Clin Genet*. 2004;66:483–487.
  29. Wonderling D, Umans-Eckerhausen MAW, Marks D, Defesche JC, Kastelein JJP, Thorogood M. A cost-effectiveness analysis of the genetic screening program for Familial Hypercholesterolemia in the Netherlands. *Semin Vasc Med*. 2004;4:97–104.
  30. Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolemia. *Curr Opin Lipidol*. 2005;16:428–433.
  31. Gray J, Jaiyeola A, Whiting M, Modell M, Wierzbicki AS. Identifying patients with familial hypercholesterolemia in primary care: an informatics-based approach in one primary care centre. *Heart*. 2008;94:754–758.
  32. Dorsch MF, Lawrence RA, Durham NP, Hall AS. Familial hypercholesterolemia is underdiagnosed after AMI. *BMJ*. 2001;322:1111.
  33. Marang-van de Mheen PJ, van Maarle MC, Stouthard MEA. Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in the Netherlands. *J Epidemiol Community Health*. 2002;56:145–147.
  34. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGe prevalence review. *Am J Epidemiol*. 2004;160:407–420.
  35. Homsma SJM, Huijgen R, Middeldorp S, Sijbrands EJG, Kastelein JJP. Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. *Eur J Hum Genet*. 2008;16:14–17.
  36. Umans-Eckenhausen MA, Oort FJ, Ferenschild KC, Defesche JC, Kastelein JJ, de Haes JC. Parental attitude towards genetic testing for familial hypercholesterolaemia in children. *J Med Genet*. 2002;39:e49.
  37. Neil HA, Hammond T, Mant D, Humphries SE. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. *BMJ*. 2004;328:500–501.
  38. Hollman G, Olsson AG, Ann-Christina EK. Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia. *J Cardiovasc Nurs*. 2006;21:103–108.
  39. Huijgen R, Kindt I, Verhoeven SBJ, et al. Two years after molecular diagnosis of familial hypercholesterolemia: Majority on cholesterol-lowering treatment by a minority reaches treatment goal. *PLoS ONE*. 2010;5:e9220.
  40. Kavey RE, Allada V, Daniels SR, et al; American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: endorsed by the American Academy of Pediatrics. *Circulation*. 2006;114:2710–2738.
  41. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol*. 2007;27:1803–1810.

